WO2024030514A1 - Extracellular vesicle-associated adeno-associated virus vectors for inhaled gene therapy - Google Patents
Extracellular vesicle-associated adeno-associated virus vectors for inhaled gene therapy Download PDFInfo
- Publication number
- WO2024030514A1 WO2024030514A1 PCT/US2023/029349 US2023029349W WO2024030514A1 WO 2024030514 A1 WO2024030514 A1 WO 2024030514A1 US 2023029349 W US2023029349 W US 2023029349W WO 2024030514 A1 WO2024030514 A1 WO 2024030514A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- vectors
- virus
- composition
- amino acid
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 259
- 241000702421 Dependoparvovirus Species 0.000 title claims description 36
- 238000001415 gene therapy Methods 0.000 title description 61
- 241000700605 Viruses Species 0.000 claims abstract description 100
- 108700019146 Transgenes Proteins 0.000 claims abstract description 63
- 239000013603 viral vector Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 156
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 112
- 210000000234 capsid Anatomy 0.000 claims description 83
- 150000001413 amino acids Chemical class 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 76
- 230000035772 mutation Effects 0.000 claims description 70
- 210000003097 mucus Anatomy 0.000 claims description 52
- 239000013607 AAV vector Substances 0.000 claims description 48
- 108090000565 Capsid Proteins Proteins 0.000 claims description 38
- 208000006673 asthma Diseases 0.000 claims description 38
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 31
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 claims description 29
- 108010003422 Circulating Thymic Factor Proteins 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 210000003855 cell nucleus Anatomy 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 230000010189 intracellular transport Effects 0.000 claims description 21
- 230000035515 penetration Effects 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 241000701161 unidentified adenovirus Species 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical class 0.000 claims description 15
- 230000008685 targeting Effects 0.000 claims description 15
- 241000713666 Lentivirus Species 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 12
- 230000037431 insertion Effects 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 11
- 230000002519 immonomodulatory effect Effects 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 241001430294 unidentified retrovirus Species 0.000 claims description 9
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000710929 Alphavirus Species 0.000 claims description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 241000710831 Flavivirus Species 0.000 claims description 6
- 241000714192 Human spumaretrovirus Species 0.000 claims description 6
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 6
- 241000709664 Picornaviridae Species 0.000 claims description 6
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 6
- 241000700618 Vaccinia virus Species 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 abstract description 66
- 230000014509 gene expression Effects 0.000 abstract description 64
- 108090000623 proteins and genes Proteins 0.000 description 79
- 235000001014 amino acid Nutrition 0.000 description 55
- 229940024606 amino acid Drugs 0.000 description 49
- 238000001727 in vivo Methods 0.000 description 28
- 230000001225 therapeutic effect Effects 0.000 description 26
- 210000005058 airway cell Anatomy 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 238000010361 transduction Methods 0.000 description 23
- 230000026683 transduction Effects 0.000 description 23
- -1 isoleucinyl Chemical group 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 239000002245 particle Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 206010036790 Productive cough Diseases 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 210000003802 sputum Anatomy 0.000 description 19
- 208000024794 sputum Diseases 0.000 description 19
- 210000001808 exosome Anatomy 0.000 description 18
- 238000001476 gene delivery Methods 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 238000010172 mouse model Methods 0.000 description 17
- 238000004806 packaging method and process Methods 0.000 description 17
- 201000009961 allergic asthma Diseases 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 108010058846 Ovalbumin Proteins 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 229940092253 ovalbumin Drugs 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000009792 diffusion process Methods 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 230000003232 mucoadhesive effect Effects 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 8
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 8
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 8
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 230000012223 nuclear import Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000010085 airway hyperresponsiveness Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000004682 mucosal barrier function Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 102000006276 Syntenins Human genes 0.000 description 4
- 108010083130 Syntenins Proteins 0.000 description 4
- 108700005077 Viral Genes Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000013608 rAAV vector Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100023688 Eotaxin Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000011623 Obstructive Lung disease Diseases 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000781 anti-lymphocytic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960000289 fluticasone propionate Drugs 0.000 description 3
- 229960000908 idarubicin Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- 229960002329 methacholine Drugs 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004963 pathophysiological condition Effects 0.000 description 3
- 230000002206 pro-fibrotic effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 2
- 108010008629 CA-125 Antigen Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100034198 Otoferlin Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- YQCGOSZYHRVOFW-UHFFFAOYSA-N n-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1h-quinoline-3-carboxamide;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 YQCGOSZYHRVOFW-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960000653 valrubicin Drugs 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- XWMVMWTVLSLJGY-FAJPTIRJSA-N (2s,5r,6r)-6-[[(2r)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 XWMVMWTVLSLJGY-FAJPTIRJSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- PAZGBAOHGQRCBP-HGWHEPCSSA-N 1-hexadecanoyl-2-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-HGWHEPCSSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical class [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 description 1
- LUDXWSVNRXAANN-YZPBMOCRSA-N 4-amino-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide;(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3, Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 LUDXWSVNRXAANN-YZPBMOCRSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- RYTZFBLERBKCRL-XQAUMGQKSA-N CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC4=C(OC(F)(F)O4)C=C3)=C(F)C=C2N1C[C@@H](O)CO.CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC4=C(OC(F)(F)O4)C=C3)=C(F)C=C2N1C[C@@H](O)CO Chemical compound CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC4=C(OC(F)(F)O4)C=C3)=C(F)C=C2N1C[C@@H](O)CO.CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC4=C(OC(F)(F)O4)C=C3)=C(F)C=C2N1C[C@@H](O)CO RYTZFBLERBKCRL-XQAUMGQKSA-N 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102000007499 CD27 Ligand Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241001337814 Erysiphe glycines Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000009596 GDP-dissociation inhibitor activity proteins Human genes 0.000 description 1
- 108040001987 GDP-dissociation inhibitor activity proteins Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101001057744 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL9 Proteins 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000005705 Keratin-5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- MVRHVFSOIWFBTE-INIZCTEOSA-N N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide Chemical compound CN1N=C(C(=C1)S(=O)(=O)NC(=O)C=1C(=NC(=CC=1)N1N=C(C=C1)OCC(C(F)(F)F)(C)C)N1C(C[C@@H](C1)C)(C)C)C MVRHVFSOIWFBTE-INIZCTEOSA-N 0.000 description 1
- NETGOEWJJZQLCO-PKLMIRHRSA-N N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 NETGOEWJJZQLCO-PKLMIRHRSA-N 0.000 description 1
- 241000737052 Naso hexacanthus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108050006335 Otoferlin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 1
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 101150052608 SIVA1 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700013125 Zolgensma Proteins 0.000 description 1
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229940090167 advair Drugs 0.000 description 1
- 210000003539 airway basal cell Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940099032 alvesco Drugs 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 229940124323 amoebicide Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
- 101150035354 araA gene Proteins 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000000254 aspartoyl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229940080593 budesonide / formoterol Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940103439 dulera Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 description 1
- 229960003262 erdosteine Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940110893 erythromycin / sulfisoxazole Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- 229940127034 fluticasone furoate/vilanterol Drugs 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000003061 homeopathic agent Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960004508 ivacaftor Drugs 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 229940005405 kalydeco Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 description 1
- 229960000998 lumacaftor Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950009805 onasemnogene abeparvovec Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940080152 orkambi Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 229940072266 pulmicort Drugs 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229940014063 qvar Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000000822 sequential centrifugation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229940027257 timentin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 125000005454 tryptophanyl group Chemical group 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940005782 umeclidinium / vilanterol Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940072251 zithromax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Definitions
- Gene therapy using adeno-associated virus is an emerging treatment modality, including for treatment of single-gene defects.
- An example of one such disease is cystic fibrosis.
- Cystic fibrosis (CF) is a lethal, autosomal-recessive disorder that affects at least 30,000 people in the U.S. alone, and at least 70,000 people worldwide. The average survival age for CF patients is about 40 years.
- CF is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a channel that conducts chloride and bicarbonate ions across epithelial cell membranes. Impaired CFTR function leads to inflammation of the airways and progressive bronchiectasis. Because of the single-gene etiology of CF and the various CFTR mutations in the patient population, gene therapy potentially provides a universal cure for CF.
- CFTR cystic fibrosis transmembrane conductance regulator
- Adeno-associated virus a member of the human parvovirus family, is a non- pathogenic virus that depends on helper viruses for its replication. For this reason, recombinant AAV (rAAV) vectors are among the most frequently used in gene therapy pre-clinical studies and clinical trials.
- a method of delivery of nucleic acid e g. a transgene
- a mucus gel layer comprises administering a composition comprising a virus vector associated with an extracellular vesicle, wherein the virus vector comprises the nucleic acid.
- the virus vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
- the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, recombinant adeno-associated virus (rAAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
- AAV adeno-associated virus
- rAAV recombinant adeno-associated virus
- the virus vector comprises one or more mutations.
- the virus vector is an AAV vector.
- the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences.
- the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids.
- the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
- the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ, DJ/8, or mutants thereof.
- the AAV is AAV serotype 6 (AAV6).
- the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells.
- the composition is formulated for oral, intratracheal/oropharyngeal, cervicovaginal, ocular or nasal delivery.
- the composition is aerosolized for delivery to the airways by inhalation or the oropharyngeal cavity.
- the composition is formulated as a liquid or gel for delivery to mucosal surfaces.
- the composition is formulated as a suppository.
- a composition comprises a virus vector associated with an extracellular vesicle, wherein the virus vector comprises the nucleic acid.
- the virus vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
- the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, recombinant adeno-associated virus (rAAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
- AAV adeno-associated virus
- rAAV recombinant adeno-associated virus
- the virus vector is an AAV vector.
- the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences.
- the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids.
- the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
- the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8.
- the AAV is AAV serotype 6 (AAV6).
- the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
- the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence.
- the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moieties. In certain embodiments, the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells.
- a device for delivery of the compositions embodied herein, to an oral cavity, nose, pharynx or to a subject in need thereof.
- a method of treating a lung disease or disorder or an oropharyngeal disease comprises administering the compositions to a subject in need thereof.
- a lung disease or disorder comprises cystic fibrosis, chronic obstructive pulmonary disease (COPD), lung inflammation, asthma, lung cancer, bronchitis, infections, or allergies.
- COPD chronic obstructive pulmonary disease
- a method of modulating an immune response for treating an immune related disorder in a subject in need thereof comprises administering a composition comprising an extracellular vesicle and an adeno-associated virus (AAV) vector, the AAV vector comprising a nucleic acid sequence encoding an immunomodulatory molecule.
- the AAV comprises one or more amino acid mutations in the AAV capsid proteins.
- the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
- the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. In certain embodiments, the AAV is AAV serotype 6 (AAV6). In certain embodiments, the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
- the immunomodulatory molecule comprises thymulin, interferons, chemokines, cytokines, tumor necrosis factor alpha, modulators of checkpoint inhibitors or ligands of checkpoint inhibitors or combinations thereof.
- an immune related disease or disorder is asthma or allergies.
- the composition is formulated for oral, mucosal, cervicovaginal, ocular or nasal delivery.
- the composition is aerosolized for delivery to the airways by inhalation or the oropharyngeal cavity.
- the composition is formulated as a liquid or gel for delivery to mucosal surfaces.
- the composition is formulated as a suppository.
- an adeno-associated virus (AAV) vector comprises one or more amino acid mutations in the AAV capsid proteins.
- the one or more mutations are located at one or more conserved phosphorylation sites.
- the mutations comprise T492V, S663 V and the combination thereof.
- the AAV vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
- a composition comprises a modified extracellular vesicle and a virus vector comprising nucleic acid (e.g. a transgene).
- the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moi eties. In certain embodiments, the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells.
- the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, , herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
- AAV adeno-associated virus
- the virus vector is an AAV vector.
- the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences.
- the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids.
- the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
- the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
- the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, I I, 12, 13, 14, 15, 16, DJ or DJ/8.
- the AAV is AAV serotype 6 (AAV6).
- a nucleic acid-based vaccine comprises an extracellular vesicle and a virus vector wherein the virus vector comprises at least one nucleic acid molecule (e.g. transgene).
- the virus vector encodes an immunogenic/antigenic molecule.
- an adjuvant is provided.
- AAV refers to adeno-associated virus and may be used to refer to the naturally occurring wild-type virus itself or derivatives thereof. The term covers all subtypes, serotypes and pseudotypes, and both naturally occurring and recombinant forms, except where required otherwise.
- the AAV genome is built of single stranded DNA and comprises inverted terminal repeats (TTRs) at both ends of the DNA strand, and two open reading frames: rep and cap, encoding replication and capsid proteins, respectively.
- a foreign polynucleotide can replace the native rep and cap genes.
- AAVs can be made with a variety of different serotype capsids which have varying transduction profdes or as used herein, “tropism” for different tissue types.
- serotype refers to an AAV which is identified by and distinguished from other AAVs based on capsid protein reactivity with defined antisera, e.g., AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8.
- serotype AAV2 is used to refer to an AAV which contains capsid proteins encoded from the cap gene of AAV2 and a genome containing 5' and 3' ITR sequences from the same AAV2 serotype.
- Pseudotyped AAV refers to an AAV that contains capsid proteins from one serotype and a viral genome including 5'-3' ITRs of a second serotype.
- Pseudotyped rAAV would be expected to have cell surface binding properties of the capsid serotype and genetic properties consistent with the ITR serotype.
- Pseudotyped rAAV are produced using standard techniques described in the art.
- the AAVs comprise mutations in the capsid proteins. These mutations comprise one or more amino acid changes at one or multiple locations of the capsid proteins.
- administering is meant a method of giving a dosage of a composition described herein (e.g., an EV AAV and/or a pharmaceutical composition thereof) to a subject.
- a composition described herein e.g., an EV AAV and/or a pharmaceutical composition thereof
- the compositions utilized in the methods described herein can be administered by any suitable route, including, for example, by inhalation, nebulization, aerosolization, intranasally, intratracheally, intrabronchially, orally, parenterally (e.g., intravenously, subcutaneously, or intramuscularly), orally, nasally, rectally, topically, or buccally.
- a composition described herein is administered in aerosolized particles intratracheally and/or intrabronchially using an atomizer sprayer (e.g., with a MADgic® laryngo-tracheal mucosal atomization device).
- an atomizer sprayer e.g., with a MADgic® laryngo-tracheal mucosal atomization device.
- amino acid refers to naturally occurring and synthetic a, 0, y, and 8 amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine.
- proteins i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine.
- the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, 0-alanyl, 0- valinyl, 0-leucinyl, 0-isoleucinyl, 0-prolinyl, 0-phenylalaninyl, 0 -tryptophanyl, 0-methioninyl, 0- glycinyl, 0-serinyl, 0-threoninyl, 0-cysteinyl, 0-tyrosinyl,
- amino acid When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of a, 0, y, and 8 glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.
- a “bioactive” or “biologically active” molecule, substance or agent for use herein may comprise a drug active recognizable by one skilled in the art of medicinal chemistry.
- bioactive substances for use herein include, but are not limited to, antibodies and antibody cocktails, nucleic acids, proteins, oligonucleotides including messenger-RNA (mRNA), antidiabetic agents, glucose elevating agents, thyroid hormones, thyroid drugs, parathyroid drugs, vitamins, antihyperlipidemic agents, cardiac drugs, respiratory drugs, nasal decongestants, gastrointestinal drugs, amphetamines, anorexiants, antirheumatic agents, anti-gout agents, migraine drugs, sedatives, hypnotics, antianxiety drugs, anticonvulsants, antidepressants, antipsychotic agents, psychotherapeutic drugs, antimicrobials, antifungals, sulfonamides, antimalaria drugs, antituberculotic drugs, amebicides, antiviral agents, anti-in
- Biomolecule takes on its ordinary and broad meaning of naturally occurring, or synthetic macromolecules that are associated with a biochemical purpose in an organism.
- Biomolecules herein may be attached to the outer surface of extracellular vesicles or contained within the extracellular vesicles, and such biomolecules may include nucleotides, nucleosides, oligonucleotides, DNA, RNA, hybridization probes, amino acids, polypeptides, proteins and fragments thereof, and antibodies and fragments thereof.
- the terms “comprising,” “comprise” or “comprised,” and variations thereof, in reference to defined or described elements of an item, composition, apparatus, method, process, system, etc. are meant to be inclusive or open ended, permitting additional elements, thereby indicating that the defined or described item, composition, apparatus, method, process, system, etc. includes those specified elements--or, as appropriate, equivalents thereof— and that other elements can be included and still fall within the scope/definition of the defined item, composition, apparatus, method, process, system, etc.
- Enhancers refers to a DNA sequence that increases transcription of, for example, a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. A large number of enhancers from a variety of different sources are well known in the art and are available as or within cloned polynucleotides (from, e.g., depositories such as the ATCC as well as other commercial or individual sources). A number of polynucleotides comprising promoters (such as the commonly used CMV promoter) also comprise enhancer sequences. Enhancers can be located upstream, within, or downstream of coding sequences.
- extracellular vesicles refers to cellular-derived lipid encased particles secreted by cells of multicellular organisms into external environments to achieve cellular homeostasis and/or for cell-to-cell communication. Further, the term is meant to include the entire family of extracellular vesicles, including the recently discovered exomeres (extracellular nanoparticles having no apparent biological function), along with engineered or modified extracellular vesicles and mimetic nanovesicles. Natural EVs can be classified into three main types.
- apoptotic bodies 500-2000 nm in size
- microvesicles 50-1000 nm in size
- exosomes (30-200 nm in size).
- the types of vesicles are also differentiated by biogenesis, release pathways, content and function.
- Exosomes formed by an endosomal route are typically 30-150 nm in diameter.
- EVs for use herein include, but are not limited to, EVs obtained from plasma, urine, semen, saliva, bronchial fluid, cerebral spinal fluid, breast milk, serum, amniotic fluid, synovial fluid, vaginal secretions, tears, lymph, bile, and gastric acid.
- EV's are obtained from producer cells such as for example, stem cells, for example, from mesenchymal stem cells (MSCs).
- the EVs are obtained from mammalian producer cells and cell lines, e.g. HEK293 cells. Further, any method of isolation presently known or developed in the future may be used.
- a “gene therapy vector” is any molecule or composition that has the ability to carry a heterologous nucleic acid sequence into a suitable host cell where synthesis of the encoded protein takes place.
- a gene therapy vector is a nucleic acid molecule that has been engineered, using recombinant DNA techniques that are known in the art, to incorporate the heterologous nucleic acid sequence.
- the gene therapy vector is comprised of DNA.
- Examples of gene therapy vectors include viral vectors.
- gene therapy vectors that are not based on nucleic acids, such as liposomes, are also known and used in the art.
- the gene therapy vector can be integrated into the host cell genome or can be present in the host cell in the form of an episome.
- a gene therapy vector is a virus vector, such as, for example, AAV.
- a modified EV described herein refers to an alteration or engineering of an EV, e.g., exosome and/or its producer cell, such that the modified EV is different from a naturally occurring EV.
- a modified EV described herein comprises a membrane that differs in composition of a protein, a lipid, a small molecular, a carbohydrate, etc. compared to the membrane of a naturally occurring EV (e.g., membrane comprises higher density or number of natural exosome proteins and/or membrane comprises proteins that are not naturally found in exosomes (e g., antigen, adjuvant, and/or immune modulator).
- such modifications to the membrane changes the exterior surface of the EV (e.g., surface engineered EV).
- such modifications to the membrane changes the lumen of the EV.
- the term “modulate” includes to “increase” or “decrease” one or more quantifiable parameters, optionally by a defined and/or statistically significant amount.
- “increase” or “increasing,” “enhance” or “enhancing,” or “stimulate” or “stimulating,” refers generally to the ability of one or more vesicle-based compositions in accordance with the present disclosure to produce or cause a greater physiological response (i.e., downstream effects) in a cell or in a subject relative to the response caused by either no vesicle-based composition or a control compound.
- An “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more times (e.g., 500, 1000 times), including all integers and decimal points in between and above 1 (e.g., 1.5, 1.6, 1.7. 1.8), the amount produced by no vesicle-based composition (the absence of a bioactive agent) or a control compound.
- the term “reduce” or “inhibit” may relate generally to the ability of one or more vesicle-based compositions to “decrease” a relevant physiological or cellular response, such as a symptom of a disease or condition described herein, as measured according to routine techniques in the diagnostic art. Relevant physiological or cellular responses (in vivo or in vitro) will be apparent to persons skilled in the art, and may include reductions in the symptoms or pathology of a disease, illness or condition, such as cancer, inflammation or pain.
- a “decrease” in a response may be “statistically significant” as compared to the response produced by no vesicle-based composition or a control composition, and may include a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% decrease, including all integers in between.
- patient or “individual” or “subject” are used interchangeably herein, and refers to a mammalian subject to be treated, with human patients being preferred.
- methods of the disclosure find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
- the term “producer cell” refers to a cell used for generating an EV, e.g., exosome.
- a producer cell can be a cell cultured in vitro, or a cell in vivo.
- a producer cell includes, but not limited to, a cell known to be effective in generating EVs, e.g., HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN® neuronal precursor cells, CAP® amniocyte cells, adipose mesenchymal stem cells, RPTEC/TERT1 cells.
- the EVs useful in the present disclosure do not carry an antigen on MHC class I or class II molecule (i.e., antigen is not presented on MHC class I or class II molecule) exposed on the surface of the EV.
- recombinant adeno-associated virus or “rAAV vector” is meant a recombinantly-produced AAV or AAV particle that comprises a polynucleotide sequence not of AAV origin (e.g., a polynucleotide comprising a transgene, which may be operably linked to one or more enhancer and/or promoters) to be delivered into a cell, either in vivo, ex vivo, or in vitro.
- Non-naturally occurring (e.g., chimeric) capsids may be used in the rAAVs.
- a “therapeutic gene,” “prophylactic gene,” “target polynucleotide,” “transgene,” “gene of interest,” “exogenous gene” and the like generally refer to a gene or genes to be transferred using a vector.
- such genes are located within the rAAV vector (which vector is flanked by inverted terminal repeat (ITR) regions and thus can be replicated and encapsidated into rAAV particles).
- ITR inverted terminal repeat
- Target polynucleotides can be used in this disclosure to generate rAAV vectors for a number of different applications.
- polynucleotides include, but are not limited to: (i) polynucleotides encoding proteins useful in other forms of gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme; (ii) polynucleotides that are transcribed into anti-sense molecules; (iii) polynucleotides that are transcribed into decoys that bind transcription or translation factors; (iv) polynucleotides that encode cellular modulators such as cytokines; (v) polynucleotides that can make recipient cells susceptible to specific drugs, such as the herpes virus thymidine kinase gene; (vi) polynucleotides for cancer therapy, such as E1A tumor suppressor genes or p53 tumor suppressor genes for the treatment of various cancers; and (vii) polynucleotides for gene editing (e.g., CRISPR).
- CRISPR CRISPR
- transgene in one embodiment operably linked to a promoter, either its own or a heterologous promoter.
- a promoter either its own or a heterologous promoter.
- suitable promoters are known in the art, the choice of which depends on the desired level of expression of the target polynucleotide, whether one desires constitutive expression, inducible expression, cell-specific or tissue-specific expression, etc.
- the rAAV vector may also contain a selectable marker.
- Exemplary transgenes include, without limitation, cystic fibrosis transmembrane conductance regulator (CFTR) or derivatives thereof (e.g., a CFTRAR mini gene; see, e.g., Ostedgaard et al. Proc. Natl. Acad.
- a-antitrypsin P-globin, y-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, erythropoietin, alpha 1 -antitrypsin, surfactant protein SP-D, SP-A or SP-C, erythropoietin, growth factors, or a cytokine, e.g., IFN- alpha, IFNy, TNF, IL-1, IL-17, or IL-6, or a prophylactic protein that is an antigen such as viral, bacterial, tumor or fungal antigen, or a neutralizing antibody or a fragment thereof that targets an epitope of an antigen such as one from a human respiratory virus, e.g., influenza virus or RSV including but not limited to HBoV protein, influenza virus protein
- a subject in need thereof refers to any human or non-human animal requiring or desirous of a pharmacological change.
- a subject in need thereof may be a human patient clinically diagnosed with a disease, such as, for example, cystic fibrosis, and is thus in need of, or is at least desirous of receiving some sort of treatment.
- treatment of a subject (e.g., a mammal, such as a human) or a cell, is any type of intervention used in an attempt to alter the natural course of the subject or cell.
- Treatment includes, but is not limited to, administration of a vesicle-based composition in accordance with the present disclosure and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent.
- prophylactic treatments which can be directed to reducing the rate of progression of the disease or condition being treated, delaying the onset of that disease or condition, or reducing the severity of its onset.
- “Treatment” or “prophylaxis” does not necessarily indicate complete eradication, cure, or prevention of the disease or condition, or associated symptoms thereof.
- a therapeutically effective amount refers to a minimum dosage of a composition in accordance with the present disclosure that provides a desired effect. Therefore, a therapeutically effective amount varies by subject, dosage form/concentration, and results desired.
- a therapeutically effective amount of an inhalable liquid or aerosol to treat a CF or COPD might be on the order of micrograms or milligrams per day.
- a therapeutically effective amount of a nasal spray composition might be on the order of 3 sprays per day per nostril, with each spray about 0.1 mL.
- compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
- FIGS. 1A -ID demonstrate that EVAAV6 prepared in HEK293 cells and harvested from the cell culture supernatant exhibits internal and external association of AAV6 with EV.
- FIG. 1A Western blot analysis of AAV6, EV and EVAAV6. Bands for VP1, 2 and 3 of AAV6 capsid and for syntenin-1 (STI) and CD9 of EV are shown.
- FIG. IB ExoView analysis demonstrating that exosomes are a primary population similarly in EV and EVAAV6.
- FIG. 1C Hydrodynamic diameters of AAV6, EV and EVAAV6 measured by DLS.
- FIGS. 2A and 2B demonstrate that AAV6 exhibits significantly greater diffusion rates compared to AAV 1 in multiple independent sputum samples freshly expectorated by patients with MOLDs.
- FIGS. 3A and 3B demonstrate that EVAAV6 exhibits efficient penetration through human airway mucus and enhanced transduction of human bronchial epithelial (HBE) cell line.
- the upper and lower red dashed lines indicate theoretical MSD values of EV in PBS calculated by the Stoke-Einstein equation and MSD values of AAV6 previously measured in CF sputum, respectively, n.s.: no significance (two-tailed Student’ s t-test) (FIG. 3B) Luciferase activity measured in lysates of HBE cells treated with EV, EVAAV6 or EV+AAV6. n.s.: no significance, ****p ⁇ 0.0001 (one-way ANOVA).
- FIGS. 4A-4E demonstrate that EVAAV6 provides widespread and enhanced reporter transgene expression in mouse lungs following intratracheal administration.
- FIG. 4A Representative confocal images demonstrating reporter transgene expression throughout the whole left lung lobes of mice intratracheally treated with normal saline, AAV6, EVAAV6 or EV+AAV6. Green: YFP, Blue: nuclei. Image-based quantification of (FIG. 4B) coverage and (FIG. 4C) intensity of YFP transgene expression in whole lung lobes treated with normal saline, AAV6, EVAAV6 or EV+AAV6. (FIGS.
- FIGS. 5A-5C demonstrate that EVAAV6 provides enhanced reporter transgene expression in mucus-secreting ALI cultures of primary wild-type (WT) or cystic fibrosis (CF) HBE cells following apical administration.
- FIG. 5A Representative confocal images demonstrating reporter transgene expression in ALI cultures of primary WT or CF HBE cells treated with normal saline, AAV6, EVAAV6 or EV+AAV6. Green: YFP, Blue: nuclei.
- FTG. 6 is a graph demonstrating that capsid- optimized AAV6 mutants exhibit greater diffusion rates in multiple independent sputum samples compared to wild-type AAV6.
- Four tested mutant AAV6 exhibit greater diffusion rates, as indicated by averages of median MSD values, compared to those of wild-type AAV6 (red dashed line).
- FIGS. 7A-7C demonstrate that thymulin gene therapy with mucus-permeable synthetic nanoparticles provides comprehensive therapeutic benefits in the lungs of OVA-induced allergic asthma model.
- CTRL-SAL sensitized/challenged with saline and treated with saline (healthy control);
- OVA-SAL sensitized/challenged with OVA and treated with saline (disease/untreated control);
- OVA- THY sensitized/challenged with OVA and treated with thymulin gene therapy.
- FIG. 7B Levels of Th-2 cytokines and pro-fibrotic mediators in BALF.
- FIG. 7C Measurement of AHR (z.e., lung mechanics). *p ⁇ 0.05 compared to the CTRL-SAL group; p ⁇ 0.05 compared to the OVA-SAL group.
- FIG. 8 is a schematic representation of specific aims and respective experiments outlined in the examples section.
- FIGS. 9A and 9B demonstrate that EV and EVAAV 6 exhibit similar particle sizes as TM measured by Spectradyne nCSl particle size analyzer.
- the average particle diameters and concentrations, respectively, for (FIG. 9A) EV are 63.0 nm and 6.15 * 10 U /mL and for (FIG. 9B) EVAAV6 are 63.1 nm and 9.47 x lO ⁇ /mL.
- the measured concentrations have been used to match the EV concentrations in EV+AAV6 and EVAAV6 samples for in vitro and in vivo comparisons.
- FIG. 10 demonstrates that EVAAV6 with a higher EV-to-AAV6 ratio exhibit greater transgene expression on average following intratracheal administration, but the difference is not statistically significant.
- the EV-to-AAV6 ratios of EVAAV6 with low and high EV contents are 2.17 and 18.5, respectively, n.s. no significance (two-sided Student’s /-test).
- FIG. 11 shows luciferase activity measured in lysates of the whole mouse lungs treated with EVAAV6 or mAAV6 vectors piggybacked on EVs (EVmAAV6).
- N 6 animals per group, *p ⁇ 0.05 (two-sided Student’s /-test).
- the disclosure involves preparation and use of extracellular vesicle (EV)-associated adeno-associated virus (AAV) for inhaled lung-directed gene therapy applications.
- EV-associated AAV serotype 6 (EVAAV6), produced during AAV preparation in HEK293 cells, provides markedly and significantly greater transgene expression in human primary airway cells and in mouse lungs (following inhaled administration) compared to AAV6 which has been shown greater performances compared to other widely used AAV serotypes (e.g., AAV1, 2 and 5) in transducing lung airway cells.
- This enhancement is attributed to the ability of EV to promote mucus penetration and cellular transduction of AAV6.
- the approach is likely applicable/beneficial to other AAV serotypes or virus vectors incapable of penetrating the airway mucus barrier, thereby broadening the AAV serotypes and other virus vectors that can be utilized for inhaled gene therapy applications.
- Gene delivery vectors within the scope of the disclosure include, but are not limited to, isolated nucleic acid, e.g., plasmid-based vectors which may be extrachromosomally maintained, and viral vectors, e.g., recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus, including viral and non-viral vectors which are present in liposomes, e.g., neutral or cationic liposomes, such as DOSPA/DOPE, DOGS/DOPE or DMRIE/DOPE liposomes, and/or associated with ether molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA/DOPE) complexes.
- viral vectors e.g., recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus, including viral
- Gene delivery vectors may be administered via any route including, but not limited to, intracranial, intrathecal, intramuscular, buccal, rectal, intravenous or intracoronary administration, and transfer to cells may be enhanced using electroporation and/or iontophoresis, and/or scaffolding such as extracellular matrix or hydrogels, e.g., a hydrogel patch.
- the gene therapy vector is a viral vector.
- Suitable viral vectors include, for example, retroviral vectors, lentivirus vectors, herpes simplex virus (HSV)-based vectors, parvovirus-based vectors, e.g., adeno-associated virus (AAV)-based vectors, AAV- adenoviral chimeric vectors, and adenovirus-based vectors.
- HSV herpes simplex virus
- AAV adeno-associated virus
- AAV- adenoviral chimeric vectors e.g., adeno-associated virus (AAV)-based vectors
- AAV- adenoviral chimeric vectors e.g., AAV- adenoviral chimeric vectors
- adenovirus-based vectors e.g., adeno-associated virus (AAV)-based vectors.
- AAV adeno-associated virus
- Retroviral Vectors exhibit several distinctive features including their ability to stably and precisely integrate into the host genome providing long-term transgene expression. These vectors can be manipulated ex vivo to eliminate infectious gene particles to minimize the risk of systemic infection and patient-to-pati ent transmission. Pseudotyped retroviral vectors can alter host cell tropism.
- Lentiviruses are derived from a family of retroviruses that Include human Immunodeficiency virus and feline immunodeficiency virus. However, unlike retroviruses that only infect dividing cells, lentiviruses can infect both dividing and nondividing cells. For instance, lentiviral vectors based on human immunodeficiency virus genome are capable of efficient transduction of cardiac myocytes in vivo. Although lentiviruses have specific tropisms, pseudotyping the viral envelope with vesicular stomatitis virus yields virus with a broader range (Schnepp et al., Meth. Mol. Med., 69:427 (2002)).
- Adenoviral Vectors may be rendered replication-incompetent by deleting the early (E1A and E1B) genes responsible for viral gene expression from the genome and are stably maintained into the host cells m an extrachromosomal form. These vectors have the ability to transfect both replicating and nonreplicating cells. Adenoviral vectors have been shown to result in transient expression of therapeutic genes in vivo, peaking at 7 days and lasting approximately 4 weeks. The duration of nucleic acid (transgene) expression may be improved in systems utilizing neural specific promoters. In addition, adenoviral vectors can be produced at very high titers, allowing efficient gene therapy with small volumes of virus.
- Adeno-Associated Virus Vectors Recombinant adeno-associated viruses (rAAV) are derived from nonpathogenic parvoviruses, evoke essentially no cellular immune response, and produce transgene expression lasting months in most systems. Moreover, like adenovirus, adeno- associated virus vectors also have the capability to infect replicating and non replicating cells and are believed to be nonpathogenic to humans.
- rAAV Recombinant adeno-associated viruses
- AAV vector which comprises a nucleic acid sequence a therapeutic molecule.
- Adeno-associated virus is a member of the Parvoviridae family and comprises a linear, single- stranded DNA genome of less than about 5,000 nucleotides.
- AAV requires co-infection with a helper virus (i.e., an adenovirus or a herpes virus), or expression of helper genes, for efficient replication.
- helper virus i.e., an adenovirus or a herpes virus
- AAV vectors used for administration of therapeutic nucleic acids typically have approximately 96% of the parental genome deleted, such that only the terminal repeats (ITRs), which contain recognition signals for DNA replication and packaging, remain.
- AAV vector comprising AAV ITRs into a specific region of the cellular genome, if desired (see, e.g., U.S. Pat. Nos. 6,342,390 and 6,821,511).
- Host cells comprising an integrated AAV genome show no change in cell growth or morphology (see, for example, U.S. Pat. No. 4,797,368).
- the AAV ITRs flank the unique coding nucleotide sequences for the non-structural replication (Rep) proteins and the structural capsid (Cap) proteins (also known as virion proteins (VPs)).
- the terminal 145 nucleotides are self-complementary and are organized so that an energetically stable intramolecular duplex forming a T-shaped hairpin may be formed. These hairpin structures function as an origin for viral DNA replication by serving as primers for the cellular DNA polymerase complex.
- the Rep genes encode the Rep proteins Rep78. Rep68, Rep62, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, and Rep 52 and Rep40 are transcribed from the pl9 promoter.
- the Rep78 and Rep68 proteins are multifunctional DNA binding proteins that perform helicase and nickase functions during productive replication to allow for the resolution of AAV termini (see. e.g., Im et al., Cell. 51 :447 (1990)). These proteins also regulate transcription from endogenous AAV promoters and promoters within helper viruses (see, e.g., Pereira et al., J. Virol., 71 : 1079 (1997). The other Rep proteins modify the function of Rep78 and Rep68.
- the cap genes encode the capsid proteins VP1, VP2, and VP3. The cap genes are transcribed from the p40 promoter.
- the AAV vector may be generated using any AAV serotype known in the art.
- AAV serotypes and over 100 AAV variants have been isolated from adenovirus stocks or from human or nonhuman primate tissues (reviewed in. e.g., Wu et al., Molecular Therapy. 14(3): 316 (2006)).
- the AAV serotypes have genomic sequences of significant homology at the nucleic acid sequence and amino acid sequence levels, such that different serotypes have an identical set of genetic functions, produce virions which are essentially physically and functionally equivalent and replicate and assemble by practically identical mechanisms.
- AAV serotypes 1-5 and 7-9 are defined as “true” serotypes, in that they do not efficiently cross-read with neutralizing sera specific for all other existing and characterized serotypes.
- AAV serotypes 6, 10 (also referred to as RhlO), and 11 are considered “variant” serotypes as they do not adhere to the definition of a “true” serotype.
- AAV serotype 2 (AAV2) has been used extensively for gene therapy due to its lack of pathogenicity, wide range of infectivity, and ability to establish longterm transgene expression (see, e g., Carter, Hum. Gone Ther., 15:541 (2005).
- Genome sequences of various AAV serotypes and comparisons thereof are disclosed in, for example, GenBank Accession numbers U89790, JOI 901, AF043303, and AF085716: Chiorini etal., J. Virol., 71:6823 (1997); Srivastava et al., J. Virol., 45:565 (1983); Chiorini et aL, J. Virol. 23: 1309 (1999); Rutledge et al., J. Virol., 22-309 (1998); and Wu etal., J. Virol., 24:8635 (2000)).
- AAV rep and ITR sequences are particularly conserved across most AAV serotypes.
- the Rep78 proteins of AAV2, AAV3 A, AAV3B, AAV4, and AAV6 are reportedly about 89-93% identical (see Bantel-Schaal et aL, J. Virol., 73(2):939 (1999)). It has been reported that AAV serotypes 2, 3 A, 3B. and 6 share about 82% total nucleotide sequence identity at the genome level (Bantel-Schaal etal., supra).
- rep sequences and ITRs of many AAV serotypes are known to efficiently cross-complement (e.g., functionally substitute) corresponding sequences from other serotypes during production of AAV particles in eukaryotic cells, such as mammalian cells or insect cells.
- the cap proteins which determine the cellular tropicity of the AAV particle, and related cap protein-encoding sequences, are significantly less conserved than Rep genes across different AAV serotypes.
- the AAV vector can comprise a mixture of serotypes and thereby be a 'chimeric' or 'pseudotyped' AAV vector.
- a chimeric AAV vector typically comprises AAV capsid proteins derived from two or more (e.g., 2, 3, 4, etc.) different AAV serotypes.
- a pseudotyped AAV vector comprises one or more ITRs of one AAV serotype packaged into a capsid of another AAV serotype.
- Chimeric and pseudotyped AAV vectors are further described in, for example, U.S. Pat. No. 6,723,551: Flotte, Mol. Ther., 12(1): 1 (2006); Gao et al., J. Virol., 78:6381 (2004); Gao et al., Proc. Natl. Acad. Sci. USA, 23: 11854 (2002); De et al., Mol. Ther., 12:67 (2006); and Gao et al., Mol. Ther., 12:77 (2006).
- the AAV comprises one or more mutations in the capsid protein at one or more locations in the capsid protein.
- the AAV vector is generated using an AAV that infects humans (e.g., AAV6).
- the AAV vector is generated using an AAV that infects non-human primates, such as, for example, the great apes (e.g., chimpanzees). Old World monkeys (e.g., macaques) and New World monkeys (e.g., marmosets).
- the AAV vector is generated using an AAV that infects a non-human primate pseudotyped with an AAV that infects humans. Examples of such pseudotyped AAV vectors are disclosed in, e.g., Cearley et al., Molecular Therapy. 12:528 (2006).
- the AAV vector may comprise expression control sequences, such as promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), and the like, that provide for the expression of the nucleic acid sequence in a host cell.
- expression control sequences such as promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), and the like.
- Exemplary expression control sequences are known in the art and described in, for example, Goeddel, Gene Expression Technology. Methods in Enzymology. Vol. 185. Academic Press. San Diego. Calif. (1990).
- promoters including constitutive, inducible, and repressive promoters, from a variety of different sources are well known in the art.
- Representative sources of promoters include for example, virus, mammal, insect, plant, yeast, and bacteria, and suitable promoters from these sources are readily available, or can be made synthetically, based on sequences publicly available, for example, from depositories such as the ATCC as well as other commercial or individual sources.
- Promoters can be unidirectional (i.e., initiate transcription in one direction) or bi-directional (i.e., initiate transcription in either a 3' or 5' direction).
- Non limiting examples of promoters include, for example, the T7 bacterial expression system, pBAD (araA) bacterial expression system, the cytomegalovirus (CMV) promoter, the SV40 promoter, and the RSV promoter.
- Inducible promoters include, for example, the Tet system (U.S. Pat. Nos. 5,464,758 and 5,814.618), the Ecdysone inducible system (No et al., Proc. Natl. Acad.
- AAV vectors are produced using well characterized plasmids.
- human embryonic kidney 293T cells are transfected with one of the transgene specific plasmids and another plasmid containing the adenovirus helper and AAV rep and cap genes. After 72 hours, the cells are harvested, and the vector is released from the cells by five freeze/thaw cycles. Subsequent centrifugation and berizonase treatment remove cellular debris and unencap si dated DNA. lodixanol gradients and ion exchange columns may be used to further purify each AAV vector. Next the purified vector is concentrated by a size exclusion centrifuge spin column to the required concentration.
- the buffer is exchanged to create the final vector products formulated (for example) in 1. times, phosphate buffered saline.
- the viral titers may be measured by TaqManTM real-time PCR and the viral purity may be assessed by SDS-PAGE.
- the present disclosure provides AAV capsid proteins comprising at least one mutation (i.e., a modification, which can be a substitution or an insertion or a deletion) in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein.
- the mutated AAV capsid proteins, and the nucleic acids encoding them are not found in nature (i.e., are non-natural) and have neither the sequence of the wild-type sequences found in nature nor the function of those sequences.
- the modifications at the one or more amino acid positions described can confer one or more desirable properties to virus vectors comprising the modified AAV capsid protein including without limitation: (i) enhancing intracellular trafficking to a target cell nucleus; (ii) enhancing the interactions with target cells; (iii) enhancing penetration through the mucus gel layer.
- the modified AAV capsid protein of the disclosure comprises one or more mutations (i.e., modifications) in the amino acid sequence of the native, e.g., AAV6 capsid protein or the corresponding amino acid residue(s) of a capsid protein from another AAV serotype, including but not limited to AAV2, AAV3, AAV6, AAV7, AAV8, AAV9, AAV10, etc.
- AAV2, AAV3, AAV6, AAV7, AAV8, AAV9, AAV10 etc.
- the amino acid positions in other AAV serotypes or modified AAV capsids that “correspond to” these positions in the native AAV6 capsid protein will be apparent to those skilled in the art and can be readily determined using sequence alignment techniques and/or crystal structure analysis (Padron et al. (2005) J Virol. 79:5047-58).
- the corresponding modification will be an insertion and/or a substitution, depending on whether the corresponding amino acid positions are partially or completely present in the virus or, alternatively, are completely absent.
- the specific amino acid position(s) may be different than the position in AAV6.
- a “mutation” or “modification” in an amino acid sequence includes substitutions, insertions and/or deletions, each of which can involve one, two, three, four, five, six, seven, eight, nine, ten or more amino acids.
- the modification is a substitution.
- the modification is an insertion (e.g., of a single amino acid residue between two amino acid residues in an amino acid sequence).
- the modification is a deletion.
- the modification is a modified amino acid.
- substitutions and insertions described in the AAV capsid proteins of this disclosure can include substitutions and/or insertions with conservative amino acid residues.
- conservative substitutions are well known in the art and include, e.g., nonpolar amino acids Gly, Ala, Vai, Leu, He, Met, Phe, Trp and Pro can be substituted for one another; polar amino acids Ser, Thr, Cys, Tyr, Asn and Gin can be substituted for one another; negatively charged amino acids Asp and Glu can be substituted for one another; and positively charged amino acids Lys, Arg and His can be substituted for one another, in any combination.
- the present disclosure also provides an AAV capsid comprising one or more mutations as well as a virus vector comprising one or more mutations.
- recombinant AAV genomes comprise a transgene and one or more AAV ITRs flanking a nucleic acid molecule.
- AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic el al., Molecular Therapy, 22(11): 1900-1909 (2014).
- rAAV particles in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided, are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from the rAAV genome, and helper virus functions.
- the AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome TTRs, including, but not limited to, AAV serotypes 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, DJ or DJ/8. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.
- Methods of generating a packaging cell comprise creating a cell line that stably expresses all the necessary components for AAV particle production.
- a plasmid or multiple plasmids
- a plasmid comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell.
- AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6.
- the packaging cell line is then infected with a helper virus such as adenovirus.
- a helper virus such as adenovirus.
- packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line).
- packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WL38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
- extracellular vesicles for delivery of virus vectors, e.g. AAV.
- exemplary extracellular vesicles may include but are not limited to exosomes.
- extracellular vesicles should be interpreted to include all nanometer-scale lipid vesicles that are secreted by cells such as secreted vesicles formed from lysosomes.
- EVs are cell-derived vesicles with a closed double-layer membrane structure. According to their size and density, EVs mainly include exosomes (30-150 nm), micro vesicles (MVs) (100- 1000 nm), and apoptotic bodies or cancer related oncosomes (1-10 pm). EVs are able to carry various molecules, such as proteins, lipids andRNAs on their surface as well as within their lumen. The EV and exosomal surface proteins can mediate organ-specific homing of circulating EVs.
- EVs are produced by many different types of cells including immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells. EVs are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells, and tumor cells. EVs for use in the disclosed compositions and methods can be derived from any suitable cells, including the cells identified above. EVs have also been isolated from physiological fluids, such as plasma, urine, amniotic fluid and malignant effusions.
- immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells.
- DCs dendritic cells
- EVs are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells, and tumor cells.
- EVs for use in the disclosed compositions and methods can be derived from any suitable cells, including the cells identified above. EVs have also been isolated from physiological
- Non-limiting examples of suitable EVs producing cells for mass production include dendritic cells (e.g., immature dendritic cell), Human Embryonic Kidney 293 (HEK) cells, 293T cells, Chinese hamster ovary (CHO) cells, and human ESC-derived mesenchymal stem cells.
- dendritic cells e.g., immature dendritic cell
- HEK Human Embryonic Kidney 293
- 293T cells e.g., 293T cells
- CHO Chinese hamster ovary
- human ESC-derived mesenchymal stem cells e.g., ESC-derived mesenchymal stem cells.
- Other cell sources are useful for providing exosomes useful for bioactive loading in accordance with the present disclosure. These include, stem cells, cancer cell, myeloid cells, brain cells, bioreactors, and exosomes from plant, fungal or bacterial cells. Also, depending on the application, either for pain management, inflammation, neurode
- EVs can also be obtained from any autologous patient-derived, heterologous haplotype- matched or heterologous stem cells so to reduce or avoid the generation of an immune response in a patient to whom the EVs are delivered. Any EV-producing cell can be used for this purpose.
- the extracellular vesicle is an EV mimetic-nanovesicles (M- NVs).
- M-NVs are a type of artificial EVs which can be generated from all cell types with comparable characteristics as EVs for alternative therapeutic modality.
- EVs produced from cells can be collected from the culture medium by any suitable method.
- a preparation of EVs can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods.
- EVs can be prepared by differential centrifugation, that is low speed ( ⁇ 20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet EVs, size filtration with appropriate filters (for example, 0.22 pm filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
- AAV may be administered to a subject by any suitable means.
- Administration may be topical (including ophthalmic and to mucus membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Vesicle-based compositions for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutically acceptable carriers, aqueous, powder or oily bases, thickeners and the like, may be necessary or desirable.
- delivery is via the intranasal or oral route. A physician will be able to determine the required route of administration for each particular patient.
- the EVAAVs are delivered as a composition.
- the composition may be formulated for inhalation, by nebulization, or by aerosolization, or is intranasal, intratracheal, intrabronchial, oral, intravenous, subcutaneous, and/or intramuscular administration.
- the compositions may be administered via parenteral intracerebral, intravascular (including intravenous), subcutaneous, or transdermal administration.
- Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
- the EVs may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharmaceutically acceptable carriers or excipients and the like in addition to the EVs.
- the EVs are loaded with a desired bioactive substance, e.g., a therapeutic, medicinal, homeopathic agent, and the resulting loaded EVAAVs are targeted to the desired location in the subject by composition dosage form and administration route where the vesicles can release their contents to the target of interest.
- a desired bioactive substance e.g., a therapeutic, medicinal, homeopathic agent
- the bioactive molecule is a toxin, toxoid, or a non-toxic mutant of a toxin.
- the biologically active molecule is an activator for a positive costimulatory molecule or an activator for a binding partner of a positive co- stimulatory molecule.
- the positive co- stimulatory molecule is a TNF receptor superfamily member.
- the TNF receptor superfamily member is selected from the group consisting of CD120a, CD120b, GDI 8, 0X40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, RANK, OCIF, TWEAK receptor, TACI, BAFF receptor, AT AR, CD271, CD269, AITR, TROY, CD358, TRAMP, and XEDAR.
- the activator for a positive co-stimulatory molecule is a TNF superfamily member.
- the TNF superfamily member is selected from the group consisting of: TNFa, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR ligand, and EDA-2.
- the positive co-stimulatory molecule is a CD28-superfamily co-stimulatory molecule.
- the CD28-superfamily co-stimulatory molecule is ICOS or CD28.
- the activator for a positive co-stimulatory molecule is ICOSL, CD80, or CD86.
- the cytokine is selected from the group consisting of IL-2, IL-7, IL-10, IL-12, and IL-15.
- the protein comprises a T-cell receptor (TCR), a T-cell co-receptor, a major histocompatibility complex (MHC), a human leukocyte antigen (HLA), or a derivative thereof.
- TCR T-cell receptor
- MHC major histocompatibility complex
- HLA human leukocyte antigen
- the protein comprises a tumor antigen.
- the tumor antigen is selected from the group consisting of: alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUCl, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, Mesothelin, VEGFR, alphafolate receptor, CE7R, IL-3, Cancer-testis antigen, MART-1 gplOO, and TNF-related apoptosisinducing ligand.
- AFP alpha-fetoprotein
- CEA carcinoembryonic antigen
- ETA
- Modified EVs In certain embodiments, the EVs are modified EVs.
- a desired modification of an EV can be introduced by transducing a eukaryotic cell line (e.g. mammalian cell line), e.g., HEK293 cells with a desired polynucleotide.
- a desired polynucleotide can encode a targeting or tropism moiety which specifically targets the EVAAVs to a desired organ, tissue or cell.
- Non-limiting examples of tropism moieties that can be used with the present disclosure include those that can bind to a marker expressed specifically on an alveolar epithelial cell (AEC), lung fibroblasts, pulmonary artery endothelial cells (PAEC), pulmonary artery smooth muscle cells (PASMC) or respiratory epithelial cells.
- AEC alveolar epithelial cell
- PAEC pulmonary artery endothelial cells
- PASMC pulmonary artery smooth muscle cells
- respiratory epithelial cells Unless indicated otherwise, the term “targeting moiety,” as used herein, encompasses tropism moieties.
- the targeting moiety can be a biological molecule, such as a protein, a peptide, a lipid, or a carbohydrate, or a synthetic molecule.
- the targeting moiety can be an affinity ligand (e.g., antibody, VHH domain, phage display peptide, fibronectin domain, camelid, aptamer, VNAR), a synthetic polymer (e.g., PEG), a natural ligand/molecule (e.g., CD40L, albumin, CD47, CD24, CD55, CD59), a recombinant protein, but not limited thereto.
- an affinity ligand e.g., antibody, VHH domain, phage display peptide, fibronectin domain, camelid, aptamer, VNAR
- a synthetic polymer e.g., PEG
- a natural ligand/molecule e.g., CD40L, albumin, CD47, CD24, CD55, CD59
- a recombinant protein but not limited thereto.
- the targeting moiety is displayed on the surface of EVs (e.g., exosomes).
- the targeting moiety can be displayed on the EV surface by being fused to a scaffold protein (e.g., as a genetically encoded fusion molecule).
- the targeting moiety can be displayed on the EV surface by chemical reaction attaching targeting moiety to an EV surface molecule.
- a non-limiting example is PEGylation.
- EVs disclosed can further comprise a targeting moiety, in addition to an antigen, adjuvant, or immune modulator.
- an engineered extracellular vesicle comprises an extracellular vesicle isolated from a biological cell with at least one lipid incorporated into the membrane thereof.
- the lipid may be a synthetic lipid or an exogenous lipid/non-native lipid or a combination thereof.
- a synthetic lipid comprises l-palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine (POPC), l-palmitoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP) or a combination thereof.
- the biological cell may be associated with a pathophysiological condition.
- the pathophysiological condition may be a cancer.
- the pathophysiological condition is cystic fibrosis, COPD, asthma, tuberculosis, or an infection, such as by a virus, bacteria or parasite.
- the biological cell may be a primary mesenchymal stem cell, an embryonic kidney cell, an embryonic fibroblast cell, an alveolar basal epithelial cell, or a monocytic cell or an immortalized cell-line thereof.
- a method for preparing an engineered extracellular vesicle comprising the steps of culturing the biological cell in vitro in a culture medium; isolating the extracellular vesicles from the biological cells; and extruding the isolated extracellular vesicles with the at least one lipid to form the engineered extracellular vesicle.
- the extracellular vesicle delivery vehicle can comprise at least one lipid hybridized with a membrane of the extracellular vesicle; a nucleic acid loaded within a core of the extracellular vesicle; and a therapeutic drug complexed with the extracellular vesicle either within or on the surface.
- the lipid may be a synthetic lipid comprising 1 -palmitoyl -2-oleoyl-sn-glycero-3- phosphocholine (POPC), l-palmitoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP) or a combination thereof.
- the nucleic acid may be a synthetic DNA, a naturally occurring DNA, a synthetic RNA, or a naturally occurring RNA, or fragments thereof.
- the synthetic RNA or naturally occurring RNA may be a small-interfering RNA (siRNA) or a microRNA (miRNA).
- Methods for preparing engineered extracellular vesicles include isolating extracellular vesicles from a biological cell of interest.
- the membranes of the extracellular vesicles are hybridized or modified with at least one synthetic lipid, for example, a synthetic hydrated lipid, such as by extrusion, to produce a modified or hybrid engineered extracellular vesicles.
- Suitable synthetic lipids are, but not limited to, 1 -Palmitoyl -2-oleoyl-sn-glycero-3 - phosphocholine (POPC), 1-Palm itoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP).
- POPC 1 -Palmitoyl -2-oleoyl-sn-glycero-3 - phosphocholine
- POPG 1-Palm itoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol
- DPPC dipalmitoylphosphatidylcholine
- DOTAP l,2-dipalmitoyl-sn-glycero-3-phosphocholine
- compositions described herein may be used in vivo as well as ex vivo.
- In vivo gene therapy comprises administering the vectors of this disclosure directly to a subject.
- Pharmaceutical compositions can be supplied as liquid solutions or suspensions, as emulsions, or as solid forms suitable for dissolution or suspension in liquid prior to use.
- one exemplary mode of administration is by aerosol, using a composition that provides either a solid or liquid aerosol when used with an appropriate aerosolubilizer device.
- Another some mode of administration into the respiratory tract is using a flexible fiberoptic bronchoscope to instill the vectors.
- the viral vectors are in a pharmaceutically suitable pyrogen-free buffer such as Ringer's balanced salt solution (pH 7.4).
- pharmaceutical compositions may optionally be supplied in unit dosage form suitable for administration of a precise amount.
- a composition described herein e g., EV-rAAVs, pharmaceutical compositions
- a composition described herein is administered in aerosolized particles intratracheally and/or intrabronchially using an atomizer sprayer (e.g., with a MADgic® laryngo-tracheal mucosal atomization device).
- the pharmaceutical composition is administered parentally.
- the pharmaceutical composition is administered systemically.
- Vectors can also be introduced by way of bioprostheses, including, by way of illustration, vascular grafts (PTFE and dacron), heart valves, intravascular stents, intravascular paving as well as other non-vascular prostheses. General techniques regarding delivery, frequency, composition and dosage ranges of vector solutions are within the skill of the art.
- compositions described herein are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the composition may take the form of a dry powder, for example, a powder mix of the agent and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form in, for example, capsules or cartridges, or, e.g., gelatine or blister packs from which the powder may be administered with the aid of an inhalator, insufflator or a metered-dose inhaler.
- the agent may be administered via nose drops, a liquid spray, such as via a plastic bottle atomizer or metered-dose inhaler.
- a liquid spray such as via a plastic bottle atomizer or metered-dose inhaler.
- atomizers are the Mistometer (Wintrop) and the Medihaler (Riker).
- Administration of the compositions described herein may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
- the EV-rAAVs or pharmaceutical compositions described herein can be administered once, or multiple times, at the same or at different sites.
- the administration of the agents of the disclosure may be essentially continuous over a preselected period of time or may be in a series of spaced doses.
- compositions described herein can be administered in combination with one or more additional therapeutic agent.
- additional therapeutic agent(s) may be used, including standard of care therapies, e g. for CF.
- the one or more additional therapeutic agents includes an antibiotic (e.g., azithromycin (ZITHROMAX®), amoxicillin and clavulanic acid (AUGMENTIN®), cioxacillin and diclocacillin, ticarcillin and clavulanic acid (TIMENTIN®), cephalexin, cefdinir, cefprozil, cefaclor; sulfamethoxazole and trimethoprim (BACTRIM®), erythromycin/sulfisoxazole, erythromycin, clarithromycin, tetracycline, doxycycline, minocycline, tigecycline, vancomycin, imipenem, meripenem, Colistimethate/COLISTIN®, linezolid, ciprofloxacin, levofloxacin, or a combination thereof), a mucus thinner (e.g., hypertonic saline or domase alfa (
- any one the compositions described herein may be administered in combination with one or more immunosuppressive agents.
- immunosuppressive agents include corticosteroids (e.g., an inhaled corticosteroid (e.g., beclomethasone (QVAR®), budesonide (PULMICORT®), budesonide/formoterol (SYMBICORT®), ciclesonide (ALVESCO®), fluticasone (FLOVENT HFA®), fluticasone propionate (FLOVENT DISKUS®), fluticasone furoate (ARNUITY ELLIPTA®), fluticasone propionate/salmeterol (ADVAIR®), fluticasone furoate/umeclidinium/vilanterol (TRELEGY ELLIPTA®), mometasone furoate (ASMANEX®), or mometasone/formoterol
- corticosteroids e.g., an inhaled corticosteroid (
- compositions described herein may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers.
- pharmaceutically acceptable carriers As noted above, the relative proportions of active ingredient and carrier are determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
- the dosage of the present compositions will vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. It is desirable that the lowest effective concentration of virus be utilized in order to reduce the risk of undesirable effects, such as toxicity.
- Augmenters The compositions can be used in combination with augmenters of AAV transduction to achieve significant increases in transduction and/or expression of nucleic acid molecules (transgenes). Any suitable augmenter can be used.
- augmenters Any suitable augmenter can be used.
- U.S. Pat. No. 7,749,491 which is incorporated by reference herein in its entirety, describes suitable augmenters.
- the augmenter may be a proteasome modulating agent.
- the proteasome modulating agent may be an anthracycline (e.g., doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, or mitoxantrone), a proteasome inhibitor (e.g., bortezomib, carfilzomib, and ixazomib), a tripeptidyl aldehyde (e.g., N-acetyl-1 -leucyl- 1 -leucyl- 1 -norleucine (LLnL)), or a combination thereof.
- the augmenter is doxorubicin.
- the augmenter is idarubicin.
- compositions e.g., EV AAV and the augmented s
- a cell e.g., EV AAV and the augmented s
- compositions e.g., pharmaceutical compositions
- the contacting or the administration of the compositions and the augmenter(s) may be sequential or simultaneous.
- Example 1 Extracellular vesicle-associated, genetically engineered adeno-associated virus 6 as a gene delivery platform for inhaled gene therapy.
- Extracellular vesicles are naturally occurring molecular vesicles produced and released from plant and animal cells and play important roles in intercellular communication (1). Due to its ability to shuttle various cargoes, including metabolites, proteins, and nucleic acids, through extracellular milieus and between cells, EV has been widely investigated as a vehicle for enhancing therapeutic delivery (2, 3).
- EVs are capable of efficiently penetrating unperturbed airway mucus samples collected from patients with muco-obstructive lung diseases (MOLDs), leading to the hypothesis that EV would enhance the inhaled gene transfer efficacy of AAV if the AAV externally associated with the EV does not compromise the mucus-penetrating property of EVs.
- MOLDs muco-obstructive lung diseases
- EV-associated AAV6 (EVAAV6) provided significantly greater reporter transgene expression in mucus-covered airliquid interface (ALI) cultures of primary human airway epithelial (HAE) cells and in mouse lungs (following intratracheal administration) compared to standard (i.e., EV-free) AAV6.
- ALI mucus-covered airliquid interface
- HAE primary human airway epithelial
- EV-free EV-free
- Non-mucoadhesive AA V6 as a background serotype for engineering novel EVmAA V6.
- AAV is a non-pathogenic parvovirus that has been most widely investigated as a virus-based delivery platform for safe, effective and long-lasting gene therapy of numerous diseases affecting different organs. Promising outcomes in preclinical studies have led to numerous human clinical trials (16- 19), and FDA has recently approved AAV-based gene therapy medicines for the treatment of a rare eye disease and spinal muscular atrophy (20-22).
- Airway mucus is essentially a “sticky net”, primarily composed of a dense mesh of mucin fibers containing negatively charged glycosylated domains flanked by periodic hydrophobic regions (39), which forms an adhesive and steric barrier to inhaled foreign matters.
- the barrier properties are further reinforced in the lungs of patients with MOLDs characterized by chronic inflammation and mucus accumulation (23, 29, 37, 40, 41). Inhaled gene vectors trapped in the airway mucus cannot efficiently traverse and distribute throughout the lung airways and are rapidly removed from the lung by physiological mucus clearance mechanisms prior to reaching the underlying airway cells (29, 37).
- sputum samples serve as a reliably representative ex vivo model of pathologically thickened human airway mucus barrier, which is a common feature of lung airways of MOLDs.
- the airway mucus is now universally appreciated as one of the key obstacles that must be overcome by inhaled gene vectors to achieve clinically relevant inhaled gene delivery efficacy (23, 29, 37, 38).
- AAV6 unlike other serotypes, possesses unique ability to avoid mucoadhesion and thus efficiently percolate the human airway mucus (FTGS. 2A, 2B) It was found that AAV6 exhibited significantly and uniformly enhanced diffusion rates in sputum samples collected from multiple independent patients compared to AAV1, a serotype shown to outperform the clinically tested AAV2 (45, 46) (10).
- AAV6 provided markedly more widespread and greater reporter transgene expression in mucus-covered ALI cultures of primary HAE cells and in mucus-plugged lung airways of transgenic mouse model of MOLDs, compared to AAV1 (10).
- AAV6 binds to a- 2,6-linked sialic acid (47) which is rich on the apical surface of human airway epithelial cells (48).
- AAV6 constitutes an excellent background serotype to implement EV piggybacking and capsid engineering for enhanced inhaled gene transfer efficacy, supposed that the non- mucoadhesive capsid property is retained.
- AAV capsid optimized AAV rationally designed to promote intracellular trafficking to cell nuclei.
- Proteasome degradation of AAV capsid protein is a primary intracellular hurdle that compromises transduction efficiency of AAV- based vectors following endocytic uptake regardless of the target cell types (49-54).
- intact AAV capsid is required for efficient delivery of DNA payloads to cell nuclei, particularly more so for postmitotic cells, such as various lung airway cells (55).
- proteasome inhibitor or capsid modification has been employed and shown to enhance the ability to AAV vectors to mediate transgene expression and/or to avoid AAV-specific immune responses by reducing antigen presentation (54, 56-60).
- Mutations in the panel are located on the AAV capsid surface to potentially contribute to vector interactions with surrounding biological entities, including Nab, cells and mucus gel.
- mAAV6 will be screened fortheir ability to resist mucoadhesion while enhancing the nuclear delivery of DNA payloads, using complementary models, including ALI culture of primary HAE cells, sputum samples collected from patients with MOLDs and the above-mentioned mucus-plugged mouse model (72). It is expected that new mAAV6 candidates would be identified that provide enhanced intracellular trafficking, reduced immunogenicity and non- mucoadhesive surface, which will be used to prepare EVmAAV6 for further in vivo evaluations.
- Thymulin gene therapy for treating allergic asthma.
- Thymulin provides remarkable anti- inflammatory and anti-fibrotic effects in the lungs of a preclinical model of allergic asthma.
- the inventors found that thymulin-expressing plasmids delivered by the newly engineered polymeric gene vectors (73) reversed key pathological hallmarks of allergic asthma, including asthmatic inflammation, pulmonary fibrosis, and mechanical dysregulation, in the lungs of an ovalbumin (OVA)-based allergic asthma model, primarily by immunomodulation (74)).
- OVA ovalbumin
- EVAAV6 is capable of efficiently penetrating the airway mucus regardless of whether AAV6 is associated with EVs internally or externally, due to the mucus-penetrating properties of both components.
- EVAAV6 can synergistically promote uptake of the DNA payload by lung airway cells, following inhaled administration, due to the natural ability of EVs to be taken up by various cells as well as the inherent affinity of AAV6 to the apical receptors on lung airway cells.
- EVAAV6 irrespective of serotype, has not been investigated for inhaled gene therapy applications until our recent pilot study demonstrating that EVAAV6 provides markedly greater reporter transgene expression in mouse lungs compared to AAV6 following intratracheal administration. EVAAV6 may also bypass neutralization by pre-existing AAV-specific NAb, increase packaging capacity, reduce clinical doses and/or enable repeated dosing to mediate sustained transgene expression. To this end, we expect our proposal to yield a novel and innovative hybrid gene delivery platform that provides unprecedented gene transfer efficacy potentially with broad applicability.
- EVAAV6 efficiently penetrates human airway mucus and provides markedly greater transgene expression compared to AAV6 in a human bronchial epithelial cell line. Based on the pilot observation thatEVs are capable of efficiently penetrating human airway mucus, it was hypothesized that EV AAV prepared with AAV vectors with non-mucoadhesive capsids (e.g, AAV6; FIGS. 2A, 2B) would efficiently penetrate the human airway mucus as well. EVAAV6, was first prepared as described herein, and comprehensive characterization was conducted using western blot analysis, tetraspanin chips, Spectradyne particle analyzer and dynamic light scattering (DLS). It was confirmed that EV and EVAAV6 similarly expressed syntenin-1 (ST-1) and CD9 (FIG. 1A), providing evidence that both are similarly exosome-rich EV populations.
- ST-1 syntenin-1
- CD9 FIG. 1A
- TEM Transmission electron microscopy
- EVAA V6, but not EV+AA V6 provides significantly greater transgene expression compared to AAV6 in mouse lungs following intratracheal administration. It was then investigated whether the enhancements in mucus penetration and cellular transduction enabled by EV piggybacking (FIGS. 4A-4E) resulted in the improvement of reporter transgene expression in the lung in vivo. Briefly, C57BL/6 mice intratracheally received AAV6, EVAAV6 or EV+AAV6 at a dose of 4 x 10 9 GC per animal and lung tissues were harvested 2 weeks after the administration for the assessment of reporter transgene expression.
- EVAAV6, but not EV+AAV6 provides significantly greater coverage and level of transgene expression in mucus-covered ALI cultures of primary HAE cells compared to AA V6.
- the model uniquely emulates the physiological human lung airways and associated biological barriers, thereby serving as an excellent testbed for evaluating the performance of lung-directed gene delivery platforms (10, 23, 9).
- capsid optimization significantly improves in vitro gene transfer efficacy of AA V6 hy enhancing intracellular trafficking to cell nuclei.
- capsid-optimized mAAV6 was engineered to facilitate the intracellular trafficking of DNA payloads loaded in the capsid to cell nuclei as an additional means to enhance transduction efficiency.
- at least three different mAAV6 were constructed carrying one or two mutation(s), including AAV6-T492V, AAV6- S663V and AAV6-492V+S663V, that exhibited significantly greater in vitro transduction efficiency compared to wild-type AAV6.
- the AAV6-T492V+S663V harbors two mutations that camouflage the AAV6 capsids from phosphorylation by intracellular kinases, thereby reducing proteasome degradation.
- a marked increase was confirmed in the nuclear fraction of the mutant compared to wild-type AAV6, suggesting that its unique ability to resist the proteasome degradation facilitated intracellular trafficking of the vector to cell nuclei.
- the proteasome degradation promotes AAV capsid presentation by antigen-presenting cells and thus the vector-associated immune responses.
- the ability to minimize the intracellular degradation is an additional mechanism by which AAV- mediated gene transfer efficacy is enhanced while potentially reducing vector-specific immune responses (71).
- AAV6-S663V Another mutant, AAV6-S663V, provided marked greater reporter transgene expression in primary human airway cells, including basal cells, compared to wild-type AAV6, presumably by enhancing nuclear import of the vector. It is thus expected that EV piggybacking and capsid engineering will synergistically enhance lung airway transduction.
- Inhaled thymulin gene therapy normalizes key pathological features in the lungs of a mouse model of allergic asthma.
- the inventors have recently demonstrated that inhaled thymulin gene therapy resolves key pathological outcomes, including allergic (/. ⁇ ?., T helper type 2 or Th2) inflammation, pulmonary fibrosis and mechanical dysregulation, manifested in a mouse model of OVA-induced allergic asthma in a therapeutic manner (74).
- the model was established with sequential sensitization and challenge with OVA (81) and it was confirmed that relevant disease phenotypes were all fully established and retained during the study period. Animals were then intratracheally treated with the synthetic nanoparticles developed to efficiently penetrate human airway mucus (73) carrying thymulin-expressing plasmids.
- bronchoalveolar fluid BALF was harvested from mice from each group and analyzed the levels of Th2 cytokines, including IL- 4 and IL-13, and pro-fibrotic mediators, including VEGF and TGF- , using enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- OVA-SAL group The levels of all these key soluble factors were significantly elevated in the model (OVA-SAL group), as observed in the lungs of patients with allergic asthma, but the inhaled thymulin gene therapy (OVA- THY group) brought them all down to the levels observed with healthy mice (CTRL- SAL group) (FIG. 7B). It was also found that the levels of chemokines for both eosinophils (CCL11 or eotaxin) and neutrophils (CXCL1) elevated in the lungs of asthmatic mice were normalized by the thymulin gene therapy (74).
- the methacholine challenge test was conducted next, commonly performed in the clinic to evaluate the lung function of patients with asthma (82).
- the airway hyperresponsiveness (AHR) in the asthmatic lungs undergoing fibrotic process (83) was confirmed by more pronounced dosedependent increase in airway resistance and decrease in dynamic compliance (C, dyn). It was found that the thymulin gene therapy normalized the AHR, underscoring that the mechanical dysregulation was resolved inthis model (FIG. 7C). Finally, it was discovered that the compelling and comprehensive therapeutic benefits were achieved primarily by immunomodulatory effects of the thymulin gene therapy.
- thymulin constitutes an excellent therapeutic agent for establishing proof-of-principle clinical relevance of the lead EVmAAV6 to be developed in this study.
- the overall goal of this study is to develop and evaluate novel hybrid gene delivery platform based on EVmAAV6 for inhaled gene therapy of MOLDs (FIG. 8).
- a recombinant library of capsid-optimized mAAV6 be constructed providing enhanced intracellular trafficking to cell nuclei, while retaining the non-mucoadhesive capsid property of wild-type AAV6.
- the mutants will then be extensively screened using complementary experimental models closely emulating MOLDs (e.g., CF, COPD, and asthma) to determine lead candidates providing efficient delivery of DNA payloads to cell nuclei of mucus-covered lung airway cells.
- testbeds include mucus-covered ALI cultures of primary HAE cells (in vitro), human airway mucus freshly collected from patients (ex vivo) and a mucus-plugged mouse model of MOLDs (in vivo).
- the mAAV6 candidates will be screened using the ALI culture, and a few selected mutants will be evaluated for efficient penetration through unperturbed sputum samples spontaneously expectorated by patients with CF and possibly patients with COPD or asthma if available.
- a mutant library will be screened the animal model to determine lead mAAV6.
- EVmAAV6 will be prepared based on lead mAAV6 candidates, which will be assessed for coverage and overall level of reporter transgene expression using ALI cultures of primary HAE cell sand the mucus-plugged mouse model of MOLDs. Two winners achieving either greater coverage or overall level will then be investigated for the ability to deliver two reporter cassettes individually packaged in mAAV6 into the same cells in vitro and in vivo for potential delivery of a large gene beyond the natural packaging capacity of AAV.
- the lead EVmAAV6 will be evaluated for their ability to provide long-term transgene expression by transducing airway progenitor cells or by allowing repeated treatment without being inactivated by the host immune system.
- EVmAAV6 will be constructed to carry thymulin-encoding DNA cassette and evaluated for therapeutic efficacy in well-established mouse models of allergic asthma.
- Number of animals to be used for each proposed study is determined by power calculations based on our preliminary data (5% significance level and 90% power). Studies will be performed with both male and female animals in equal proportions. Two- tailed Student’s /-tests (assuming an unequal variance) and ANOVA, followed by post-hoc analysis, will be executed for two- and multi-group comparisons, respectively.
- a panel of capsid-optimized mAAV6 that potentially enhance intracellular trafficking to cell nuclei, while retaining the capsid integrity will be established.
- a library of mAAV6 will be generated by substituting one or up to three amino acid(s) at 29 conserved positions. The previously implemented substitutions were based on similarity in the amino acid structure, but here these will replace amino acids at these positions with all 20 naturally occurring amino acids used in protein synthesis in humans. The theoretical complexity of all these permutations would be approximately 3 x 10 7 , which is relatively lower than the previously reported capsid recombinant libraries (84-92).
- the library will be prepared by site-directed mutagenesis on already constructed plasmids with randomized primers and subsequent self-packaging of all mutants simultaneously in AAV-producing HEK293 cells at a low capsid-mutated plasmid library to helper plasmid ratio of 1 :5,000 to ensure self-packaging while minimizing the probability of possible cross-packaging (93).
- recombinant mAAV6 will be screened first for intracellular trafficking to cell nuclei using mucus-covered ALI cultures of human primary airway cells.
- Human primary airway cells will be obtained from the CF Clinical and Translational Center at University of Alabama at Birmingham (Dr. Steven Rowe). Cells will be plated apically on collagen coated 6-well semi-permeable transmembrane snapwell culture inserts and grown submerged in media for 3 - 4 days until the cells reach -100% confluency. The apical media will then be removed to create an ALI culture where cells will be differentiated to mimic a polarized conducting epithelium found in human lung airways (10).
- the cells will form a monolayer with high transepithelial electrical resistance (TEER; 500-700 Q cm 2 ), an indicative of intact tight junctions (94).
- TEER transepithelial electrical resistance
- the ALI cultures will be prepared with CF (and potentially COPD) airway cells, but it would be challenging to obtain airway cells from asthma patients generally not undergoing lung transplant.
- the model should serve as a reliable representative model to test the ability of m AAV6 to resist adhesion to pathologically-thicken airway mucus gel and deliver self-encoding DNA payloads into the nuclei of human primary airway cells.
- NAb against wild-type AAV6 1 x 10 10 - 10 11 wildtype AAV6 will be intravenously injected into C57BL/6 mice, serum harvested 2 - 3 weeks after the inj ection and determine the NAb titer using ELISA (95).
- the library of mAAV6 will be added to the apical surface of the ALI culture, with or without pre-incubation with serum containing anti-AAV6 NAb, and cells will be harvested two days after the administration (i.e., sufficient time for cell uptake and nuclear localization if any).
- the nuclear fraction will be isolated and genomic DNA extracted, followed by PCR amplification with AAV6 capsid specific primers and evaluation of relevant abundance of associated mutants by sequencing of individual clones.
- mAAV6 in the nuclear fraction are those successfully penetrate the apical mucus gel layer, internalize into airway cells, bypass proteasome degradation and traffic to cell nuclei.
- Three rounds of enrichment procedure will be conducted where capsid specific primers will be used to amplify and re-package only variants isolated from previous selection steps.
- the selection criteria will be applied to collect clones with over 5%, 10% and 25% frequency at round one, two and three, respectively, to determine up to 12 lead mAAV6 candidates providing greatest nuclear import in primary HAE cells.
- the selection process is straightforward, as it involves infection of the ALI culture simultaneously with the whole library, followed by selection and analysis of lead mutants via high-throughput next-generation sequencing.
- An additional selection pressure will be applied to ensure that the mAAV6 selected esist mucoadhesion and thus not to compromise the mucus-penetrating property of EV upon external association.
- the diffusion rates of up to 12 mutants selected will be quantified in unperturbed sputum samples spontaneously expectorated by patients vising the Johns Hopkins Adult CF clinic using MPT, which have been routinely conducted (10, 44, 73, 96, 97).
- Alexa Fluor 647-labeled AAV vectors will be added to freshly collected sputum samples and x- and y- coordinates of particle trajectories will be recorded over time to calculate MSD values.
- the labeling strategy does not alter the surface property and infectivity of AAV (12). Sputum samples will be stored at 4 °C for ⁇ 24 hours after the collection to ensure that the biophysical properties are retained (29).
- the MSD value previously determined for wild-type AAV6 i.e., MSD > 0.3 pm 2 at a timescale of 1 second; (10)
- MSD > 0.3 pm 2 at a timescale of 1 second; (10) will be considered “non-mucoadhesive” and thus serve as a minimal inclusion criterion.
- the lead mAAV6 desired for human lung-directed gene therapy that also provides favorable performances in a mouse model of MOLDs will be selected.
- a transgenic mouse model of MOLDs exhibiting more pronounced airway mucus barrier i.e., Scnnlh-A mice; (10, 79)
- Scnnlh-A mice (10, 79)
- Scnnlb- mice at the age of 4 weeks will intratracheally receive a library of enriched mAAV6, and one week after the administration, lung tissues will be thoroughly washed via bronchoalveolar lavage to remove mucus-associated mAAV6, and CD45-negative cells will be harvested (73). Subsequently, lead candidates will be then selected using the method described herein.
- a separate group of animals will intratracheally receive wild-type AAV6 as described above, 2 weeks prior to the administration of the enriched mAAV6 library.
- lead candidates that exhibit greatest accumulation of self-encoding DNA cassettes in cell nuclei of lung airway cells while satisfying the selection criterion for human airway mucus penetration will be selected.
- the lead mutants selected here may or may not overlap with those identified for primary HAEs. If the lead candidates are sharply distinct between two species (i.e., human versus mouse), subsequent studies using respective lead mAAV6 for the ALI cultures and the mouse model will be pursued.
- EVmAAV6 will be prepared based on 6 lead mAAV6 candidates and confirmed for ex vivo mucus penetration and human airway mucus using MPT. Reporter transgene expression will be evaluated in ALI cultures in vitro. Briefly, after transfection of HEK293 cells with packaging plasmids, including ITP-containing plasmid carrying YFP and luciferase co-expressing cassette, cells and supernatants will be harvested.
- EV-free mAAV6 While standard i.e., EV-free) mAAV6 will be obtained from cells using a standard procedure, respective EVmAAV6 will be collected from the supernatant via sequential centrifugation at 100,000 x g and filtration with a 0.45-pm cellulose acetate filter. EVmAAV6 will then be characterized for structure, EV concentration and size (z.e., hydrodynamic diameter) using TEM, a Spectradyne particle analyzer and a Malvern Zetasizer i.e., DLS). In parallel, EVmAAV6 will be screened for common EV biomarkers by single-particle interferometric reflectance imaging sensing with fluorescence using tetraspanin chips.
- AAV titers of mAAV6 and EVmAAV6 will be analyzed by quantitative PCR.
- EVs will also be harvested from untransfected HEK293 cells for preparation of post-mixtures of EVs and lead mAAV6 candidates (i.e., EV+mAAV6).
- EV-free mAAV6, EVmAAV6 or respective EV+mAAV6 will be administered to the apical surface of the mucus-covered ALI culture, and cells will be then harvested two days after the administration, and a half of the harvested cells will be evaluated for the percentage of YFP-positive cells that indicates the coverage of transgene expression, using confocal microscopy and flow cytometry.
- the rest of cells will be used for homogenate-based luciferase assay to determine the overall level of transgene expression.
- Three different versions (i.e., EV-free, EV-associated and post-mixture) ofwild-type AAV6 will also be prepared and tested for comparison.
- Lung tissues will be harvested to assess the percentage of transduced cells or coverage using flow cytometry or confocal microscopy, respectively, as we routinely conduct (10, 73).
- lung tissues will be harvested from separate sets of transduced animals and the overall level of transgene expression will be evaluated by in vivo imaging with an In Vivo Imaging System (IVIS), followed by homogenate-based luciferase assay.
- IVIS In Vivo Imaging System
- One EVmAAV6 each exhibiting either greatest distribution or overall levels of reporter transgene expression in the mouse lungs (so up to 2 lead EVmAAV6) will be determined for further evaluation.
- Example 3 Evaluation of EVAA V6 and lead EVmAA V6 to provide sustained pulmonary transgene expression.
- A Evaluate the ability to transduce human primary airway progenitor cells (i.e., basal cells) and ALI cultures of human primary airway cells after incubation in AAV6-seropositive human serum.
- B Determine the humoral and cell-mediated immune responses against AAV6 in vivo.
- C Assess the ability to retain the transduction efficacy in the lung in vivo (i) after incubation in AAV6-seropositive human serum or (ii) upon repeated dosing.
- TLR9/MyD88 The acute inflammation associated with activation of TLR9/MyD88 will be assessed by Multiplex Bead Array Assay for detection of 25 soluble pro- inflammatory cytokines/chemokines (GM-CSF, IL-1
- 3, IL-6, IL-2, IL- 2R, IL-4, IL-5, IL-10, and MCP-1, etc.) on serum samples collected 2, 8 and 24 hours (short-term) and 7, 14, 21 and 28 days (long-term) after the intratracheal administration of EVAAV6 or lead EVmAAV6 (N 6 mice per group).
- the level of neutralizing activity of AAV-specific NAbs will be evaluated by transduction inhibition-based assay (102).
- Cellular immune responses will be measured by interferon gamma (IFNy/TNFa) ELISpot assay for both CD8 + and CD4 + on cells isolated from splenocytes with AAV6 capsid dominant peptides (103).
- the inhibitory effect or escape from neutralization will be evaluated by assessing the overall luciferase transgene expression level in the mouse lungs by live animal imaging and tissue homogenate-based luciferase assay.
- Example 4 Safety and therapeutic efficacy of inhaled thymulin gene therapy by EVAAV6 and lead EVmAAV6 in vivo.
- A Determine the doses providing the greatest thymulin transgene expression in the lung without incurring adverse effects using healthy mice.
- B Assess the therapeutic efficacy of the inhaled thymulin gene therapy using mouse models of allergic asthma.
- EVAAV6 and up to two lead EVmAAV6 will be constructed to carry a thymulin-expressing cassette and will be administered intratracheally into the lungs of C57BL/6 mice.
- Triplicate sets of animals will be used to evaluate thymulin transgene expression and local and systemic safety profiles. Lungs of the animals in the first set will be harvested in 2 weeks after the administration, followed by the quantification of the level of thymulin transgene expression by ELISA. Animals in the other two sets will be subjected to short- and long-term safety assessment.
- animals will be sacrificed 24 hours and 2 weeks after the administration and lung tissues and whole blood samples will be harvested. Lung tissues will then be subjected to quantification of pro-inflammatory mediators, including but not limited to NF-KB, TRL9, MyD88, IL-ip, IL-6 and IL-12, covered by a commercially available quantitative RT-PCR array.
- pro-inflammatory mediators including but not limited to NF-KB, TRL9, MyD88, IL-ip, IL-6 and IL-12
- blood samples collected from the animals will be used to conduct blood biochemistry analysis. Based on the findings here, will determine optimal doses for EVAAV6 and lead EVmAAV6 that provide maximal thymulin transgene expression in the lung without eliciting local and systemic adverse effects, which will be employed in the preclinical thymulin gene therapy.
- OVA-based model will be established by a series of sequential intraperitoneal sensitization (7 times every other day starting on Day 1) and intratracheal challenge (3 times every third day starting on Day 40) with OVA at 10 and 20 pg, respectively (74).
- HDM-based model will be established by intranasal instillation of 25 pg HDM (z.e., Dermatophagoides pteronyssinus) 5 days a week for 4 weeks (77).
- OVA-based model animals will be treated on Day 47 and efficacy will be evaluated on Day 67 from the initial sensitization, based on key disease phenotypes that are fully established and retained without selfresolution during this time window (74).
- all key disease phenotypes are established by the end of the 4- week 5-day weekly HDM instillation and lasted up 8 th week with minor increases in asthmatic inflammation and pulmonary fibrosis upon a continuous HDM instillation (77).
- Animals will be treated at the beginning of 5 th week and efficacy evaluated at the end of 8 th week. Live animals will be subjected to methacholine challenge test to determine AHR (i.e., airway resistance and dynamic compliance), as shown in FIG. 9. Animals will then be subjected to comprehensive assessments of immunomodulatory and therapeutic efficacy assessments. Histopathological analysis will be conducted to assess the goblet cell metaplasia (AB - PAS staining), lung inflammation (H&E), airway constriction (H&E; contraction index) and collagen deposition (Masson’s trichrome staining).
- AHR i.e., airway resistance and dynamic compliance
- BALF and/or whole lung tissues will be collected to evaluate immune infiltration (total and differential cell counting) and levels of soluble factors using ELISA as shown in FIG. 8.
- Those include Th2 cytokines (IL-4 and IL-13), an anti-inflammatory cytokine (IL-10), pro-fibrotic/remodeling mediators (VEGF and TGF-P) and immune cell-recruiting chemokines (eosinophil: CCL11; neutrophil: CXCL1; macrophage: CCL5; Treg: CCL17).
- Th2 vs. Treg Th2 vs. Treg
- M2 vs. M2 macrophages
- AAV-Containing Exosomes as a Novel Vector for Improved Gene Delivery to Lung Cancer Cells. Front Cell Dev Biol.
- Keeler AM Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu Rev Virol. 2019. Epub 2019/07/10. doi: 10.1146/annurev-virology-092818- 015530. PubMed PMID: 31283441.
Abstract
An extracellular vesicle (EV) associated with a viral vector is provided. The combination of the EV and virus vectors provide widespread and highly efficient transgene expression in lungs, following localized administration, as well as in mucus-covered air-liquid interface (ALT) cultures with primary human bronchial epithelial (HBE) cells and nasal epithelial (HNE) cells.
Description
EXTRACELLULAR VESICLE-ASSOCIATED ADENO-ASSOCIATED VIRUS
VECTORS FOR INHALED GENE THERAPY
CROSS-REFERENCE TO RELATED APPLICATION
The present application claims priority of U.S. provisional application no. 63/394,498 filed August 2, 2022, which is incorporated by reference herein in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made with government support under grant NS111102 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND
[0001] Gene therapy using adeno-associated virus (AAV) is an emerging treatment modality, including for treatment of single-gene defects. An example of one such disease is cystic fibrosis. Cystic fibrosis (CF) is a lethal, autosomal-recessive disorder that affects at least 30,000 people in the U.S. alone, and at least 70,000 people worldwide. The average survival age for CF patients is about 40 years. CF is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a channel that conducts chloride and bicarbonate ions across epithelial cell membranes. Impaired CFTR function leads to inflammation of the airways and progressive bronchiectasis. Because of the single-gene etiology of CF and the various CFTR mutations in the patient population, gene therapy potentially provides a universal cure for CF.
[0002] Adeno-associated virus (AAV), a member of the human parvovirus family, is a non- pathogenic virus that depends on helper viruses for its replication. For this reason, recombinant AAV (rAAV) vectors are among the most frequently used in gene therapy pre-clinical studies and clinical trials.
SUMMARY
[0003] Compositions for achieving therapeutically relevant gene transfer efficacy in the lung following localized administration are provided.
[0004] Accordingly, in certain aspects, a method of delivery of nucleic acid (e g. a transgene), through a mucus gel layer comprises administering a composition comprising a virus vector associated with an extracellular vesicle, wherein the virus vector comprises the nucleic acid. In certain embodiments, the virus vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle. In certain embodiments, the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, recombinant adeno-associated virus (rAAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors. In certain embodiments, the virus vector comprises one or more mutations. In certain embodiments, the virus vector is an AAV vector. In certain embodiments, the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences. In certain embodiments, the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids. In certain embodiments, the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ, DJ/8, or mutants thereof. In certain embodiments, the AAV is AAV serotype 6 (AAV6). In certain embodiments, the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells. In certain embodiments, the composition is formulated for oral, intratracheal/oropharyngeal, cervicovaginal, ocular or nasal delivery. In certain embodiments, the composition is aerosolized for delivery to the airways by inhalation or the oropharyngeal cavity. In certain embodiments, the composition is formulated as a liquid or gel for delivery to mucosal surfaces. In certain embodiments, the composition is formulated as a suppository.
[0005] In another aspect, a composition comprises a virus vector associated with an extracellular vesicle, wherein the virus vector comprises the nucleic acid. In certain embodiments, the virus
vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle. In certain embodiments, the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, recombinant adeno-associated virus (rAAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors. In certain embodiments, the virus vector is an AAV vector. In certain embodiments, the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences. In certain embodiments, the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids. In certain embodiments, the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. In certain embodiments, the AAV is AAV serotype 6 (AAV6). In certain embodiments, the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moieties. In certain embodiments, the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells.
[0006] In another aspect, a device is provided for delivery of the compositions embodied herein, to an oral cavity, nose, pharynx or to a subject in need thereof.
[0007] In another aspect, a method of treating a lung disease or disorder or an oropharyngeal disease comprises administering the compositions to a subject in need thereof. In certain
embodiments, a lung disease or disorder comprises cystic fibrosis, chronic obstructive pulmonary disease (COPD), lung inflammation, asthma, lung cancer, bronchitis, infections, or allergies.
[0008] In another aspect, a method of modulating an immune response for treating an immune related disorder in a subject in need thereof, comprises administering a composition comprising an extracellular vesicle and an adeno-associated virus (AAV) vector, the AAV vector comprising a nucleic acid sequence encoding an immunomodulatory molecule. In certain embodiments, the AAV comprises one or more amino acid mutations in the AAV capsid proteins. In certain embodiments, the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. In certain embodiments, the AAV is AAV serotype 6 (AAV6). In certain embodiments, the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle. In certain embodiments, the immunomodulatory molecule comprises thymulin, interferons, chemokines, cytokines, tumor necrosis factor alpha, modulators of checkpoint inhibitors or ligands of checkpoint inhibitors or combinations thereof. In certain embodiments, an immune related disease or disorder is asthma or allergies. In certain embodiments, the composition is formulated for oral, mucosal, cervicovaginal, ocular or nasal delivery. In certain embodiments, the composition is aerosolized for delivery to the airways by inhalation or the oropharyngeal cavity. In certain embodiments, the composition is formulated as a liquid or gel for delivery to mucosal surfaces. In certain embodiments, the composition is formulated as a suppository.
[0009] In another aspect an adeno-associated virus (AAV) vector comprises one or more amino acid mutations in the AAV capsid proteins. In certain embodiments, the one or more mutations are located at one or more conserved phosphorylation sites. In certain embodiments, the mutations comprise T492V, S663 V and the combination thereof. In certain embodiments, the AAV vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
[0010] Tn another aspect, a composition comprises a modified extracellular vesicle and a virus vector comprising nucleic acid (e.g. a transgene). In certain embodiments, the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids. In certain embodiments, the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moi eties. In certain embodiments, the extracellular vesicle is derived from eukaryotic cells, such as mammalian cells or insect cells. In certain embodiments, the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, , herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors. In certain embodiments, the virus vector is an AAV vector. In certain embodiments, the AAV vector comprises one or more AAV capsid proteins comprising modified amino acid sequences. In certain embodiments, the modified amino acid capsid proteins comprise one or more insertions, deletions, or substitutions of one or more amino acids. In certain embodiments, the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations. In certain embodiments, the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, I I, 12, 13, 14, 15, 16, DJ or DJ/8. In certain embodiments, the AAV is AAV serotype 6 (AAV6).
[0011] In another aspect, a nucleic acid-based vaccine comprises an extracellular vesicle and a virus vector wherein the virus vector comprises at least one nucleic acid molecule (e.g. transgene). Tn certain embodiments, the virus vector encodes an immunogenic/antigenic molecule. Tn certain embodiments, an adjuvant is provided.
[0012] Definitions
[0013] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, and biochemistry).
[0014] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”
[0015] As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
[0016] The term “about” is used herein to mean a value that is ±10% of the recited value.
[0017] The term “AAV” refers to adeno-associated virus and may be used to refer to the naturally occurring wild-type virus itself or derivatives thereof. The term covers all subtypes, serotypes and pseudotypes, and both naturally occurring and recombinant forms, except where required otherwise. The AAV genome is built of single stranded DNA and comprises inverted terminal repeats (TTRs) at both ends of the DNA strand, and two open reading frames: rep and cap, encoding replication and capsid proteins, respectively. A foreign polynucleotide can replace the native rep and cap genes. AAVs can be made with a variety of different serotype capsids which have varying transduction profdes or as used herein, “tropism” for different tissue types. As used herein, the term “serotype” refers to an AAV which is identified by and distinguished from other AAVs based on capsid protein reactivity with defined antisera, e.g., AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. For example, serotype AAV2 is used to refer to an AAV which contains capsid proteins encoded from the cap gene of AAV2 and a genome containing 5' and 3' ITR sequences from the same AAV2 serotype. Pseudotyped AAV as refers to an AAV that contains capsid proteins from one serotype and a viral genome including 5'-3' ITRs of a second serotype. Pseudotyped rAAV would be expected to have cell surface binding properties of the capsid serotype and genetic properties consistent with the ITR serotype. Pseudotyped rAAV are produced using standard techniques described in the art. In certain embodiments, the AAVs
comprise mutations in the capsid proteins. These mutations comprise one or more amino acid changes at one or multiple locations of the capsid proteins.
[0018] As used herein, by “administering” is meant a method of giving a dosage of a composition described herein (e.g., an EV AAV and/or a pharmaceutical composition thereof) to a subject. The compositions utilized in the methods described herein can be administered by any suitable route, including, for example, by inhalation, nebulization, aerosolization, intranasally, intratracheally, intrabronchially, orally, parenterally (e.g., intravenously, subcutaneously, or intramuscularly), orally, nasally, rectally, topically, or buccally. In some embodiments, a composition described herein is administered in aerosolized particles intratracheally and/or intrabronchially using an atomizer sprayer (e.g., with a MADgic® laryngo-tracheal mucosal atomization device).
[0019] The term “amino acid” as used herein refers to naturally occurring and synthetic a, 0, y, and 8 amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, 0-alanyl, 0- valinyl, 0-leucinyl, 0-isoleucinyl, 0-prolinyl, 0-phenylalaninyl, 0 -tryptophanyl, 0-methioninyl, 0- glycinyl, 0-serinyl, 0-threoninyl, 0-cysteinyl, 0-tyrosinyl, 0-asparaginyl, 0-glutaminyl, 0- aspartoyl, 0-glutaroyl, 0-lysinyl, 0-argininyl or 0-histidinyl. When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of a, 0, y, and 8 glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.
[0020] As used herein, a “bioactive” or “biologically active” molecule, substance or agent for use herein may comprise a drug active recognizable by one skilled in the art of medicinal chemistry. Such bioactive substances for use herein include, but are not limited to, antibodies and antibody cocktails, nucleic acids, proteins, oligonucleotides including messenger-RNA (mRNA), antidiabetic agents, glucose elevating agents, thyroid hormones, thyroid drugs, parathyroid drugs, vitamins, antihyperlipidemic agents, cardiac drugs, respiratory drugs, nasal decongestants,
gastrointestinal drugs, amphetamines, anorexiants, antirheumatic agents, anti-gout agents, migraine drugs, sedatives, hypnotics, antianxiety drugs, anticonvulsants, antidepressants, antipsychotic agents, psychotherapeutic drugs, antimicrobials, antifungals, sulfonamides, antimalaria drugs, antituberculotic drugs, amebicides, antiviral agents, anti-infectives, leprostatics, antihelmintics, antihistamines, antimetabolites, anticholinergics, steroidal anti-inflammatories, anesthetics, antiplatelet drugs, NSAIDs, ace inhibitors, calcium channel blockers, alpha-blockers, muscle relaxers, antihypertensives, vasodilators, diuretics, antiemetics, sex hormones, pituitary hormones, analgesics, uterine hormones, chemotherapeutics, immune checkpoint inhibitors, cytokines, chemokines adrenal steroid inhibitors and the like.
[0021] As used herein, a “biomolecule” takes on its ordinary and broad meaning of naturally occurring, or synthetic macromolecules that are associated with a biochemical purpose in an organism. Biomolecules herein may be attached to the outer surface of extracellular vesicles or contained within the extracellular vesicles, and such biomolecules may include nucleotides, nucleosides, oligonucleotides, DNA, RNA, hybridization probes, amino acids, polypeptides, proteins and fragments thereof, and antibodies and fragments thereof.
[0022] As used herein, the terms “comprising,” “comprise” or “comprised,” and variations thereof, in reference to defined or described elements of an item, composition, apparatus, method, process, system, etc. are meant to be inclusive or open ended, permitting additional elements, thereby indicating that the defined or described item, composition, apparatus, method, process, system, etc. includes those specified elements--or, as appropriate, equivalents thereof— and that other elements can be included and still fall within the scope/definition of the defined item, composition, apparatus, method, process, system, etc.
[0023] The term “enhancer” as used herein, refers to a DNA sequence that increases transcription of, for example, a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. A large number of enhancers from a variety of different sources are well known in the art and are available as or within cloned polynucleotides (from, e.g., depositories such as the ATCC as well as other commercial or individual sources). A number of polynucleotides comprising
promoters (such as the commonly used CMV promoter) also comprise enhancer sequences. Enhancers can be located upstream, within, or downstream of coding sequences.
[0024] As used herein, the term “extracellular vesicles,” or “EV” for short (“EVs” for plural), refers to cellular-derived lipid encased particles secreted by cells of multicellular organisms into external environments to achieve cellular homeostasis and/or for cell-to-cell communication. Further, the term is meant to include the entire family of extracellular vesicles, including the recently discovered exomeres (extracellular nanoparticles having no apparent biological function), along with engineered or modified extracellular vesicles and mimetic nanovesicles. Natural EVs can be classified into three main types. Namely, apoptotic bodies (500-2000 nm in size), microvesicles (50-1000 nm in size), and exosomes (30-200 nm in size). Besides these size differentiations, the types of vesicles are also differentiated by biogenesis, release pathways, content and function. Exosomes formed by an endosomal route are typically 30-150 nm in diameter. There is no apparent limit as to the type or source of EVs for loading with bioactive substances and formulation into compositions in accordance with the present disclosure. EVs for use herein include, but are not limited to, EVs obtained from plasma, urine, semen, saliva, bronchial fluid, cerebral spinal fluid, breast milk, serum, amniotic fluid, synovial fluid, vaginal secretions, tears, lymph, bile, and gastric acid. In various embodiments, EV's are obtained from producer cells such as for example, stem cells, for example, from mesenchymal stem cells (MSCs). In various embodiments, the EVs are obtained from mammalian producer cells and cell lines, e.g. HEK293 cells. Further, any method of isolation presently known or developed in the future may be used. Current methods for isolating EVs include ultracentrifugation, density gradient methods, size exclusion methods, immunoaffinity capture, and precipitation. For a comprehensive review, see L. M. Doyle, et al., “Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis,” Cells, 8, 727 (2019).
[0025] As herein a “gene therapy vector” is any molecule or composition that has the ability to carry a heterologous nucleic acid sequence into a suitable host cell where synthesis of the encoded protein takes place. Typically, a gene therapy vector is a nucleic acid molecule that has been engineered, using recombinant DNA techniques that are known in the art, to incorporate the heterologous nucleic acid sequence. Desirably, the gene therapy vector is comprised of DNA. Examples of gene therapy vectors include viral vectors. However, gene therapy vectors that are not based on nucleic acids, such as liposomes, are also known and used in the art. The gene therapy
vector can be integrated into the host cell genome or can be present in the host cell in the form of an episome. In certain embodiments, a gene therapy vector is a virus vector, such as, for example, AAV.
[0026] The term “modified,” when used in the context of EVs described herein, refers to an alteration or engineering of an EV, e.g., exosome and/or its producer cell, such that the modified EV is different from a naturally occurring EV. In some aspects, a modified EV described herein comprises a membrane that differs in composition of a protein, a lipid, a small molecular, a carbohydrate, etc. compared to the membrane of a naturally occurring EV (e.g., membrane comprises higher density or number of natural exosome proteins and/or membrane comprises proteins that are not naturally found in exosomes (e g., antigen, adjuvant, and/or immune modulator). In certain aspects, such modifications to the membrane changes the exterior surface of the EV (e.g., surface engineered EV). In certain aspects, such modifications to the membrane changes the lumen of the EV.
[0027] As used herein, the term “modulate” includes to “increase” or “decrease” one or more quantifiable parameters, optionally by a defined and/or statistically significant amount. By “increase” or “increasing,” “enhance” or “enhancing,” or “stimulate” or “stimulating,” refers generally to the ability of one or more vesicle-based compositions in accordance with the present disclosure to produce or cause a greater physiological response (i.e., downstream effects) in a cell or in a subject relative to the response caused by either no vesicle-based composition or a control compound. Relevant physiological or cellular responses (in vivo or in vitro) upon administration of vesicle-based compositions will be apparent to persons skilled in the art. An “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more times (e.g., 500, 1000 times), including all integers and decimal points in between and above 1 (e.g., 1.5, 1.6, 1.7. 1.8), the amount produced by no vesicle-based composition (the absence of a bioactive agent) or a control compound. The term “reduce” or “inhibit” may relate generally to the ability of one or more vesicle-based compositions to “decrease” a relevant physiological or cellular response, such as a symptom of a disease or condition described herein, as measured according to routine techniques in the diagnostic art. Relevant physiological or cellular responses (in vivo or in vitro) will be apparent to persons skilled in the art, and may include reductions in the symptoms or pathology of a disease, illness or condition, such as cancer, inflammation or pain. A “decrease” in a response
may be “statistically significant” as compared to the response produced by no vesicle-based composition or a control composition, and may include a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% decrease, including all integers in between.
[0028] The terms “patient” or “individual” or “subject” are used interchangeably herein, and refers to a mammalian subject to be treated, with human patients being preferred. In some cases, the methods of the disclosure find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
[0029] As used herein, the term “producer cell” refers to a cell used for generating an EV, e.g., exosome. A producer cell can be a cell cultured in vitro, or a cell in vivo. A producer cell includes, but not limited to, a cell known to be effective in generating EVs, e.g., HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN® neuronal precursor cells, CAP® amniocyte cells, adipose mesenchymal stem cells, RPTEC/TERT1 cells. In some aspects, the EVs useful in the present disclosure do not carry an antigen on MHC class I or class II molecule (i.e., antigen is not presented on MHC class I or class II molecule) exposed on the surface of the EV.
[0030] As used herein, “recombinant adeno-associated virus (AAV)” or “rAAV vector” is meant a recombinantly-produced AAV or AAV particle that comprises a polynucleotide sequence not of AAV origin (e.g., a polynucleotide comprising a transgene, which may be operably linked to one or more enhancer and/or promoters) to be delivered into a cell, either in vivo, ex vivo, or in vitro. Non-naturally occurring (e.g., chimeric) capsids may be used in the rAAVs.
[0031] A “therapeutic gene,” “prophylactic gene,” “target polynucleotide,” “transgene,” “gene of interest,” “exogenous gene” and the like generally refer to a gene or genes to be transferred using a vector. Typically, in the context of the present disclosure, such genes are located within the rAAV vector (which vector is flanked by inverted terminal repeat (ITR) regions and thus can be replicated and encapsidated into rAAV particles). Target polynucleotides can be used in this disclosure to generate rAAV vectors for a number of different applications. Such polynucleotides include, but are not limited to: (i) polynucleotides encoding proteins useful in other forms of gene
therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme; (ii) polynucleotides that are transcribed into anti-sense molecules; (iii) polynucleotides that are transcribed into decoys that bind transcription or translation factors; (iv) polynucleotides that encode cellular modulators such as cytokines; (v) polynucleotides that can make recipient cells susceptible to specific drugs, such as the herpes virus thymidine kinase gene; (vi) polynucleotides for cancer therapy, such as E1A tumor suppressor genes or p53 tumor suppressor genes for the treatment of various cancers; and (vii) polynucleotides for gene editing (e.g., CRISPR). To effect expression of the transgene in a recipient host cell, it is in one embodiment operably linked to a promoter, either its own or a heterologous promoter. A large number of suitable promoters are known in the art, the choice of which depends on the desired level of expression of the target polynucleotide, whether one desires constitutive expression, inducible expression, cell-specific or tissue-specific expression, etc. The rAAV vector may also contain a selectable marker. Exemplary transgenes include, without limitation, cystic fibrosis transmembrane conductance regulator (CFTR) or derivatives thereof (e.g., a CFTRAR mini gene; see, e.g., Ostedgaard et al. Proc. Natl. Acad. Sci. USA 108(7):2921-6, 2011, which is incorporated by reference herein in its entirety), a-antitrypsin, P-globin, y-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, erythropoietin, alpha 1 -antitrypsin, surfactant protein SP-D, SP-A or SP-C, erythropoietin, growth factors, or a cytokine, e.g., IFN- alpha, IFNy, TNF, IL-1, IL-17, or IL-6, or a prophylactic protein that is an antigen such as viral, bacterial, tumor or fungal antigen, or a neutralizing antibody or a fragment thereof that targets an epitope of an antigen such as one from a human respiratory virus, e.g., influenza virus or RSV including but not limited to HBoV protein, influenza virus protein, RSV protein, or SARS protein.
[0032] As used herein, the term “subject” or the phrase “a subject in need thereof’ refers to any human or non-human animal requiring or desirous of a pharmacological change. For example, a subject in need thereof may be a human patient clinically diagnosed with a disease, such as, for example, cystic fibrosis, and is thus in need of, or is at least desirous of receiving some sort of treatment.
[0033] As used herein, the term “treatment” of a subject (e.g., a mammal, such as a human) or a cell, is any type of intervention used in an attempt to alter the natural course of the subject or cell. Treatment includes, but is not limited to, administration of a vesicle-based composition in accordance with the present disclosure and may be performed either prophylactically or
subsequent to the initiation of a pathologic event or contact with an etiologic agent. Also included are “prophylactic” treatments, which can be directed to reducing the rate of progression of the disease or condition being treated, delaying the onset of that disease or condition, or reducing the severity of its onset. “Treatment” or “prophylaxis” does not necessarily indicate complete eradication, cure, or prevention of the disease or condition, or associated symptoms thereof.
[0034] As used herein, the term “therapeutically effective amount” refers to a minimum dosage of a composition in accordance with the present disclosure that provides a desired effect. Therefore, a therapeutically effective amount varies by subject, dosage form/concentration, and results desired. For example, a therapeutically effective amount of an inhalable liquid or aerosol to treat a CF or COPD, might be on the order of micrograms or milligrams per day. Tn other examples, a therapeutically effective amount of a nasal spray composition, might be on the order of 3 sprays per day per nostril, with each spray about 0.1 mL.
[0035] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] The patent or application fde contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
[0037] FIGS. 1A -ID demonstrate that EVAAV6 prepared in HEK293 cells and harvested from the cell culture supernatant exhibits internal and external association of AAV6 with EV. (FIG. 1A) Western blot analysis of AAV6, EV and EVAAV6. Bands for VP1, 2 and 3 of AAV6 capsid and for syntenin-1 (STI) and CD9 of EV are shown. (FIG. IB) ExoView analysis demonstrating that exosomes are a primary population similarly in EV and EVAAV6. (FIG. 1C) Hydrodynamic diameters of AAV6, EV and EVAAV6 measured by DLS. (FIG. ID) Representative transmission electron micrographs of AAV6, EV, EVAAV6 and EV+AAV6. Scale bar = 50 nm.
[0038] FIGS. 2A and 2B demonstrate that AAV6 exhibits significantly greater diffusion rates compared to AAV 1 in multiple independent sputum samples freshly expectorated by patients with MOLDs. (FIG. 2A) Representative AAV trajectories in different sputum samples. Scale bar = 1
pm. (FTG. 2B) Box-and- whisker plots of MSD of gene vectors at t = 1 s in sputum samples collected from 8 different CF patients. *p < 0.05 (Student’s /-test).
[0039] FIGS. 3A and 3B demonstrate that EVAAV6 exhibits efficient penetration through human airway mucus and enhanced transduction of human bronchial epithelial (HBE) cell line. (FIG. 3A) Median MSD values of EV and EVAAV6 in sputum samples spontaneously expectorated by CF patients. MSD is a square of distance traveled by an individual particulate matter within a predetermined time interval (i.e., time scale; r = 1 s) and thus is directly proportional to the particle diffusion rate. The upper and lower red dashed lines indicate theoretical MSD values of EV in PBS calculated by the Stoke-Einstein equation and MSD values of AAV6 previously measured in CF sputum, respectively, n.s.: no significance (two-tailed Student’ s t-test) (FIG. 3B) Luciferase activity measured in lysates of HBE cells treated with EV, EVAAV6 or EV+AAV6. n.s.: no significance, ****p < 0.0001 (one-way ANOVA).
[0040] FIGS. 4A-4E demonstrate that EVAAV6 provides widespread and enhanced reporter transgene expression in mouse lungs following intratracheal administration. (FIG. 4A) Representative confocal images demonstrating reporter transgene expression throughout the whole left lung lobes of mice intratracheally treated with normal saline, AAV6, EVAAV6 or EV+AAV6. Green: YFP, Blue: nuclei. Image-based quantification of (FIG. 4B) coverage and (FIG. 4C) intensity of YFP transgene expression in whole lung lobes treated with normal saline, AAV6, EVAAV6 or EV+AAV6. (FIGS. 4D-4E) Luciferase activity measured in lysates of the whole mouse lungs treated with normal saline, AAV6, EVAAV6 or EV+AAV6. Mice receiving EVAAV6 or EV+AAV6 were treated at a (FIG. 4D) lower and (FIG. 4E) higher EV-to-AAV6 ratios, n.s.: no significance, **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA).
[0041] FIGS. 5A-5C demonstrate that EVAAV6 provides enhanced reporter transgene expression in mucus-secreting ALI cultures of primary wild-type (WT) or cystic fibrosis (CF) HBE cells following apical administration. (FIG. 5A) Representative confocal images demonstrating reporter transgene expression in ALI cultures of primary WT or CF HBE cells treated with normal saline, AAV6, EVAAV6 or EV+AAV6. Green: YFP, Blue: nuclei. Image-based quantification of (FIG. 5B) coverage and (FIG. 5C) intensity of YFP transgene expression in the ALI cultures treated with normal saline, AAV6, EVAAV6 or EV+AAV6. n.s.: no significance, ***p < 0.001, ****/? < 0.0001 (two-way ANOVA).
[0042] FTG. 6 is a graph demonstrating that capsid- optimized AAV6 mutants exhibit greater diffusion rates in multiple independent sputum samples compared to wild-type AAV6. Four tested mutant AAV6 (mAAV6) exhibit greater diffusion rates, as indicated by averages of median MSD values, compared to those of wild-type AAV6 (red dashed line).
[0043] FIGS. 7A-7C demonstrate that thymulin gene therapy with mucus-permeable synthetic nanoparticles provides comprehensive therapeutic benefits in the lungs of OVA-induced allergic asthma model. CTRL-SAL: sensitized/challenged with saline and treated with saline (healthy control); OVA-SAL: sensitized/challenged with OVA and treated with saline (disease/untreated control); OVA- THY: sensitized/challenged with OVA and treated with thymulin gene therapy. (FTG. 7A) Representative photomicrographs of histologically stained with hematoxylin and eosin (H&E). Scale bars denote 200= pm. (FIG. 7B) Levels of Th-2 cytokines and pro-fibrotic mediators in BALF. (FIG. 7C) Measurement of AHR (z.e., lung mechanics). *p < 0.05 compared to the CTRL-SAL group; p < 0.05 compared to the OVA-SAL group.
[0044] FIG. 8 is a schematic representation of specific aims and respective experiments outlined in the examples section.
[0045] FIGS. 9A and 9B demonstrate that EV and EVAAV 6 exhibit similar particle sizes as TM measured by Spectradyne nCSl particle size analyzer. The average particle diameters and concentrations, respectively, for (FIG. 9A) EV are 63.0 nm and 6.15 * 10U/mL and for (FIG. 9B) EVAAV6 are 63.1 nm and 9.47 x lO^/mL. The measured concentrations have been used to match the EV concentrations in EV+AAV6 and EVAAV6 samples for in vitro and in vivo comparisons.
[0046] FIG. 10 demonstrates that EVAAV6 with a higher EV-to-AAV6 ratio exhibit greater transgene expression on average following intratracheal administration, but the difference is not statistically significant. The EV-to-AAV6 ratios of EVAAV6 with low and high EV contents are 2.17 and 18.5, respectively, n.s. no significance (two-sided Student’s /-test).
[0047] FIG. 11 shows luciferase activity measured in lysates of the whole mouse lungs treated with EVAAV6 or mAAV6 vectors piggybacked on EVs (EVmAAV6). N = 6 animals per group, *p < 0.05 (two-sided Student’s /-test).
DETAILED DESCRIPTION
[0048] The disclosure involves preparation and use of extracellular vesicle (EV)-associated adeno-associated virus (AAV) for inhaled lung-directed gene therapy applications. It was discovered that EV-associated AAV serotype 6 (EVAAV6), produced during AAV preparation in HEK293 cells, provides markedly and significantly greater transgene expression in human primary airway cells and in mouse lungs (following inhaled administration) compared to AAV6 which has been shown greater performances compared to other widely used AAV serotypes (e.g., AAV1, 2 and 5) in transducing lung airway cells. This enhancement is attributed to the ability of EV to promote mucus penetration and cellular transduction of AAV6. The approach is likely applicable/beneficial to other AAV serotypes or virus vectors incapable of penetrating the airway mucus barrier, thereby broadening the AAV serotypes and other virus vectors that can be utilized for inhaled gene therapy applications.
[0049] Gene Therapy Vectors
[0050] Gene delivery vectors within the scope of the disclosure include, but are not limited to, isolated nucleic acid, e.g., plasmid-based vectors which may be extrachromosomally maintained, and viral vectors, e.g., recombinant adenovirus, retrovirus, lentivirus, herpesvirus, poxvirus, papilloma virus, or adeno-associated virus, including viral and non-viral vectors which are present in liposomes, e.g., neutral or cationic liposomes, such as DOSPA/DOPE, DOGS/DOPE or DMRIE/DOPE liposomes, and/or associated with ether molecules such as DNA-anti-DNA antibody-cationic lipid (DOTMA/DOPE) complexes. Exemplary viral gene delivery vectors are desorbed below. Gene delivery vectors may be administered via any route including, but not limited to, intracranial, intrathecal, intramuscular, buccal, rectal, intravenous or intracoronary administration, and transfer to cells may be enhanced using electroporation and/or iontophoresis, and/or scaffolding such as extracellular matrix or hydrogels, e.g., a hydrogel patch.
[0051] In one embodiment, the gene therapy vector is a viral vector. Suitable viral vectors include, for example, retroviral vectors, lentivirus vectors, herpes simplex virus (HSV)-based vectors, parvovirus-based vectors, e.g., adeno-associated virus (AAV)-based vectors, AAV- adenoviral chimeric vectors, and adenovirus-based vectors. These viral vectors can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring
Harbor, N.Y. (2001), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley 4 Sons, New York, N.Y. (1994).
[0052] Retroviral Vectors: Retroviral vectors exhibit several distinctive features including their ability to stably and precisely integrate into the host genome providing long-term transgene expression. These vectors can be manipulated ex vivo to eliminate infectious gene particles to minimize the risk of systemic infection and patient-to-pati ent transmission. Pseudotyped retroviral vectors can alter host cell tropism.
[0053] Lentiviruses: Lentiviruses are derived from a family of retroviruses that Include human Immunodeficiency virus and feline immunodeficiency virus. However, unlike retroviruses that only infect dividing cells, lentiviruses can infect both dividing and nondividing cells. For instance, lentiviral vectors based on human immunodeficiency virus genome are capable of efficient transduction of cardiac myocytes in vivo. Although lentiviruses have specific tropisms, pseudotyping the viral envelope with vesicular stomatitis virus yields virus with a broader range (Schnepp et al., Meth. Mol. Med., 69:427 (2002)).
[0054] Adenoviral Vectors’. Adenoviral vectors may be rendered replication-incompetent by deleting the early (E1A and E1B) genes responsible for viral gene expression from the genome and are stably maintained into the host cells m an extrachromosomal form. These vectors have the ability to transfect both replicating and nonreplicating cells. Adenoviral vectors have been shown to result in transient expression of therapeutic genes in vivo, peaking at 7 days and lasting approximately 4 weeks. The duration of nucleic acid (transgene) expression may be improved in systems utilizing neural specific promoters. In addition, adenoviral vectors can be produced at very high titers, allowing efficient gene therapy with small volumes of virus.
[0055] Adeno-Associated Virus Vectors: Recombinant adeno-associated viruses (rAAV) are derived from nonpathogenic parvoviruses, evoke essentially no cellular immune response, and produce transgene expression lasting months in most systems. Moreover, like adenovirus, adeno- associated virus vectors also have the capability to infect replicating and non replicating cells and are believed to be nonpathogenic to humans.
[0056] Exemplary AAV Vectors: In certain embodiments, the disclosure provides an adeno- associated virus (AAV) vector which comprises a nucleic acid sequence a therapeutic molecule. Adeno-associated virus is a member of the Parvoviridae family and comprises a linear, single-
stranded DNA genome of less than about 5,000 nucleotides. AAV requires co-infection with a helper virus (i.e., an adenovirus or a herpes virus), or expression of helper genes, for efficient replication. AAV vectors used for administration of therapeutic nucleic acids typically have approximately 96% of the parental genome deleted, such that only the terminal repeats (ITRs), which contain recognition signals for DNA replication and packaging, remain. This eliminates immunologic or toxic side effects due to expression of viral genes. In addition, delivering specific AAV proteins to producing cells enables integration of the AAV vector comprising AAV ITRs into a specific region of the cellular genome, if desired (see, e.g., U.S. Pat. Nos. 6,342,390 and 6,821,511). Host cells comprising an integrated AAV genome show no change in cell growth or morphology (see, for example, U.S. Pat. No. 4,797,368).
[0057] The AAV ITRs flank the unique coding nucleotide sequences for the non-structural replication (Rep) proteins and the structural capsid (Cap) proteins (also known as virion proteins (VPs)). The terminal 145 nucleotides are self-complementary and are organized so that an energetically stable intramolecular duplex forming a T-shaped hairpin may be formed. These hairpin structures function as an origin for viral DNA replication by serving as primers for the cellular DNA polymerase complex. The Rep genes encode the Rep proteins Rep78. Rep68, Rep62, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, and Rep 52 and Rep40 are transcribed from the pl9 promoter. The Rep78 and Rep68 proteins are multifunctional DNA binding proteins that perform helicase and nickase functions during productive replication to allow for the resolution of AAV termini (see. e.g., Im et al., Cell. 51 :447 (1990)). These proteins also regulate transcription from endogenous AAV promoters and promoters within helper viruses (see, e.g., Pereira et al., J. Virol., 71 : 1079 (1997). The other Rep proteins modify the function of Rep78 and Rep68. The cap genes encode the capsid proteins VP1, VP2, and VP3. The cap genes are transcribed from the p40 promoter.
[0058] The AAV vector may be generated using any AAV serotype known in the art. Several AAV serotypes and over 100 AAV variants have been isolated from adenovirus stocks or from human or nonhuman primate tissues (reviewed in. e.g., Wu et al., Molecular Therapy. 14(3): 316 (2006)). Generally, the AAV serotypes have genomic sequences of significant homology at the nucleic acid sequence and amino acid sequence levels, such that different serotypes have an identical set of genetic functions, produce virions which are essentially physically and functionally equivalent and replicate and assemble by practically identical mechanisms. AAV serotypes 1-5
and 7-9 are defined as “true” serotypes, in that they do not efficiently cross-read with neutralizing sera specific for all other existing and characterized serotypes. In contrast, AAV serotypes 6, 10 (also referred to as RhlO), and 11 are considered “variant” serotypes as they do not adhere to the definition of a “true” serotype. AAV serotype 2 (AAV2) has been used extensively for gene therapy due to its lack of pathogenicity, wide range of infectivity, and ability to establish longterm transgene expression (see, e g., Carter, Hum. Gone Ther., 15:541 (2005). Genome sequences of various AAV serotypes and comparisons thereof are disclosed in, for example, GenBank Accession numbers U89790, JOI 901, AF043303, and AF085716: Chiorini etal., J. Virol., 71:6823 (1997); Srivastava et al., J. Virol., 45:565 (1983); Chiorini et aL, J. Virol. 23: 1309 (1999); Rutledge et al., J. Virol., 22-309 (1998); and Wu etal., J. Virol., 24:8635 (2000)).
[0059] AAV rep and ITR sequences are particularly conserved across most AAV serotypes. For example, the Rep78 proteins of AAV2, AAV3 A, AAV3B, AAV4, and AAV6 are reportedly about 89-93% identical (see Bantel-Schaal et aL, J. Virol., 73(2):939 (1999)). It has been reported that AAV serotypes 2, 3 A, 3B. and 6 share about 82% total nucleotide sequence identity at the genome level (Bantel-Schaal etal., supra). Moreover, the rep sequences and ITRs of many AAV serotypes are known to efficiently cross-complement (e.g., functionally substitute) corresponding sequences from other serotypes during production of AAV particles in eukaryotic cells, such as mammalian cells or insect cells.
[0060] Generally, the cap proteins, which determine the cellular tropicity of the AAV particle, and related cap protein-encoding sequences, are significantly less conserved than Rep genes across different AAV serotypes. In view of the ability Rep and ITR sequences to cross-complement corresponding sequences of other serotypes, the AAV vector can comprise a mixture of serotypes and thereby be a 'chimeric' or 'pseudotyped' AAV vector. A chimeric AAV vector typically comprises AAV capsid proteins derived from two or more (e.g., 2, 3, 4, etc.) different AAV serotypes. In contrast, a pseudotyped AAV vector comprises one or more ITRs of one AAV serotype packaged into a capsid of another AAV serotype. Chimeric and pseudotyped AAV vectors are further described in, for example, U.S. Pat. No. 6,723,551: Flotte, Mol. Ther., 12(1): 1 (2006); Gao et al., J. Virol., 78:6381 (2004); Gao et al., Proc. Natl. Acad. Sci. USA, 23: 11854 (2002); De et al., Mol. Ther., 12:67 (2006); and Gao et al., Mol. Ther., 12:77 (2006). In certain embodiments, the AAV comprises one or more mutations in the capsid protein at one or more locations in the capsid protein.
[0061] Tn one embodiment, the AAV vector is generated using an AAV that infects humans (e.g., AAV6). Alternatively, the AAV vector is generated using an AAV that infects non-human primates, such as, for example, the great apes (e.g., chimpanzees). Old World monkeys (e.g., macaques) and New World monkeys (e.g., marmosets). In one embodiment, the AAV vector is generated using an AAV that infects a non-human primate pseudotyped with an AAV that infects humans. Examples of such pseudotyped AAV vectors are disclosed in, e.g., Cearley et al., Molecular Therapy. 12:528 (2006).
[0062] In addition to the nucleic acid sequence encoding a therapeutic gene, the AAV vector may comprise expression control sequences, such as promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), and the like, that provide for the expression of the nucleic acid sequence in a host cell. Exemplary expression control sequences are known in the art and described in, for example, Goeddel, Gene Expression Technology. Methods in Enzymology. Vol. 185. Academic Press. San Diego. Calif. (1990).
[0063] A large number of promoters, including constitutive, inducible, and repressive promoters, from a variety of different sources are well known in the art. Representative sources of promoters include for example, virus, mammal, insect, plant, yeast, and bacteria, and suitable promoters from these sources are readily available, or can be made synthetically, based on sequences publicly available, for example, from depositories such as the ATCC as well as other commercial or individual sources. Promoters can be unidirectional (i.e., initiate transcription in one direction) or bi-directional (i.e., initiate transcription in either a 3' or 5' direction). Non limiting examples of promoters include, for example, the T7 bacterial expression system, pBAD (araA) bacterial expression system, the cytomegalovirus (CMV) promoter, the SV40 promoter, and the RSV promoter. Inducible promoters include, for example, the Tet system (U.S. Pat. Nos. 5,464,758 and 5,814.618), the Ecdysone inducible system (No et al., Proc. Natl. Acad. Sci., J2:3346 (1996)), the T-REX™ system (Invitrogen, Carlsbad, Calif.), LACSWITCH™ System (Stratagene, San Diego, Calif), and the Cre-ERT tamoxifen inducible recombinase system (Indra et al., Nuc. Acid. Res., 22:4324 (1999); Nuc. Acid. Res., 28:e99 (2000); U.S. Pat. No. 7,112,715: and Kramer & Fuseenegger. Methods Mol. Bid., 308:123 (2005)).
[0064] Typically, AAV vectors are produced using well characterized plasmids. For example, human embryonic kidney 293T cells are transfected with one of the transgene specific plasmids
and another plasmid containing the adenovirus helper and AAV rep and cap genes. After 72 hours, the cells are harvested, and the vector is released from the cells by five freeze/thaw cycles. Subsequent centrifugation and berizonase treatment remove cellular debris and unencap si dated DNA. lodixanol gradients and ion exchange columns may be used to further purify each AAV vector. Next the purified vector is concentrated by a size exclusion centrifuge spin column to the required concentration. Finally, the buffer is exchanged to create the final vector products formulated (for example) in 1. times, phosphate buffered saline. The viral titers may be measured by TaqMan™ real-time PCR and the viral purity may be assessed by SDS-PAGE.
[0065] Modified AA V Capsid Proteins and Virus Capsids and Virus Vectors
[0066] The present disclosure provides AAV capsid proteins comprising at least one mutation (i.e., a modification, which can be a substitution or an insertion or a deletion) in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The mutated AAV capsid proteins, and the nucleic acids encoding them, are not found in nature (i.e., are non-natural) and have neither the sequence of the wild-type sequences found in nature nor the function of those sequences. In certain embodiments, the modifications at the one or more amino acid positions described can confer one or more desirable properties to virus vectors comprising the modified AAV capsid protein including without limitation: (i) enhancing intracellular trafficking to a target cell nucleus; (ii) enhancing the interactions with target cells; (iii) enhancing penetration through the mucus gel layer.
[0067] In certain embodiments, the modified AAV capsid protein of the disclosure comprises one or more mutations (i.e., modifications) in the amino acid sequence of the native, e.g., AAV6 capsid protein or the corresponding amino acid residue(s) of a capsid protein from another AAV serotype, including but not limited to AAV2, AAV3, AAV6, AAV7, AAV8, AAV9, AAV10, etc. The amino acid positions in other AAV serotypes or modified AAV capsids that “correspond to” these positions in the native AAV6 capsid protein will be apparent to those skilled in the art and can be readily determined using sequence alignment techniques and/or crystal structure analysis (Padron et al. (2005) J Virol. 79:5047-58).
[0068] Those skilled in the art will appreciate that for some AAV capsid proteins the corresponding modification will be an insertion and/or a substitution, depending on whether the corresponding amino acid positions are partially or completely present in the virus or, alternatively,
are completely absent. Likewise, when modifying AAV, the specific amino acid position(s) may be different than the position in AAV6.
[0069] As used herein, a “mutation” or “modification” in an amino acid sequence includes substitutions, insertions and/or deletions, each of which can involve one, two, three, four, five, six, seven, eight, nine, ten or more amino acids. In certain embodiments, the modification is a substitution. In other embodiments, the modification is an insertion (e.g., of a single amino acid residue between two amino acid residues in an amino acid sequence). In certain embodiments, the modification is a deletion. In certain embodiments, the modification is a modified amino acid.
[0070] It is to be understood that the substitutions and insertions described in the AAV capsid proteins of this disclosure can include substitutions and/or insertions with conservative amino acid residues. Such conservative substitutions are well known in the art and include, e.g., nonpolar amino acids Gly, Ala, Vai, Leu, He, Met, Phe, Trp and Pro can be substituted for one another; polar amino acids Ser, Thr, Cys, Tyr, Asn and Gin can be substituted for one another; negatively charged amino acids Asp and Glu can be substituted for one another; and positively charged amino acids Lys, Arg and His can be substituted for one another, in any combination.
[0071] The present disclosure also provides an AAV capsid comprising one or more mutations as well as a virus vector comprising one or more mutations.
[0072] In certain embodiments, recombinant AAV genomes comprise a transgene and one or more AAV ITRs flanking a nucleic acid molecule. AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic el al., Molecular Therapy, 22(11): 1900-1909 (2014).
[0073] Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided, are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from the rAAV genome, and helper virus functions. The AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV
genome TTRs, including, but not limited to, AAV serotypes 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, DJ or DJ/8. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.
[0074] Methods of generating a packaging cell comprise creating a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79: 2077- 2081), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23: 65-73) or by direct, blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259: 4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.
[0075] In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WL38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
[0076] Extracellular Vesicles
[0077] Also provided herein are extracellular vesicles (EVs) for delivery of virus vectors, e.g. AAV. Exemplary extracellular vesicles may include but are not limited to exosomes. However, the term “extracellular vesicles” should be interpreted to include all nanometer-scale lipid vesicles that are secreted by cells such as secreted vesicles formed from lysosomes.
[0078] EVs are cell-derived vesicles with a closed double-layer membrane structure. According to their size and density, EVs mainly include exosomes (30-150 nm), micro vesicles (MVs) (100- 1000 nm), and apoptotic bodies or cancer related oncosomes (1-10 pm). EVs are able to carry
various molecules, such as proteins, lipids andRNAs on their surface as well as within their lumen. The EV and exosomal surface proteins can mediate organ-specific homing of circulating EVs.
[0079] EVs are produced by many different types of cells including immune cells such as B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cells. EVs are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells, and tumor cells. EVs for use in the disclosed compositions and methods can be derived from any suitable cells, including the cells identified above. EVs have also been isolated from physiological fluids, such as plasma, urine, amniotic fluid and malignant effusions. Non-limiting examples of suitable EVs producing cells for mass production include dendritic cells (e.g., immature dendritic cell), Human Embryonic Kidney 293 (HEK) cells, 293T cells, Chinese hamster ovary (CHO) cells, and human ESC-derived mesenchymal stem cells. Other cell sources are useful for providing exosomes useful for bioactive loading in accordance with the present disclosure. These include, stem cells, cancer cell, myeloid cells, brain cells, bioreactors, and exosomes from plant, fungal or bacterial cells. Also, depending on the application, either for pain management, inflammation, neurodegenerative, autoimmune, cancer or recreational applications, the source of exosomes may vary as well as the desired cells to target will vary depending on the application and disease.
[0080] EVs can also be obtained from any autologous patient-derived, heterologous haplotype- matched or heterologous stem cells so to reduce or avoid the generation of an immune response in a patient to whom the EVs are delivered. Any EV-producing cell can be used for this purpose.
[0081] In certain embodiments, the extracellular vesicle is an EV mimetic-nanovesicles (M- NVs). M-NVs are a type of artificial EVs which can be generated from all cell types with comparable characteristics as EVs for alternative therapeutic modality.
[0082] EVs produced from cells can be collected from the culture medium by any suitable method. Typically, a preparation of EVs can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods. For example, EVs can be prepared by differential centrifugation, that is low speed (<20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet EVs, size filtration with appropriate filters (for example, 0.22 pm filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
[0083] The compositions embodied herein, e.g., EV-virus vector (e.g. AAV), may be administered to a subject by any suitable means. Administration may be topical (including ophthalmic and to mucus membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Vesicle-based compositions for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutically acceptable carriers, aqueous, powder or oily bases, thickeners and the like, may be necessary or desirable. In certain embodiments, delivery is via the intranasal or oral route. A physician will be able to determine the required route of administration for each particular patient.
[0084] In certain embodiments, the EVAAVs are delivered as a composition. The composition may be formulated for inhalation, by nebulization, or by aerosolization, or is intranasal, intratracheal, intrabronchial, oral, intravenous, subcutaneous, and/or intramuscular administration. In addition, the compositions may be administered via parenteral intracerebral, intravascular (including intravenous), subcutaneous, or transdermal administration. Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. The EVs may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharmaceutically acceptable carriers or excipients and the like in addition to the EVs.
[0085] In certain embodiments, the EVs are loaded with a desired bioactive substance, e.g., a therapeutic, medicinal, homeopathic agent, and the resulting loaded EVAAVs are targeted to the desired location in the subject by composition dosage form and administration route where the vesicles can release their contents to the target of interest. In certain embodiments, the bioactive molecule is a toxin, toxoid, or a non-toxic mutant of a toxin.
[0086] In some embodiments, the biologically active molecule is an activator for a positive costimulatory molecule or an activator for a binding partner of a positive co- stimulatory molecule. In some embodiments, the positive co- stimulatory molecule is a TNF receptor superfamily member. In some embodiments, the TNF receptor superfamily member is selected from the group
consisting of CD120a, CD120b, GDI 8, 0X40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, RANK, OCIF, TWEAK receptor, TACI, BAFF receptor, AT AR, CD271, CD269, AITR, TROY, CD358, TRAMP, and XEDAR. In some embodiments, the activator for a positive co-stimulatory molecule is a TNF superfamily member. In some embodiments, the TNF superfamily member is selected from the group consisting of: TNFa, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR ligand, and EDA-2. In some embodiments, the positive co-stimulatory molecule is a CD28-superfamily co-stimulatory molecule. In some embodiments, the CD28-superfamily co-stimulatory molecule is ICOS or CD28. In some embodiments, the activator for a positive co-stimulatory molecule is ICOSL, CD80, or CD86.
[0087] In other embodiments, the cytokine is selected from the group consisting of IL-2, IL-7, IL-10, IL-12, and IL-15. In some embodiments, the protein comprises a T-cell receptor (TCR), a T-cell co-receptor, a major histocompatibility complex (MHC), a human leukocyte antigen (HLA), or a derivative thereof. In some embodiments, the protein comprises a tumor antigen. In some embodiments, the tumor antigen is selected from the group consisting of: alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUCl, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, Mesothelin, VEGFR, alphafolate receptor, CE7R, IL-3, Cancer-testis antigen, MART-1 gplOO, and TNF-related apoptosisinducing ligand.
[0088] Modified EVs: In certain embodiments, the EVs are modified EVs. A desired modification of an EV can be introduced by transducing a eukaryotic cell line (e.g. mammalian cell line), e.g., HEK293 cells with a desired polynucleotide. For example, a desired polynucleotide can encode a targeting or tropism moiety which specifically targets the EVAAVs to a desired organ, tissue or cell. Non-limiting examples of tropism moieties that can be used with the present disclosure include those that can bind to a marker expressed specifically on an alveolar epithelial cell (AEC), lung fibroblasts, pulmonary artery endothelial cells (PAEC), pulmonary artery smooth muscle cells (PASMC) or respiratory epithelial cells. Unless indicated otherwise, the term “targeting moiety,” as used herein, encompasses tropism moieties. The targeting moiety can be a
biological molecule, such as a protein, a peptide, a lipid, or a carbohydrate, or a synthetic molecule. For example, the targeting moiety can be an affinity ligand (e.g., antibody, VHH domain, phage display peptide, fibronectin domain, camelid, aptamer, VNAR), a synthetic polymer (e.g., PEG), a natural ligand/molecule (e.g., CD40L, albumin, CD47, CD24, CD55, CD59), a recombinant protein, but not limited thereto.
[0089] In certain aspects, the targeting moiety, is displayed on the surface of EVs (e.g., exosomes). The targeting moiety can be displayed on the EV surface by being fused to a scaffold protein (e.g., as a genetically encoded fusion molecule). In some aspects, the targeting moiety can be displayed on the EV surface by chemical reaction attaching targeting moiety to an EV surface molecule. A non-limiting example is PEGylation. Tn some aspects, EVs disclosed can further comprise a targeting moiety, in addition to an antigen, adjuvant, or immune modulator.
[0090] In certain embodiments, an engineered extracellular vesicle (eEV), comprises an extracellular vesicle isolated from a biological cell with at least one lipid incorporated into the membrane thereof.
[0091] In this embodiment the lipid may be a synthetic lipid or an exogenous lipid/non-native lipid or a combination thereof. A synthetic lipid comprises l-palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine (POPC), l-palmitoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP) or a combination thereof. Also, the biological cell may be associated with a pathophysiological condition. In one aspect the pathophysiological condition may be a cancer. In another aspect the pathophysiological condition is cystic fibrosis, COPD, asthma, tuberculosis, or an infection, such as by a virus, bacteria or parasite. In another aspect the biological cell may be a primary mesenchymal stem cell, an embryonic kidney cell, an embryonic fibroblast cell, an alveolar basal epithelial cell, or a monocytic cell or an immortalized cell-line thereof.
[0092] In another embodiment, there is provided a method for preparing an engineered extracellular vesicle, comprising the steps of culturing the biological cell in vitro in a culture medium; isolating the extracellular vesicles from the biological cells; and extruding the isolated extracellular vesicles with the at least one lipid to form the engineered extracellular vesicle.
[0093] The extracellular vesicle delivery vehicle can comprise at least one lipid hybridized with a membrane of the extracellular vesicle; a nucleic acid loaded within a core of the extracellular
vesicle; and a therapeutic drug complexed with the extracellular vesicle either within or on the surface. The lipid may be a synthetic lipid comprising 1 -palmitoyl -2-oleoyl-sn-glycero-3- phosphocholine (POPC), l-palmitoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP) or a combination thereof. Also, the nucleic acid may be a synthetic DNA, a naturally occurring DNA, a synthetic RNA, or a naturally occurring RNA, or fragments thereof. Particularly, the synthetic RNA or naturally occurring RNA may be a small-interfering RNA (siRNA) or a microRNA (miRNA).
[0094] Methods for preparing engineered extracellular vesicles (eEV) include isolating extracellular vesicles from a biological cell of interest. The membranes of the extracellular vesicles are hybridized or modified with at least one synthetic lipid, for example, a synthetic hydrated lipid, such as by extrusion, to produce a modified or hybrid engineered extracellular vesicles. Examples of suitable synthetic lipids are, but not limited to, 1 -Palmitoyl -2-oleoyl-sn-glycero-3 - phosphocholine (POPC), 1-Palm itoyl-2-oleoyl-sn-glycero-3 -phosphoglycerol (POPG), dipalmitoylphosphatidylcholine (DPPC), or l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DOTAP).
[0095] Delivery
[0096] Compositions described herein (e.g., EV-rAAVs, pharmaceutical compositions) may be used in vivo as well as ex vivo. In vivo gene therapy comprises administering the vectors of this disclosure directly to a subject. Pharmaceutical compositions can be supplied as liquid solutions or suspensions, as emulsions, or as solid forms suitable for dissolution or suspension in liquid prior to use. For administration into the respiratory tract, one exemplary mode of administration is by aerosol, using a composition that provides either a solid or liquid aerosol when used with an appropriate aerosolubilizer device. Another some mode of administration into the respiratory tract is using a flexible fiberoptic bronchoscope to instill the vectors. Typically, the viral vectors are in a pharmaceutically suitable pyrogen-free buffer such as Ringer's balanced salt solution (pH 7.4). Although not required, pharmaceutical compositions may optionally be supplied in unit dosage form suitable for administration of a precise amount.
[0097] A composition described herein (e g., EV-rAAVs, pharmaceutical compositions) can be administered by any suitable route, e.g., by inhalation, nebulization, aerosolization, intranasally,
intratracheally, intrabronchially, orally, parenterally (e.g., intravenously, subcutaneously, or intramuscularly), orally, nasally, rectally, topically, or buccally. They can also be administered locally or systemically. In some embodiments, a composition described herein is administered in aerosolized particles intratracheally and/or intrabronchially using an atomizer sprayer (e.g., with a MADgic® laryngo-tracheal mucosal atomization device). In some embodiments, the pharmaceutical composition is administered parentally. In other some embodiments, the pharmaceutical composition is administered systemically. Vectors can also be introduced by way of bioprostheses, including, by way of illustration, vascular grafts (PTFE and dacron), heart valves, intravascular stents, intravascular paving as well as other non-vascular prostheses. General techniques regarding delivery, frequency, composition and dosage ranges of vector solutions are within the skill of the art.
[0098] For administration to the upper (nasal) or lower respiratory tract by inhalation, the compositions described herein (e.g., EV-rAAVs, pharmaceutical compositions.) are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.
[0099] Alternatively, for administration by inhalation or insufflation, the composition may take the form of a dry powder, for example, a powder mix of the agent and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges, or, e.g., gelatine or blister packs from which the powder may be administered with the aid of an inhalator, insufflator or a metered-dose inhaler.
[00100] For intra-nasal administration, the agent may be administered via nose drops, a liquid spray, such as via a plastic bottle atomizer or metered-dose inhaler. Typical of atomizers are the Mistometer (Wintrop) and the Medihaler (Riker).
[00101] Administration of the compositions described herein (e.g., EV-rAAVs, pharmaceutical compositions) may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners. The EV-rAAVs or pharmaceutical compositions
described herein can be administered once, or multiple times, at the same or at different sites. The administration of the agents of the disclosure may be essentially continuous over a preselected period of time or may be in a series of spaced doses.
[00102] The compositions described herein (e.g., rAAVs, pharmaceutical compositions) can be administered in combination with one or more additional therapeutic agent. Any suitable additional therapeutic agent(s) may be used, including standard of care therapies, e g. for CF. In some embodiments, the one or more additional therapeutic agents includes an antibiotic (e.g., azithromycin (ZITHROMAX®), amoxicillin and clavulanic acid (AUGMENTIN®), cioxacillin and diclocacillin, ticarcillin and clavulanic acid (TIMENTIN®), cephalexin, cefdinir, cefprozil, cefaclor; sulfamethoxazole and trimethoprim (BACTRIM®), erythromycin/sulfisoxazole, erythromycin, clarithromycin, tetracycline, doxycycline, minocycline, tigecycline, vancomycin, imipenem, meripenem, Colistimethate/COLISTIN®, linezolid, ciprofloxacin, levofloxacin, or a combination thereof), a mucus thinner (e.g., hypertonic saline or domase alfa (PULMOZYME®)), a CFTR modulator (e.g., ivacaftor (KALYDECO®), lumacaftor, lumacaftor/ivacaftor (ORKAMBI®), tezacaftor/ivacaftor (SYMDEKO®), or TRIKAFTA® (elexacaftor/ivacaftor/tezacaftor)), a mucolytic (e.g., acetylcysteine, ambroxol, bromhexine, carbocisteine, erdosteine, mecysteine, and dornase alfa), an immunosuppressive agent, normal saline, hypertonic saline, or a combination thereof.
[00103] For example, any one the compositions described herein may be administered in combination with one or more immunosuppressive agents. Any suitable immunosuppressive agent may be used. For example, non-limiting examples of immunosuppressive agents include corticosteroids (e.g., an inhaled corticosteroid (e.g., beclomethasone (QVAR®), budesonide (PULMICORT®), budesonide/formoterol (SYMBICORT®), ciclesonide (ALVESCO®), fluticasone (FLOVENT HFA®), fluticasone propionate (FLOVENT DISKUS®), fluticasone furoate (ARNUITY ELLIPTA®), fluticasone propionate/salmeterol (ADVAIR®), fluticasone furoate/umeclidinium/vilanterol (TRELEGY ELLIPTA®), mometasone furoate (ASMANEX®), or mometasone/formoterol (DULERA®), predisone, or methylprednisone), polyclonal antilymphocyte antibodies (e.g., anti -lymphocyte globulin (ALG) and anti-thymocyte globulin (ATG) antibodies, which may be, for example, horse- or rabbit-derived), monoclonal anti-lymphocyte antibodies (e g., anti-CD3 antibodies (e g., murmomab and alemtuzumab) or anti-CD20 antibodies (e.g., rituximab)), interleukin-2 (IL-2) receptor antagonists (e.g., daclizumab and basiliximab),
calcineurin inhibitors (e.g., cyclosporin A and tacrolimus), cell cycle inhibitors (e.g., azathioprine, mycophenolate mofetil (MMF), and mycophenolic acid (MPA)), mammalian target of rapamycin (mTOR) inhibitors (e.g., sirolimus (rapamycin) and everolimus), methotrexate, cyclophosphamide, an anthracycline (e.g., doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, mitoxantrone, or a combination thereof), a taxane (e.g., TAXOL® (paclitaxel)), and a combination thereof (e.g., a combination of a calcineurin inhibitor, a cell cycle inhibitor, and a corticosteroid).
[00104] The compositions described herein may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers. As noted above, the relative proportions of active ingredient and carrier are determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
[00105] The dosage of the present compositions will vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. It is desirable that the lowest effective concentration of virus be utilized in order to reduce the risk of undesirable effects, such as toxicity.
[00106] Augmenters: The compositions can be used in combination with augmenters of AAV transduction to achieve significant increases in transduction and/or expression of nucleic acid molecules (transgenes). Any suitable augmenter can be used. For example, U.S. Pat. No. 7,749,491, which is incorporated by reference herein in its entirety, describes suitable augmenters. The augmenter may be a proteasome modulating agent. The proteasome modulating agent may be an anthracycline (e.g., doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, or mitoxantrone), a proteasome inhibitor (e.g., bortezomib, carfilzomib, and ixazomib), a tripeptidyl aldehyde (e.g., N-acetyl-1 -leucyl- 1 -leucyl- 1 -norleucine (LLnL)), or a combination thereof. In some embodiments, the augmenter is doxorubicin. In other embodiments, the augmenter is idarubicin.
[00107] The compositions, e.g., EV AAV and the augmented s) may be contacted with a cell, or administered to a subject, in the same composition or in different compositions (e.g., pharmaceutical compositions). The contacting or the administration of the compositions and the augmenter(s) may be sequential or simultaneous.
EXAMPLES
[00108] Example 1: Extracellular vesicle-associated, genetically engineered adeno-associated virus 6 as a gene delivery platform for inhaled gene therapy.
[00109] Extracellular vesicles (EVs) are naturally occurring molecular vesicles produced and released from plant and animal cells and play important roles in intercellular communication (1). Due to its ability to shuttle various cargoes, including metabolites, proteins, and nucleic acids, through extracellular milieus and between cells, EV has been widely investigated as a vehicle for enhancing therapeutic delivery (2, 3).
[00110] The inventors have recently discovered that EVs are capable of efficiently penetrating unperturbed airway mucus samples collected from patients with muco-obstructive lung diseases (MOLDs), leading to the hypothesis that EV would enhance the inhaled gene transfer efficacy of AAV if the AAV externally associated with the EV does not compromise the mucus-penetrating property of EVs.
[00111] To test this hypothesis, EVAAVs were prepared based on AAV serotype 6 (AAV6) leveraging on the inventors previous finding that AAV6, unlike other widely used AAV serotypes, possesses unique ability to resist mucoadhesion. The diffusion rates of EV and EVAA6 in human airway mucus were confirmed to be virtually identical, underscoring that AAV6 association did not negatively impact on the newly discovered ability of EV to efficiently traverse the airway mucus gel. Encouraged by this observation, a pilot study was conducted to investigate whether piggybacking on EV would enhance the transduction efficiency of AAV6 in mucus-covered airway epithelial cells in vitro and in vivo. In this study, it was found that EV-associated AAV6 (EVAAV6) provided significantly greater reporter transgene expression in mucus-covered airliquid interface (ALI) cultures of primary human airway epithelial (HAE) cells and in mouse lungs (following intratracheal administration) compared to standard (i.e., EV-free) AAV6. It was noted that pre-existing neutralizing antibody (Nab) not only compromises cellular uptake but also can promote AAV entrapment in airway mucus via multivalent interactions between N-gly can-rich Fc regions of virus-associated NAb and mucin fibers (11-13). However, it is expected that such effects would be at least partially evaded by the association of AAV with EVs, in conjunction with capsid engineering, which will be tested for use of this hybrid system for patients with pre-existing AAV- specific immunity or for repeated administration. Embracing the limited packaging capacity of AAV (i.e., 4.7 kb), we will also assess the ability of EVAAV6 and newly engineered mutant AAV6
vectors (m A AV6) piggybacked on EVs (EVm A AV6) to deliver two reporter cassettes individually packaged in individual AAV vectors into the same cells for potential delivery of large genes beyond the natural AAV packaging capacity (e.g., CFTR gene).
[00112] Non-mucoadhesive AA V6 as a background serotype for engineering novel EVmAA V6. AAV is a non-pathogenic parvovirus that has been most widely investigated as a virus-based delivery platform for safe, effective and long-lasting gene therapy of numerous diseases affecting different organs. Promising outcomes in preclinical studies have led to numerous human clinical trials (16- 19), and FDA has recently approved AAV-based gene therapy medicines for the treatment of a rare eye disease and spinal muscular atrophy (20-22). However, such clinical breakthrough is yet to be realized for inhaled gene therapy of chronic MOLDs, such as asthma, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), due to inability of clinically tested gene vectors to provide therapeutically relevant gene transfer efficacy in the lung (23- 26). The only AAV serotype tested in clinical trials of inhaled gene therapy to date, AAV2, is not efficient in transducing airway cells in human lungs and readily rejected by Nab upon initial and/or subsequent treatment(s) (23, 27). While underappreciated in early clinical studies, airway mucus is now recognized as a rate-limiting extracellular barrier to inhaled therapeutics (28-38). Airway mucus is essentially a “sticky net”, primarily composed of a dense mesh of mucin fibers containing negatively charged glycosylated domains flanked by periodic hydrophobic regions (39), which forms an adhesive and steric barrier to inhaled foreign matters. The barrier properties are further reinforced in the lungs of patients with MOLDs characterized by chronic inflammation and mucus accumulation (23, 29, 37, 40, 41). Inhaled gene vectors trapped in the airway mucus cannot efficiently traverse and distribute throughout the lung airways and are rapidly removed from the lung by physiological mucus clearance mechanisms prior to reaching the underlying airway cells (29, 37). Indeed, we have demonstrated that many of leading and/or clinically tested gene vectors, including various AAV serotypes (i.e., AAV1, 2 and 5 (12, 42)), adenovirus (42), and polymeric non-viral gene vectors (43, 44), cannot efficiently penetrate human airway mucus collected from patients with MOLDs (i.e., sputum). Of note, sputum samples serve as a reliably representative ex vivo model of pathologically thickened human airway mucus barrier, which is a common feature of lung airways of MOLDs. Collectively, the airway mucus is now universally appreciated as one of the key obstacles that must be overcome by inhaled gene vectors to achieve clinically relevant inhaled gene delivery efficacy (23, 29, 37, 38). Encouragingly, the inventors have discovered that AAV6, unlike other serotypes, possesses unique ability to avoid
mucoadhesion and thus efficiently percolate the human airway mucus (FTGS. 2A, 2B) It was found that AAV6 exhibited significantly and uniformly enhanced diffusion rates in sputum samples collected from multiple independent patients compared to AAV1, a serotype shown to outperform the clinically tested AAV2 (45, 46) (10). As a result, AAV6 provided markedly more widespread and greater reporter transgene expression in mucus-covered ALI cultures of primary HAE cells and in mucus-plugged lung airways of transgenic mouse model of MOLDs, compared to AAV1 (10). Of note, AAV6 binds to a- 2,6-linked sialic acid (47) which is rich on the apical surface of human airway epithelial cells (48). To this end, AAV6 constitutes an excellent background serotype to implement EV piggybacking and capsid engineering for enhanced inhaled gene transfer efficacy, supposed that the non- mucoadhesive capsid property is retained.
[00113] Recombinant library of capsid optimized AAV rationally designed to promote intracellular trafficking to cell nuclei. Proteasome degradation of AAV capsid protein is a primary intracellular hurdle that compromises transduction efficiency of AAV- based vectors following endocytic uptake regardless of the target cell types (49-54). Of note, intact AAV capsid is required for efficient delivery of DNA payloads to cell nuclei, particularly more so for postmitotic cells, such as various lung airway cells (55). To address this critical restriction, proteasome inhibitor or capsid modification has been employed and shown to enhance the ability to AAV vectors to mediate transgene expression and/or to avoid AAV-specific immune responses by reducing antigen presentation (54, 56-60). 29 conservative amino acid positions on the AAV capsid were identified that tolerate mutagenesis (FIGS. 2A, 2B). Several mutations were introduced to different AAV serotypes, and the improvement in vector performances was validated. Specifically, these mutant vectors were demonstrated to facilitate intracellular processing and trafficking to nuclei (62, 65, 68, 69) and/or reduce AAV-specific immune responses (70, 71) by minimizing the proteasome degradation of AAV vectors. It was thus proposed to engineer a panel of self-encoding mutants, backgrounded on the non-mucoadhesive AAV6, to possess one or more (up to three) substitution(s) at each of 29 conserved phosphorylation sites with 20 naturally- occurring amino acids. Mutations in the panel are located on the AAV capsid surface to potentially contribute to vector interactions with surrounding biological entities, including Nab, cells and mucus gel. mAAV6 will be screened fortheir ability to resist mucoadhesion while enhancing the nuclear delivery of DNA payloads, using complementary models, including ALI culture of primary HAE cells, sputum samples collected from patients with MOLDs and the above-mentioned mucus-plugged mouse model (72). It is expected
that new mAAV6 candidates would be identified that provide enhanced intracellular trafficking, reduced immunogenicity and non- mucoadhesive surface, which will be used to prepare EVmAAV6 for further in vivo evaluations. Overall, it is hypothesized that combination of (i) piggybacking of non-mucoadhesive AAV6 on EVs and (ii) rational capsid_engineering to facilitate intracellular trafficking will collectively result in an innovative hybrid delivery platform capable of overcoming multiple biological delivery barriers to provide unprecedented, inhaled gene transfer efficacy (Table 1).
[00114J Proof-of-principle preclinical therapeutic efficacy study: thymulin gene therapy for treating allergic asthma. Thymulin provides remarkable anti- inflammatory and anti-fibrotic effects in the lungs of a preclinical model of allergic asthma. Specifically, the inventors found that thymulin-expressing plasmids delivered by the newly engineered polymeric gene vectors (73) reversed key pathological hallmarks of allergic asthma, including asthmatic inflammation, pulmonary fibrosis, and mechanical dysregulation, in the lungs of an ovalbumin (OVA)-based allergic asthma model, primarily by immunomodulation (74)). Thus, it is proposed to investigate the therapeutic efficacy of EVAAV6 and lead EVmAAV6 carrying a transgene expression cassette encoding the thymulin to establish proof-of-principle clinical relevance. Despite being widely used in preclinical settings, it is noted that OVA-based models hold inherent limitations, including weak relevance to human asthma-causing allergens, lack of continuous challenge and relatively shortlived nature (75). To this end, therapeutic approach will be evaluated additionally in a more human
asthma-like preclinical model, specifically mouse model of chronic allergic asthma established by continuous inhaled challenges with house dust mite (HDM) (76-78). While the primary goal of is to develop a hybrid gene delivery platform universally applicable to MOLDs, successful outcomes in this efficacy study will pave a way for clinical development of inhaled gene therapy of highly refractory chronic asthma.
[00115] Development of EVmAA V6 as a novel gene delivery platform for inhaled gene therapy of MOLDs. As summarized in Table 1, association with EVs potentially enhances AAV6 transduction in mucus-covered lung airways in a multi-pronged manner. EVAAV6 is capable of efficiently penetrating the airway mucus regardless of whether AAV6 is associated with EVs internally or externally, due to the mucus-penetrating properties of both components. Likewise, EVAAV6 can synergistically promote uptake of the DNA payload by lung airway cells, following inhaled administration, due to the natural ability of EVs to be taken up by various cells as well as the inherent affinity of AAV6 to the apical receptors on lung airway cells. Of note, EV AAV, irrespective of serotype, has not been investigated for inhaled gene therapy applications until our recent pilot study demonstrating that EVAAV6 provides markedly greater reporter transgene expression in mouse lungs compared to AAV6 following intratracheal administration. EVAAV6 may also bypass neutralization by pre-existing AAV-specific NAb, increase packaging capacity, reduce clinical doses and/or enable repeated dosing to mediate sustained transgene expression. To this end, we expect our proposal to yield a novel and innovative hybrid gene delivery platform that provides unprecedented gene transfer efficacy potentially with broad applicability.
[00116] Investigation of a recombinant panel of rationally-designed, capsid-optimized AAV6 variants. Prior studies of novel AAV vector development involve screening of libraries composed of randomly introduced mutations. Here, a recombinant library of rationally designed, selfencoding mAAV6 (/.< ., ~3 x 107 different variants) is established. The mutants possess one or up to three single amino acid substitution(s) at 29 phosphorylation sites where mutation in each location has been confirmed not to compromise viral particle structure/integrity and general infectivity, while endowing AAV vectors with an additional functional arm to facilitate intracellular trafficking to cell nuclei, ultimately to enhance gene transfer efficacy.
[00117] Use of most relevant in vitro, ex vivo and in vivo experimental settings to develop clinically-relevant inhaled gene delivery strategies. Limited preclinical-to-clinical correlation
observed in many of the inhaled gene delivery studies is largely attributed to the lack of a single experimental model reliably recapitulating delivery hurdles found in relevant human lung disease conditions. Here, it is proposed to use complementary in vitro (mucus-covered ALI cultures established with airway cells harvested from patients), ex vivo (unperturbed sputum freshly collected from patients) and in vivo (mouse model exhibiting chronic inflammation and airway mucus hypersecretion) models concurrently to evaluate and screen mAAV6 and EVmAAV6 in experimental settings exhibiting key delivery and immunological barriers found in the lungs of patients with MOLDs.
[00118] Potential development of novel immunomodulatory gene therapy for treating asthma. The proof-of-principle study shows that inhaled thymulin gene therapy, due to its unique immunomodulatory properties, provides compelling therapeutic benefits in a mouse model of OVA-induced allergic asthma. We expect to establish promising therapeutic efficacy in a more human asthma- like model (i.e., HDM-challenged chronic allergic asthma model) via efficient thymulin transgene expression mediated by our lead EVmAAV6. Despite not being the primary goal of this proposal, successful execution of this study may promote clinical development of long- lasting gene therapy of asthma.
[00119] EVAAV6 efficiently penetrates human airway mucus and provides markedly greater transgene expression compared to AAV6 in a human bronchial epithelial cell line. Based on the pilot observation thatEVs are capable of efficiently penetrating human airway mucus, it was hypothesized that EV AAV prepared with AAV vectors with non-mucoadhesive capsids (e.g, AAV6; FIGS. 2A, 2B) would efficiently penetrate the human airway mucus as well. EVAAV6, was first prepared as described herein, and comprehensive characterization was conducted using western blot analysis, tetraspanin chips, Spectradyne particle analyzer and dynamic light scattering (DLS). It was confirmed that EV and EVAAV6 similarly expressed syntenin-1 (ST-1) and CD9 (FIG. 1A), providing evidence that both are similarly exosome-rich EV populations.
[00120] Transmission electron microscopy (TEM) revealed that AAV6 was internally and externally associated with EV for EVAAV6 produced in HEK293 cells, whereas post-mixture of individually prepared EV and AAV6 (EV+AAV6) showed no association. In parallel, DLS analysis showed greater hydrodynamic diameters of EVAAV6 compared to EV, reflecting the presence of
the externally associated AAV6 on EVAAV6. For this hypothesis, EV and EVAAV6 were fluorescently labeled, and their diffusion behaviors were investigated in CF sputum using multiple particle tracking (MPT). It was found that both EV and EVAAV6 exhibited the mean square displacement (MSD) values greater than those of mucus-penetrating AAV6 on average, underscoring that EV further enhanced the mucus-penetrating ability of AAV6 upon their association. Transduction efficiency of AAV6, EVAAV6 and EV+AAV6 was next compared in human lung airway cell line (i.e., human bronchial epithelia or HBE cells). At all multiplicity of infection (MOI) tested, EVAAV6, but not EV+AAV6, provided roughly two orders of magnitude greater luciferase transgene expression in HBE cells compared to AAV6.
[00121] EVAA V6, but not EV+AA V6, provides significantly greater transgene expression compared to AAV6 in mouse lungs following intratracheal administration. It was then investigated whether the enhancements in mucus penetration and cellular transduction enabled by EV piggybacking (FIGS. 4A-4E) resulted in the improvement of reporter transgene expression in the lung in vivo. Briefly, C57BL/6 mice intratracheally received AAV6, EVAAV6 or EV+AAV6 at a dose of 4 x 109 GC per animal and lung tissues were harvested 2 weeks after the administration for the assessment of reporter transgene expression. Lung tissues from individual animals were then cryosection and imaged under a confocal microscope without amplification of the signal with immunohistochemical staining. The representative tile-scanned images showed that all three treatments mediated uniform YPF transgene expression, but EVAAV6 exhibited greater fluorescence intensity compared to the other groups (FIG. 4A), which was quantitatively validated by Image-based quantitative analysis with a custom-written MATLAB software (10) (FIG. 4B). In a separate set of animals, it was also found that EVAAV6 provided an order of magnitude greater luciferase activity compared to AAV6 and EV+AAV6 (FIG. 4C).
[00122] EVAAV6, but not EV+AAV6, provides significantly greater coverage and level of transgene expression in mucus-covered ALI cultures of primary HAE cells compared to AA V6. For clinical relevance, it is critical that our hybrid delivery strategy enhances transduction of lung airway cells found in human lungs. To test this, we assessed the ability of AAV6, EVAAV6 and EV+AAV6 to transduce mucus-covered ALI culture of primary HAE cells, specifically bronchial epithelial cells. Of note, the model uniquely emulates the physiological human lung airways and associated biological barriers, thereby serving as an excellent testbed for evaluating the performance of lung-directed gene delivery platforms (10, 23, 9). Representative confocal images
revealed that EVAAV6, but not EV+AAV6, mediated more uniform and enhanced reporter transgene expression compared to AAV6, in agreement with the in vivo observations. Quantitatively, EVAAV6 exhibited markedly and significantly greater coverage and level (i.e., intensity) of transgene expression compared to AAV6 and EV+AAV6. The series of the in vitro and in vivo analyses (FIGS. 3A, 3B, 4A-4E, 5A-5C) consistently and collectively suggests that EV markedly enhances the ability of AAV6 to transduce lung airway cells by breaching multiple biological delivery barriers. Further, it appears that the association of EV and AAV6 during the production, rather than post- mixture after independent preparation of EV and AAV6, is essential for the enhancement.
[00123] Capsid optimization significantly improves in vitro gene transfer efficacy of AA V6 hy enhancing intracellular trafficking to cell nuclei. In parallel to the EV piggybacking strategy, capsid-optimized mAAV6 was engineered to facilitate the intracellular trafficking of DNA payloads loaded in the capsid to cell nuclei as an additional means to enhance transduction efficiency. Specifically, at least three different mAAV6 were constructed carrying one or two mutation(s), including AAV6-T492V, AAV6- S663V and AAV6-492V+S663V, that exhibited significantly greater in vitro transduction efficiency compared to wild-type AAV6. Of note, the AAV6-T492V+S663V harbors two mutations that camouflage the AAV6 capsids from phosphorylation by intracellular kinases, thereby reducing proteasome degradation. A marked increase was confirmed in the nuclear fraction of the mutant compared to wild-type AAV6, suggesting that its unique ability to resist the proteasome degradation facilitated intracellular trafficking of the vector to cell nuclei. In addition, the proteasome degradation promotes AAV capsid presentation by antigen-presenting cells and thus the vector-associated immune responses. To this end, the ability to minimize the intracellular degradation is an additional mechanism by which AAV- mediated gene transfer efficacy is enhanced while potentially reducing vector-specific immune responses (71). It was also confirmed that another mutant, AAV6-S663V, provided marked greater reporter transgene expression in primary human airway cells, including basal cells, compared to wild-type AAV6, presumably by enhancing nuclear import of the vector. It is thus expected that EV piggybacking and capsid engineering will synergistically enhance lung airway transduction.
[00124] Multiple capsid-optimized mAAV6 efficiently penetrate human airway mucus. Given that newly engineered mAAV6 would be both internally and externally associated with EV to form EVmAAV6, it is critical that mAAV6 retains the unique non- mucoadhesive property inherent to
wild-type A AV6 (FTGS. 2A, 2B and (10)). Using MPT the diffusion rates of several m A AV6 were thus quantitatively evaluated, including one that confirmed for significantly improved intracellular trafficking and cellular transduction (AAV6- T492V+S663V, in multiple independent CF sputum samples. It was found that all these mAAV6 exhibited similar or greater MSD values on average compared to wild-type AAV6 (FIG. 6), suggesting that the capsid optimization did not compromise the non-mucoadhesive property of the parent wild-type AAV6.
|00125] Inhaled thymulin gene therapy normalizes key pathological features in the lungs of a mouse model of allergic asthma. The inventors have recently demonstrated that inhaled thymulin gene therapy resolves key pathological outcomes, including allergic (/.<?., T helper type 2 or Th2) inflammation, pulmonary fibrosis and mechanical dysregulation, manifested in a mouse model of OVA-induced allergic asthma in a therapeutic manner (74). The model was established with sequential sensitization and challenge with OVA (81) and it was confirmed that relevant disease phenotypes were all fully established and retained during the study period. Animals were then intratracheally treated with the synthetic nanoparticles developed to efficiently penetrate human airway mucus (73) carrying thymulin-expressing plasmids. It was first histologically determined that immune cell infiltration, mucus hypersecretion and airway constriction were normalized by the therapy (FIG. 7A). In parallel, bronchoalveolar fluid (BALF) was harvested from mice from each group and analyzed the levels of Th2 cytokines, including IL- 4 and IL-13, and pro-fibrotic mediators, including VEGF and TGF- , using enzyme-linked immunosorbent assay (ELISA). The levels of all these key soluble factors were significantly elevated in the model (OVA-SAL group), as observed in the lungs of patients with allergic asthma, but the inhaled thymulin gene therapy (OVA- THY group) brought them all down to the levels observed with healthy mice (CTRL- SAL group) (FIG. 7B). It was also found that the levels of chemokines for both eosinophils (CCL11 or eotaxin) and neutrophils (CXCL1) elevated in the lungs of asthmatic mice were normalized by the thymulin gene therapy (74).
[00126] The methacholine challenge test was conducted next, commonly performed in the clinic to evaluate the lung function of patients with asthma (82). The airway hyperresponsiveness (AHR) in the asthmatic lungs undergoing fibrotic process (83) was confirmed by more pronounced dosedependent increase in airway resistance and decrease in dynamic compliance (C, dyn). It was found that the thymulin gene therapy normalized the AHR, underscoring that the mechanical dysregulation was resolved inthis model (FIG. 7C). Finally, it was discovered that the compelling
and comprehensive therapeutic benefits were achieved primarily by immunomodulatory effects of the thymulin gene therapy. Specifically, the therapy mediated therapeutically favorable phenotypic shifts of key immune cells: lymphocytes from pathological Th2 to therapeutic regulatory T (Treg) subtype and macrophages from M2 to Ml subtype (74). To this end, thymulin constitutes an excellent therapeutic agent for establishing proof-of-principle clinical relevance of the lead EVmAAV6 to be developed in this study.
[00127 J Example 2: Research Strategy.
[00128] The overall goal of this study is to develop and evaluate novel hybrid gene delivery platform based on EVmAAV6 for inhaled gene therapy of MOLDs (FIG. 8). A recombinant library of capsid-optimized mAAV6 be constructed providing enhanced intracellular trafficking to cell nuclei, while retaining the non-mucoadhesive capsid property of wild-type AAV6. The mutants will then be extensively screened using complementary experimental models closely emulating MOLDs (e.g., CF, COPD, and asthma) to determine lead candidates providing efficient delivery of DNA payloads to cell nuclei of mucus-covered lung airway cells. Those testbeds include mucus-covered ALI cultures of primary HAE cells (in vitro), human airway mucus freshly collected from patients (ex vivo) and a mucus-plugged mouse model of MOLDs (in vivo). First, the mAAV6 candidates will be screened using the ALI culture, and a few selected mutants will be evaluated for efficient penetration through unperturbed sputum samples spontaneously expectorated by patients with CF and possibly patients with COPD or asthma if available. A mutant library will be screened the animal model to determine lead mAAV6. Subsequently, EVmAAV6 will be prepared based on lead mAAV6 candidates, which will be assessed for coverage and overall level of reporter transgene expression using ALI cultures of primary HAE cell sand the mucus-plugged mouse model of MOLDs. Two winners achieving either greater coverage or overall level will then be investigated for the ability to deliver two reporter cassettes individually packaged in mAAV6 into the same cells in vitro and in vivo for potential delivery of a large gene beyond the natural packaging capacity of AAV. In parallel, the lead EVmAAV6 will be evaluated for their ability to provide long-term transgene expression by transducing airway progenitor cells or by allowing repeated treatment without being inactivated by the host immune system. These lead EVmAAV6 will be constructed to carry thymulin-encoding DNA cassette and evaluated for therapeutic efficacy in well-established mouse models of allergic asthma. Number of animals to be used for each proposed study is determined by power calculations based on our preliminary data (5% significance level and 90%
power). Studies will be performed with both male and female animals in equal proportions. Two- tailed Student’s /-tests (assuming an unequal variance) and ANOVA, followed by post-hoc analysis, will be executed for two- and multi-group comparisons, respectively.
[00129] Screen a panel of newly engineered recombinant mAA V6 for mucus penetration and nuclear import in vitro, ex vivo and/or in vivo. Engineer and screen capsid- optimized, selfencoding mAAV6 for (A) nuclear import in mucus-covered ALI cultures of primary human airway cells in vitro, (B) penetration through human airway mucus ex vivo and (C) nuclear import in lung airway cells of a transgenic mouse model exhibiting an enhanced mucus barrier manifested in human MOLDs.
[00130] A panel of capsid-optimized mAAV6 that potentially enhance intracellular trafficking to cell nuclei, while retaining the capsid integrity will be established. Specifically, a library of mAAV6 will be generated by substituting one or up to three amino acid(s) at 29 conserved positions. The previously implemented substitutions were based on similarity in the amino acid structure, but here these will replace amino acids at these positions with all 20 naturally occurring amino acids used in protein synthesis in humans. The theoretical complexity of all these permutations would be approximately 3 x 107, which is relatively lower than the previously reported capsid recombinant libraries (84-92). However, most of them will likely possess intact capsid structure and inherent infectivity of wild- type AAV6 due to the implementation at conserved sites only, providing a sufficient number of variations to be screened. Of note, the library will be prepared by site-directed mutagenesis on already constructed plasmids with randomized primers and subsequent self-packaging of all mutants simultaneously in AAV-producing HEK293 cells at a low capsid-mutated plasmid library to helper plasmid ratio of 1 :5,000 to ensure self-packaging while minimizing the probability of possible cross-packaging (93).
[00131] Upon the preparation of the library, recombinant mAAV6 will be screened first for intracellular trafficking to cell nuclei using mucus-covered ALI cultures of human primary airway cells. Human primary airway cells will be obtained from the CF Clinical and Translational Center at University of Alabama at Birmingham (Dr. Steven Rowe). Cells will be plated apically on collagen coated 6-well semi-permeable transmembrane snapwell culture inserts and grown submerged in media for 3 - 4 days until the cells reach -100% confluency. The apical media will then be removed to create an ALI culture where cells will be differentiated to mimic a polarized
conducting epithelium found in human lung airways (10). The cells will form a monolayer with high transepithelial electrical resistance (TEER; 500-700 Q cm2), an indicative of intact tight junctions (94). The ALI cultures will be prepared with CF (and potentially COPD) airway cells, but it would be challenging to obtain airway cells from asthma patients generally not undergoing lung transplant. However, the model should serve as a reliable representative model to test the ability of m AAV6 to resist adhesion to pathologically-thicken airway mucus gel and deliver self-encoding DNA payloads into the nuclei of human primary airway cells. To obtain NAb against wild-type AAV6, 1 x 1010 - 1011 wildtype AAV6 will be intravenously injected into C57BL/6 mice, serum harvested 2 - 3 weeks after the inj ection and determine the NAb titer using ELISA (95). The library of mAAV6 will be added to the apical surface of the ALI culture, with or without pre-incubation with serum containing anti-AAV6 NAb, and cells will be harvested two days after the administration (i.e., sufficient time for cell uptake and nuclear localization if any). The nuclear fraction will be isolated and genomic DNA extracted, followed by PCR amplification with AAV6 capsid specific primers and evaluation of relevant abundance of associated mutants by sequencing of individual clones. Of note, mAAV6 in the nuclear fraction are those successfully penetrate the apical mucus gel layer, internalize into airway cells, bypass proteasome degradation and traffic to cell nuclei. Three rounds of enrichment procedure will be conducted where capsid specific primers will be used to amplify and re-package only variants isolated from previous selection steps. The selection criteria will be applied to collect clones with over 5%, 10% and 25% frequency at round one, two and three, respectively, to determine up to 12 lead mAAV6 candidates providing greatest nuclear import in primary HAE cells. The selection process is straightforward, as it involves infection of the ALI culture simultaneously with the whole library, followed by selection and analysis of lead mutants via high-throughput next-generation sequencing.
[00132] An additional selection pressure will be applied to ensure that the mAAV6 selected esist mucoadhesion and thus not to compromise the mucus-penetrating property of EV upon external association. Briefly, the diffusion rates of up to 12 mutants selected will be quantified in unperturbed sputum samples spontaneously expectorated by patients vising the Johns Hopkins Adult CF clinic using MPT, which have been routinely conducted (10, 44, 73, 96, 97). Alexa Fluor 647-labeled AAV vectors will be added to freshly collected sputum samples and x- and y- coordinates of particle trajectories will be recorded over time to calculate MSD values. Of note, the labeling strategy does not alter the surface property and infectivity of AAV (12). Sputum
samples will be stored at 4 °C for < 24 hours after the collection to ensure that the biophysical properties are retained (29). The MSD value previously determined for wild-type AAV6 (i.e., MSD > 0.3 pm2 at a timescale of 1 second; (10)) will be considered “non-mucoadhesive” and thus serve as a minimal inclusion criterion.
[00133] The lead mAAV6 desired for human lung-directed gene therapy that also provides favorable performances in a mouse model of MOLDs will be selected. To do this, the library enriched over three rounds in primary HAE cell nuclei will be used (i.e., top 10%) to determine mAAV6 candidates providing efficient nuclear import in the lung airways of the mouse model following intratracheal administration (N = 6 mice per group). A transgenic mouse model of MOLDs exhibiting more pronounced airway mucus barrier (i.e., Scnnlh-A mice; (10, 79)) will be used, thereby implementing more stringent criteria potentially for broader utility of finally selected candidates. Scnnlb- mice at the age of 4 weeks will intratracheally receive a library of enriched mAAV6, and one week after the administration, lung tissues will be thoroughly washed via bronchoalveolar lavage to remove mucus-associated mAAV6, and CD45-negative cells will be harvested (73). Subsequently, lead candidates will be then selected using the method described herein. To evaluate the effect of pre-existing NAb against wild-type AAV6, a separate group of animals will intratracheally receive wild-type AAV6 as described above, 2 weeks prior to the administration of the enriched mAAV6 library. It is expected that 6 lead candidates that exhibit greatest accumulation of self-encoding DNA cassettes in cell nuclei of lung airway cells while satisfying the selection criterion for human airway mucus penetration will be selected. The lead mutants selected here may or may not overlap with those identified for primary HAEs. If the lead candidates are sharply distinct between two species (i.e., human versus mouse), subsequent studies using respective lead mAAV6 for the ALI cultures and the mouse model will be pursued.
[00134] Assessing the coverage and overall level of reporter transgene expression by EVmAAV6 prepared with selected mutants in vitro and in vivo. Determine the percentages of transduced cells and the overall levels of reporter transgene expression by EVmAAV6 prepared with mAAV6 selected in (A) ALI cultures of human primary airway cells and (B) the lungs of the mucus-plugged mouse model. (C) Investigate the ability of EVmAAV6 to deliver two reporter cassettes individually packaged in mAAV6 into the same cells for potential delivery of large genes beyond the natural AAV packaging capacity.
[00135] EVmAAV6, will be prepared based on 6 lead mAAV6 candidates and confirmed for ex vivo mucus penetration and human airway mucus using MPT. Reporter transgene expression will be evaluated in ALI cultures in vitro. Briefly, after transfection of HEK293 cells with packaging plasmids, including ITP-containing plasmid carrying YFP and luciferase co-expressing cassette, cells and supernatants will be harvested. While standard i.e., EV-free) mAAV6 will be obtained from cells using a standard procedure, respective EVmAAV6 will be collected from the supernatant via sequential centrifugation at 100,000 x g and filtration with a 0.45-pm cellulose acetate filter. EVmAAV6 will then be characterized for structure, EV concentration and size (z.e., hydrodynamic diameter) using TEM, a Spectradyne particle analyzer and a Malvern Zetasizer i.e., DLS). In parallel, EVmAAV6 will be screened for common EV biomarkers by single-particle interferometric reflectance imaging sensing with fluorescence using tetraspanin chips. AAV titers of mAAV6 and EVmAAV6 will be analyzed by quantitative PCR. EVs will also be harvested from untransfected HEK293 cells for preparation of post-mixtures of EVs and lead mAAV6 candidates (i.e., EV+mAAV6). EV-free mAAV6, EVmAAV6 or respective EV+mAAV6 will be administered to the apical surface of the mucus-covered ALI culture, and cells will be then harvested two days after the administration, and a half of the harvested cells will be evaluated for the percentage of YFP-positive cells that indicates the coverage of transgene expression, using confocal microscopy and flow cytometry. The rest of cells will be used for homogenate-based luciferase assay to determine the overall level of transgene expression. Three different versions (i.e., EV-free, EV-associated and post-mixture) ofwild-type AAV6 will also be prepared and tested for comparison.
[00136] EVmAAV6 will be prepared based on 6 lead mAAV6 candidates that have been confirmed for ex vivo mucus penetration. The ability of these EVmAAV6 to penetrate human airway mucus using MPT, will be first confirmed. Distribution and overall level of transgene expression in the mucus-plugged lungs of the transgenic mouse model will be evaluated (i.e., Scnnlb-H mice) (N = 6 mice per group). A pair of AAV6 and EVAAV6 will also be prepared for comparisons with lead mutant pairs. Each animal will intratracheally receive either AAV6/mAAV6 or EVAAV6/EVmAAV6 carrying the above-mentioned dual reporter coexpressing cassette, and lung tissue will be harvested 2 weeks after the administration. Lung tissues will be harvested to assess the percentage of transduced cells or coverage using flow cytometry or confocal microscopy, respectively, as we routinely conduct (10, 73). In parallel, lung tissues will
be harvested from separate sets of transduced animals and the overall level of transgene expression will be evaluated by in vivo imaging with an In Vivo Imaging System (IVIS), followed by homogenate-based luciferase assay. One EVmAAV6 each exhibiting either greatest distribution or overall levels of reporter transgene expression in the mouse lungs (so up to 2 lead EVmAAV6) will be determined for further evaluation.
[00137] The potential of using EVmAAV6 for delivery of a large gene beyond the natural AAV packaging capacity (i.e., 4.7 kb) will be evaluated. Dual AAV vectors carrying either upstream or downstream transgene sequence have been used to deliver of large genes (98-100), but such approaches often lead to poor transgene expression as simultaneous delivery of dual vectors to the same cells is not readily achieved. On the other hand, it is hypothesized that two or more AAV vectors, individually carrying different DNA cassettes, co-associated with the same EVs will likely enhance the probability of simultaneous delivery and thus the production of large therapeutic proteins. To test this hypothesis, a pair of lead mAAV6 and EVmAAV6, will be prepared with two different ITR-containing plasmids carrying either ZsGreen- or mCherry-expressing DNA cassette and assess their ability to mediate dual reporter expression in the same cells in vitro and in vivo (N = 6 mice per group). Treatment will be executed as described and efficacy of the samecell dual reporter transgene expression will be assessed using confocal microscopy and/or flow cytometry.
[00138] Example 3: Evaluation of EVAA V6 and lead EVmAA V6 to provide sustained pulmonary transgene expression. (A) Evaluate the ability to transduce human primary airway progenitor cells (i.e., basal cells) and ALI cultures of human primary airway cells after incubation in AAV6-seropositive human serum. (B) Determine the humoral and cell-mediated immune responses against AAV6 in vivo. (C) Assess the ability to retain the transduction efficacy in the lung in vivo (i) after incubation in AAV6-seropositive human serum or (ii) upon repeated dosing.
[00139] The in vitro primary ALI culture transduction experiments will be conducted after pretreating EVAAV6 and lead EVmAAV6 with serum from wild-type AAV6-seropositive patients. The level of transgene expression in comparison to the outcomes without serum incubation will be used as a readout confirming the escape from neutralization. In parallel, the ability to transduce p63- and cytokeratin 5-positive human primary airway basal cells will be assessed using undifferentiated primary human airway cells.
[00140] Humoral and cell-mediated immune responses as well as vector associated inflammation will be evaluated using C57BL/6 mice that serves as a background strain for mouse models of MOLDs (i.e., Scnnlb- g mice; Aim 1 and 2) and allergic asthma. The acute inflammation associated with activation of TLR9/MyD88 will be assessed by Multiplex Bead Array Assay for detection of 25 soluble pro- inflammatory cytokines/chemokines (GM-CSF, IL-1|3, IL-6, IL-2, IL- 2R, IL-4, IL-5, IL-10, and MCP-1, etc.) on serum samples collected 2, 8 and 24 hours (short-term) and 7, 14, 21 and 28 days (long-term) after the intratracheal administration of EVAAV6 or lead EVmAAV6 (N = 6 mice per group). The level of neutralizing activity of AAV-specific NAbs will be evaluated by transduction inhibition-based assay (102). Cellular immune responses will be measured by interferon gamma (IFNy/TNFa) ELISpot assay for both CD8+ and CD4+ on cells isolated from splenocytes with AAV6 capsid dominant peptides (103).
[00141] Immunodeficient NOD SCID gamma (NSG) mice will be intratracheally treated with EVAAV6 or lead EVmAAV6, following intravenous infusion of immunoglobulins from wild-type AAV6-seropositive patients at escalating doses of 5, 50, and 500 mg/kg (N = 6 mice per group). The inhibitory effect or escape from neutralization will be evaluated by assessing the overall luciferase transgene expression level in the mouse lungs by live animal imaging and tissue homogenate-based luciferase assay. Using C57BL/6 mice, we will also evaluate the possibility to overcome AAV-mediated humoral immunity by repeating the dosing of EVAAV6 or lead EVmAAV6 carrying different reporter genes (i.e., mCherry and luciferase for the first and second doses, respectively, to make comparisons with the single dose study) at different time intervals, including 1, 3 and 5 month(s), with varying degrees of neutralizing activity if any (N = 6 mice per group). In parallel, the level of AAV-specific NAb will be evaluated 1, 3 and 5 month(s) after the initial administration.
[00142] Example 4: Safety and therapeutic efficacy of inhaled thymulin gene therapy by EVAAV6 and lead EVmAAV6 in vivo. (A) Determine the doses providing the greatest thymulin transgene expression in the lung without incurring adverse effects using healthy mice. (B) Assess the therapeutic efficacy of the inhaled thymulin gene therapy using mouse models of allergic asthma.
[00143] A dose escalation study will be conducted where three incrementing doses in the range of 4 x 109 - 1 x 1012 will be tested (N = 6 mice per group). Specifically, EVAAV6 and up to two lead
EVmAAV6 will be constructed to carry a thymulin-expressing cassette and will be administered intratracheally into the lungs of C57BL/6 mice. Triplicate sets of animals will be used to evaluate thymulin transgene expression and local and systemic safety profiles. Lungs of the animals in the first set will be harvested in 2 weeks after the administration, followed by the quantification of the level of thymulin transgene expression by ELISA. Animals in the other two sets will be subjected to short- and long-term safety assessment. Specifically, animals will be sacrificed 24 hours and 2 weeks after the administration and lung tissues and whole blood samples will be harvested. Lung tissues will then be subjected to quantification of pro-inflammatory mediators, including but not limited to NF-KB, TRL9, MyD88, IL-ip, IL-6 and IL-12, covered by a commercially available quantitative RT-PCR array. In parallel, blood samples collected from the animals will be used to conduct blood biochemistry analysis. Based on the findings here, will determine optimal doses for EVAAV6 and lead EVmAAV6 that provide maximal thymulin transgene expression in the lung without eliciting local and systemic adverse effects, which will be employed in the preclinical thymulin gene therapy.
[00144] The immunomodulatory and therapeutic effects will be investigated in two mouse models of allergic asthma established on C57BL/6 mice, following intratracheal administration of EVAAV6 or lead EVmAAV6 carrying a thymulin-expressing cassette, at respective optimal doses determined in Aim 3A (N= 8 mice per group). OVA-based model will be established by a series of sequential intraperitoneal sensitization (7 times every other day starting on Day 1) and intratracheal challenge (3 times every third day starting on Day 40) with OVA at 10 and 20 pg, respectively (74). HDM-based model will be established by intranasal instillation of 25 pg HDM (z.e., Dermatophagoides pteronyssinus) 5 days a week for 4 weeks (77). For the OVA-based model, animals will be treated on Day 47 and efficacy will be evaluated on Day 67 from the initial sensitization, based on key disease phenotypes that are fully established and retained without selfresolution during this time window (74). For the HDM-based model, all key disease phenotypes are established by the end of the 4- week 5-day weekly HDM instillation and lasted up 8th week with minor increases in asthmatic inflammation and pulmonary fibrosis upon a continuous HDM instillation (77). Animals will be treated at the beginning of 5th week and efficacy evaluated at the end of 8th week. Live animals will be subjected to methacholine challenge test to determine AHR (i.e., airway resistance and dynamic compliance), as shown in FIG. 9. Animals will then be subjected to comprehensive assessments of immunomodulatory and therapeutic efficacy
assessments. Histopathological analysis will be conducted to assess the goblet cell metaplasia (AB - PAS staining), lung inflammation (H&E), airway constriction (H&E; contraction index) and collagen deposition (Masson’s trichrome staining). Using a duplicate set of animals, BALF and/or whole lung tissues will be collected to evaluate immune infiltration (total and differential cell counting) and levels of soluble factors using ELISA as shown in FIG. 8. Those include Th2 cytokines (IL-4 and IL-13), an anti-inflammatory cytokine (IL-10), pro-fibrotic/remodeling mediators (VEGF and TGF-P) and immune cell-recruiting chemokines (eosinophil: CCL11; neutrophil: CXCL1; macrophage: CCL5; Treg: CCL17). In parallel, phenotypic changes of T cells (Th2 vs. Treg) and macrophages (Ml vs. M2) will be evaluated by the disease and therapeutic intervention (by thymulin gene therapy) using RT-PCR (74).
REFERENCES
1. Maas SLN, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2017;27(3): 172-88. Epub 2016/12/17. doi:
10. 1016/j.tcb.2016. 11.003. PubMed PMID: 27979573; PMCID: PMC5318253.
2. Nam GH, Choi Y, Kim GB, Kim S, Kim SA, Kim IS. Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. Adv Mater. 2020;32(51):e2002440. Epub 2020/10/06. doi: 10.1002/adma.202002440.
PubMed PMID: 33015883.
3. Mishra A, Singh P, Qayoom I, Prasad A, Kumar A. Current strategies in tailoring methods for engineered exosomes and future avenues in biomedical applications. J Mater Chem B. 2021;9(32):6281-309. Epub 2021/07/22. doi: 10.1039/dltb01088c. PubMed PMID: 34286815.
4. Gyorgy B, Maguire CA. Extracellular vesicles: nature's nanoparticles for improving gene transfer with adeno-associated virus vectors. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10(3):el488. Epub 2017/08/12. doi: 10.1002/wnan.l488. PubMed PMID: 28799250.
5. Hudry E, Martin C, Gandhi S, Gyorgy B, Scheffer DI, Mu D, Merkel SF, Mingozzi F, Fitzpatrick Z, Dimant H, Masek M, Ragan T, Tan S, Brisson AR, Ramirez SH, Hyman BT, Maguire CA. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 2016;23(4):380-92. Epub 2016/02/03. doi: 10. 1038/gt.2016. 11. PubMed PMID: 26836117; PMCID: PMC4824662.
6. Wassmer SJ, Carvalho LS, Gyorgy B, Vandenberghe LH, Maguire CA. Exosome- associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection. Sci Rep. 2017;7:45329. Epub 2017/04/01. doi: 10.1038/srep45329. PubMed PMID: 28361998; PMCID: PMC5374486.
7. Liu B, Li Z, Huang S, Yan B, He S, Chen F, Liang Y. AAV-Containing Exosomes as a Novel Vector for Improved Gene Delivery to Lung Cancer Cells. Front Cell Dev Biol.
2021;9:707607. Epub 2021/09/07. doi: 10.3389/fcell.2021.707607. PubMed PMID:
34485293; PMCID: PMC8414974.
8. Gyorgy B, Sage C, Indzhykulian AA, Scheffer DI, Brisson AR, Tan S, Wu X, Volak A, Mu D, Tamvakologos PI, Li Y, Fitzpatrick Z, Ericsson M, Breakefield XO, Corey DP, Maguire CA. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome- Associated AAV. Mol Then 2017;25(2):379-91. Epub 2017/01/14. doi:
10.1016/j.ymthe.2016.12.010. PubMed PMID: 28082074; PMCID: PMC5368844.
9. Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva- Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO, Skog J. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther.
2012;20(5):960-71. Epub 2012/02/09. doi: 10.1038/mt.2011.303. PubMed PMID: 22314290; PMCID: PMC3345986.
10. Duncan GA, Kim N, Colon-Cortes Y, Rodriguez J, Mazur M, Birket SE, Rowe SM, West NE, Livraghi- Butrico A, Boucher RC, Hanes J, Aslanidi G, Suk JS. An Adeno- Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev. 2018;9:296-304. doi: 10.1016/j.omtm.2018.03.006. PubMed PMID: 30038933; PMCID: PMC6054694.
1 1. Wang YY, Harit D, Subramani DB, Arora H, Kumar PA, Lai SK. Influenza-binding antibodies immobilise influenza viruses in fresh human airway mucus. Eur Respir J. 2017;49(l). doi: 10.1183/13993003.01709-2016. PubMed PMID: 28122865.
12. Schuster BS, Kim AJ, Kay JC, Kanzawa MM, Guggino WB, Boyle MP, Rowe SM, Muzyczka N, Suk IS, Hanes J. Overcoming the cystic fibrosis barrier to leading adeno- associated virus gene therapy vectors. Mol Ther. 2014;in press.
13. Jensen MA, Wang YY, Lai SK, Forest MG, McKinley SA. Antibody -Mediated Immobilization of Virions in Mucus. Bull Math Biol. 2019;81(10):4069-99. doi:
10.1007/sl 1538-019-00653-6. PubMed PMID: 31468263; PMCID: PMC6764938.
14. Gyorgy B, Fitzpatrick Z, Crommentuijn MH, Mu D, Maguire CA. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials. 2014;35(26):7598-609. Epub 2014/06/12. doi:
10.1016/j. biomaterials.2014.05.032. PubMed PMID: 24917028; PMCTD: PMC4104587.
15. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013; 122(l):23-36. Epub 2013/04/19. doi: 10.1182/blood- 2013-01-306647. PubMed PMID: 23596044; PMCID: PMC3701904.
16. High KA, Aubourg P. rAAV human trial experience. Methods in molecular biology (Clifton, NJ. 2011;807:429-57. PubMed PMID: 22034041.
17. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark KR. Gene therapy for muscular dystrophy: Lessons learned and path forward. Neuroscience letters. 2012. PubMed PMID: 22609847.
18. Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, Hauswirth WW. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20): 1920-6. Epub 2015/05/06. doi: 10.1056/NEJMoal412965. PubMed PMID: 25936984; PMCID: PMC4450362.
19. Flotte TR, Mueller C Gene therapy for alpha-1 antitrypsin deficiency. Human molecular genetics. 2012;20(Rl):R87-92. PubMed PMID: 21498872.
20. Smalley E. First AAV gene therapy poised for landmark approval. Nat Biotechnol. 2017;35(l l):998-9. Epub 2017/11/10. doi: 10.1038/nbtl 117-998. PubMed PMID: 29121014.
21. Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu Rev Virol. 2019. Epub 2019/07/10. doi: 10.1146/annurev-virology-092818- 015530. PubMed PMID: 31283441.
22. Cooney AL, McCray PB, Jr., Sinn PL. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes (Basel). 2018;9(l 1). Epub 2018/11/09. doi: 10.3390/genes9110538. PubMed PMID: 30405068; PMCID: PMC6266271.
23. Kim N, Duncan GA, Hanes J, Suk JS. Barriers to inhaled gene therapy of obstructive lung diseases: A review. J Control Release. 2016;240:465-88. Epub 2016/05/20. doi: 10.1016/j.jconrel.2016.05.031. PubMed PMID: 27196742; PMCID: PMC5064827.
24. Griesenbach U, Alton EW, Consortium UKCFGT. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 2009;61(2): 128-39. doi: 10.1016/j.addr.2008.09.010. PubMed PMID: 19138713.
25. Guggino WB, Cebotaru L. Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther.
2017;17(10):1265-73. Epub 2017/06/29. doi: 10.1080/14712598.2017.1347630. PubMed PMID: 28657358; PMCID: PMC5858933.
26. Yan Z, McCray PB, Jr., Engelhardt JF. Advances In Gene Therapy For Cystic Fibrosis Lung Disease. Human molecular genetics. 2019. Epub 2019/07/25. doi: 10.1093/hmg/ddzl39. PubMed PMID: 31332440.
27. van Haasteren J, Hyde SC, Gill DR. Lessons learned from lung and liver in- vivo gene therapy: implications for the future. Expert Opin Biol Ther.
2018;18(9):959-72. Epub 2018/08/02. doi: 10.1080/14712598.2018.1506761.
PubMed PMID: 30067117; PMCID: PMC6134476.
28. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev.
2009;61 :75-85. doi: 10.1016/j.addr.2008.09.008. PubMed PMID: 19135107.
29. Duncan GA, Jung J, Hanes J, Suk JS. The Mucus Barrier to Inhaled Gene Therapy. Mol Ther. 2016;24(12):2043-53. Epub 2016/11/02. doi: 10.1038/mt.2016.182. PubMed PMID: 27646604; PMCID: PMC5167788.
30. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54(l 1): 1373-93. Epub 2002/11/30. doi: 10.1016/S0169- 409X(02)00145-X. PubMed PMID: 12458150.
31. Kim N, Duncan GA, Hanes J, Suk JS. Barriers to inhaled gene therapy of obstructive lung diseases: A review. Journal of Controlled Release. 2016;240:465-88.
32. Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, Morales MM, Hanes J, Suk JS. Highly compacted biodegradable DNA nanoparticles capable of overcoming
the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A.
2015;l 12(28):8720-5. Epub 2015/07/01. doi: 10.1073/pnas.l502281112. PubMed PMID: 26124127; PMCID: 4507234.
33. Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, Henning A, Ensign LM, Lee E, Adstamongkonkul P, Simons BW, Wang SS, Gong X, Yu T, Boyle MP, Suk JS, Hanes J. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv. 2017;3(4):el601556. Epub 2017/04/25. doi: 10.1126/sciadv.1601556. PubMed PMID: 28435870; PMCID:
5381952.
34. Suk JS, Kim AJ, Trehan K, Schneider CS, Cebotaru L, Woodward OM, Boylan NJ, Boyle MP, Lai SK, Guggino WB, Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. Journal of Controlled Release. 2014;178:8-17. Epub 2014/01/21. doi: 10.1016/j.jconrel.2014.01 .007. PubMed PMID: 24440664; PMCID: 3951606.
35. Suk JS. Could recent advances in DNA-loaded nanoparticles lead to effective inhaled gene therapies? Nanomedicine (Lond). 2016. Epub 2016/01/20. doi: 10.2217/nnm.l5.194. PubMed PMID: 26783765.
36. Forier K, Messiaen AS, Raemdonck K, Deschout H, Rejman J, De Baets F, Nelis H, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine (Lond) 2013;8(6):935-49. Epub 2012/10/06. doi: 10.2217/nnm.12.129. PubMed PMID: 23035662
37. Chen D, Liu J, Wu J, Suk JS. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Deliv. 2020:1-12. Epub 2020/1 1/22. doi: 10.1080/17425247.2021.1854222. PubMed PMID: 33218265.
38. Cameiro A, Lee H, Lin L, van Haasteren J, Schaffer DV. Novel Lung Tropic Adeno- Associated Virus Capsids for Therapeutic Gene Delivery. Hum Gene Ther. 2020;31(17- 18):996-1009. Epub 2020/08/18. doi: 10.1089/hum.2020.169. PubMed PMID: 32799685.
39. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75-85. Epub 2009/01/13. doi: S0169-409X(08)00259-7 [pii]
10.1016/j.addr.2008.09.008. PubMed PMID: 19135107.
40. Chisholm JF, Shenoy SK, Shade JK, Kim V, Putcha N, Carson KA, Wise R, Hansel NN, Hanes JS, Suk JS, Neptune E. Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD. Eur Respir J. 2019;54(2). Epub 2019/06/06. doi: 10.1183/13993003.00088-2019. PubMed PMID: 31164433; PMCID: PMC8081045.
41. Morgan LE, Jaramillo AM, Shenoy SK, Raclawska D, Emezienna NA, Richardson VL, Hara N, Harder AQ, NeeDell JC, Hennessy CE, ELBatal HM, Magin CM, Grove Villalon DE, Duncan G, Hanes JS, Suk JS, Thornton DJ, Holguin F, Janssen WJ, Thelin WR, Evans CM. Disulfide disruption reverses mucus dysfunction in allergic airway disease. Nat Commun. 2021;12(l):249. Epub 2021/01/13. doi: 10.1038/s41467-020-20499-0. PubMed PMID: 33431872; PMCID: PMC7801631.
42. Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PloS one.
2011;6(5):el9919. Epub 2011/06/04. doi: 10.1371/joumal.pone.0019919. PubMed PMID: 21637751; PMCID: 3103503.
43. Boylan NJ, Suk JS, Lai SK, Jelinek R, Boyle MP, Cooper MJ, Hanes J. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J Control Release. 201 l;157(l):72-9. Epub 2011/09/10. doi: S0168- 3659(11)00643-2 [pii]
10.1016/j.jconrel.2011.08.031. PubMed PMID: 21903145.
44. Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JM, Boyle MP, Zeitlin PL, Lai SK, Cooper MJ, Hanes J. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther. 2011; 19(11): 1981-9. Epub 2011/08/1 1. doi: mt2011 160 [pii] 10.1038/mt.201 1 .160. PubMed PMID: 21829177.
45. Liu X, Luo M, Tiygg C, Yan Z, Lei-Butters DC, Smith CI, Fischer AC, Munson K, Guggino WB, Bunnell BA, Engelhardt JF. Biological differences in rAAV transduction of airway epithelia in humans and in old world non-human primates. Mol Ther.
2007;15(12):21 14-23. Epub 2007/08/02. doi: 10.1038/sj. mt.6300277. PubMed PMID: 17667945; PMCID: 2121582.
46. Liu X, Luo M, Guo C, Yan Z, Wang Y, Engelhardt J. Comparative biology of rAAV transduction in ferret, pig and human airway epithelia. Gene Therapy. 2007; 14(21): 1543.
47. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol. 2006;80(18):9093-
103. Epub 2006/08/31. doi: 10.1128/JVI.00895-06. PubMed PMID: 16940521; PMCID: PMC1563919.
48. Wu NH, Yang W, Beineke A, Dijkman R, Matrosovich M, Baumgartner W, Thiel V, Valentin-Weigand P, Meng F, Herrler G. The differentiated airway epithelium infected by influenza viruses maintains the barrier function despite a dramatic loss of ciliated cells. Sci Rep. 2016;6:39668. Epub 2016/12/23. doi: 10.1038/srep39668. PubMed PMID: 28004801; PMCID: PMC5177954.
49. Ding K, Shen J, Hackett S, Khan M, Campochiaro PA. Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina. Gene Ther. 2021. Epub 2021/02/06. doi: 10.1038/s41434- 021-00233-1. PubMed PMID: 33542456; PMCID: PMC8333227.
50. Monahan PE, Lothrop CD, Sun J, Hirsch ML, Kafri T, Kantor B, Sarkar R, Tillson DM, Elia JR, Samulski RJ. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther. 2010; 18(11): 1907-16. Epub 2010/08/12. doi: 10.1038/mt.2010.170. PubMed PMID: 20700109; PMCID: PMC2990516.
51. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel- Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular
trafficking and transgene expression. Virology. 2008;381(2): 194-
202. Epub 2008/10/07. doi: 10.1016/j.virol.2008.08.027. PubMed PMID: 18834608; PMCID: PMC2643069.
52. Dhungel BP, Bailey CG, Rasko JEJ. Journey to the Center of the Cell: Tracing the Path of AAV Transduction. Trends Mol Med. 2021 ;27(2): 172-84. Epub 2020/10/20. doi: 10.1016/j.molmed.2020.09.010. PubMed PMID: 33071047.
53. Cooney AL, Thornell IM, Singh BK, Shah VS, Stoltz DA, McCray PB, Jr., Zabner J, Sinn PL. A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs. Am J Respir Cell Mol Biol. 2019;61(6):747-54. Epub 2019/06/12. doi: 10.1165/rcmb.2O19- 0006GC. PubMed PMID: 31184507; PMCID: PMC6890402.
54. Nidetz NF, McGee MC, Tse LV, Li C, Cong L, Li Y, Huang W. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther. 2020;207: 107453. Epub 2019/12/15. doi: 10.1016/j.pharmthera.2019.107453. PubMed PMID: 31836454; PMCID: PMC6980784.
55. Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021. Epub 2021/03/05. doi: 10.1038/s41434-021-00243-z. PubMed PMID: 33658649; PMCID: PMC8413391.
56. Naso MF, Tomkowicz B, Perry WL, 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31(4):317-34. Epub 2017/07/03. doi: 10.1007/s40259-017-0234-5. PubMed PMID: 28669112; PMCID: PMC5548848.
57. Li C, He Y, Nicolson S, Hirsch M, Weinberg MS, Zhang P, Kafri T, Samulski RJ. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest. 2013;123(3): 1390-401. Epub 2013/03/05. doi: 10.1172/JCI66611. PubMed PMID: 23454772; PMCID: PMC3582142.
58. Karman J, Gumlaw NK, Zhang J, Jiang JL, Cheng SH, Zhu Y. Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno- associated viral vectors. PloS one. 2012;7(4):e34684. Epub 2012/04/20. doi:
10.1371/journal. pone.0034684. PubMed PMID: 22514654; PMCID: PMC3326043.
59. Buning H, Srivastava A. Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors. Mol Ther Methods Clin Dev. 2019;12:248-65. Epub 2019/03/01. doi: 10.1016/j.omtm.2019.01.008. PubMed PMID: 30815511; PMCID: PMC6378346.
60. Li B, Ma W, Ling C, Van Vliet K, Huang LY, Agbandje-McKenna M, Srivastava A, Aslanidi GV. Site- Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo. Hum Gene Ther Methods. 2015;26(6):211-20. Epub 2015/10/01. doi: 10.1089/hgtb .2015.115. PubMed PMID: 26421998; PMCID: PMC4677520.
61. Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther. 2010;18(12):2048-56. Epub 2010/08/26. doi: mt2010172 [pii]
10.1038/mt.2010.172. PubMed PMID: 20736929; PMCID: 2997584.
62. Aslanidi GV, Rivers AE, Ortiz L, Song L, Ling C, Govindasamy L, Van Vliet
K, Tan M, Agbandje- McKenna M, Srivastava A. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PloS one.
2013;8(3):e59142. Epub 2013/03/26. doi: 10.1371/joumal.pone.0059142
PONE-D- 12-28292 [pii], PubMed PMID: 23527116; PMCID: 3602601.
63. Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol. 2014;92(2):l 16-23. doi: 10.1038/icb.2013.74. PubMed PMID: 24217810.
64. Ling C, Wang Y, Lu Y, Wang L, Jayandharan GR, Aslanidi GV, Li B, Cheng B, Ma W, Lentz T, Ling C, Xiao X, Samulski RJ, Muzyczka N, Srivastava A. Enhanced transgene expression from recombinant single- stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J Virol. 2015;89(2):952- 61. doi: 10.1128/JVI.02581-14. PubMed PMID: 25355884; PMCID: PMC4300666.
65. Pandya M, Britt K, Hoffman B, Ling C, Aslanidi GV. Reprogramming Immune Response With Capsid- Optimized AAV6 Vectors for Immunotherapy of Cancer. J Immunother. 2015;38(7):292-8. Epub 2015/08/12. doi: 10.1097/C JI.0000000000000093
00002371-201509000-00005 [pii], PubMed PMID: 26261893; PMCID: 4535186.
66. Ling C, Yin Z, Li J, Zhang D, Aslanidi G, Srivastava A. Strategies to generate high- titer, high-potency recombinant AAV3 serotype vectors. Mol Ther Methods Clin Dev. 2016;3: 16029. doi: 10.1038/mtm.2016.29. PubMed PMID: 27200382; PMCID: PMC4856060.
67. Chen M, Maeng K, Nawab A, Francois RA, Bray JK, Reinhard MK, Boye SL, Hauswirth WW, Kaye FJ, Aslanidi G, Srivastava A, Zajac-Kaye M. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(l):49-59. doi: 10.1089/hgtb.2016.089. PubMed PMID: 28125909; PMCID: PMC5314986.
68. Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol. 2013. Epub 2013/11/13. doi: 10.1038/icb.2013.74 icb201374 [pii], PubMed PMID: 24217810.
69. Sayroo R, Nolasco D, Yin Z, Colon-Cortes Y, Pandya M, Ling C, Aslanidi G. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 2015. Epub 2015/08/14. doi: 10.1038/gt.2015.89 gt201589 [pii], PubMed PMID: 26270885.
70. McCraw DM, O'Donnell JK, Taylor KA, Stagg SM, Chapman MS. Structure of adeno- associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology.
2012;431(l-2):40-9. Epub 2012/06/12. doi: 10.1016/j.virol.2012.05.004. PubMed PMID: 22682774; PMCID: PMC3383000.
71. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S,
Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsidspecific CD8+ T cells. Blood. 2013;121(12):2224-33. Epub 2013/01/18. doi: 10.1182/blood- 2012-10-460733 blood-2012-10-460733 [pii], PubMed PMID: 23325831 ; PMCID: 3606062.
72. Birket SE, Davis JM, Fernandez CM, Tuggle KL, Oden AM, Chu KK, Tearney GJ, Fanucchi MV, Sorscher EJ, Rowe SM. Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight. 2018;3(l). Epub 2018/01/13. doi: 10.1172/jci.insight.97199. PubMed PMTD: 29321377; PMCID: PMC5821204.
73. Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, Morales MM, Hanes J, Suk JS. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A.
2015 ; 1 12(28): 8720-5. Epub 2015/07/01 . doi : 10.1073/pnas.1502281112. PubMed PMTD : 26124127; PMCID: 4507234.
74. da Silva AL, de Oliveira GP, Kim N, Cruz FF, Kitoko JZ, Blanco NG, Martini SV, Hanes J, Rocco PRM, Suk JS, Morales MM. Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma. Sci Adv.
2020;6(24):eaay7973. Epub 2020/06/25. doi: 10.1126/sciadv.aay7973. PubMed PMID: 32577505; PMCID: PMC7286682.
75. Piyadasa H, Altieri A, Basu S, Schwartz J, Halayko AJ, Mookheijee N. Biosignature for airway inflammation in a house dust mite-challenged murine model of allergic asthma. Biol Open. 2016,5(2): 112-21. doi: 10.1242/bio.014464. PubMed PMID: 26740570; PMCID: PMC4823983.
76. Bracken SJ, Adami AJ, Szczepanek SM, Ehsan M, Natarajan P, Guernsey LA, Shahriari N, Rafti E, Matson AP, Schramm CM, Thrall RS. Long-Term Exposure to House Dust Mite Leads to the Suppression of Allergic Airway Disease Despite Persistent Lung Inflammation. Int Arch Allergy Immunol. 2015;166(4):243-58. doi: 10.1159/000381058. PubMed PMID: 25924733; PMCID: PMC4485530.
77. Woo LN, Guo WY, Wang X, Young A, Salehi S, Hin A, Zhang Y, Scott JA, Chow CW. A 4-Week Model of House Dust Mite (HDM) Induced Allergic Airways Inflammation with Airway Remodeling. Sci Rep. 2018;8(l):6925. doi: 10.1038/s41598-018-24574-x. PubMed PMID: 29720689; PMCID: PMC5932037.
78. Johnson JR, Pacitto SR, Wong J, Archer EW, Eirefelt S, Miller-Larsson A, Jordana M. Combined budesonide/formoterol therapy in conjunction with allergen avoidance ameliorates house dust mite-induced airway remodeling and dysfunction. Am J Physiol Lung Cell Mol Physiol. 2008;295(5):L780-8. doi: 10.1152/ajplung.90229.2008. PubMed PMID: 18776055.
79. Kim N, Kwak G, Rodriguez J, Livraghi-Butrico A, Zuo X, Simon V, Han E, Shenoy SK, Pandey N, Mazur M, Birket SE, Kim A, Rowe SM, Boucher R, Hanes J, Suk JS. Inhaled gene therapy of preclinical muco- obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier. Thorax. 2021. Epub 2021/10/27. doi: 10.1136/thoraxjnl- 2020-215185. PubMed PMID: 34697091.
80. Rosario AM, Cruz PE, Ceballos-Diaz C, Strickland MR, Siemienski Z, Pardo M, Schob KL, Li A, Aslanidi GV, Srivastava A, Golde TE, Chakrabarty P. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev. 2016;3: 16026. Epub 2016/06/17. doi: 10.1038/mtm.2016.26. PubMed PMID: 27308302; PMCID: PMC4909093.
81. da Silva AL, Martini SV, Abreu SC, Samary Cdos S, Diaz BL, Fernezlian S, de Sa VK, Capelozzi VL, Boylan NJ, Goya RG, Suk JS, Rocco PR, Hanes J, Morales MM. DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J Control Release. 2014;180:125-33. Epub 2014/02/22. doi:
10.1016/j.jconreL2014.02.010. PubMed PM1D: 24556417; PMCID: PMC3992277.
Porpodis K, Domvri K, Kontakiotis T, Fouka E, Kontakioti E, Zarogoulidis K, Papakosta D. Comparison of diagnostic validity of mannitol and methacholine challenges and relationship to clinical status and airway inflammation in steroid-naive asthmatic patients. The Journal of asthma : official journal of the Association for the Care of Asthma. 2017;54(5):520-9. doi: 10.1080/02770903.2016.1238926. PubMed PMID: 27686218.
82. Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax. 2002;57(8):694-700. doi: 10.1136/thorax.57.8.694. PubMed PMID: 12149529; PMCID: 1746396.
83. Li C, Wu S, Albright B, Hirsch M, Li W, Tseng YS, Agbandje-McKenna M, McPhee S, Asokan A, Samulski RJ. Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Mol Ther. 2016;24(l):53-65. doi: 10.1038/mt.2015.134. PubMed PMID: 26220272; PMCID: PMC4754536.
84. Tse LV, Kline KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje- McKenna M, Asokan A. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A.
2017;114(24):E4812-E2L doi: 10.1073/pnas.1704766114. PubMed PMID: 28559317; PMCID: PMC5474820.
85. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014; 15(7):445-51. doi: 10.1038/nrg3742. PubMed PMID: 24840552; PMCID: PMC4393649.
86. Pekrun K, De Alencastro G, Luo QJ, Liu J, Kim Y, Nygaard S, Galivo F, Zhang F, Song R, Tiffany MR, Xu J, Hebrok M, Grompe M, Kay MA. Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight. 2019;4(22). doi: 10.1172/jci. insight.131610. PubMed PMID: 31723052; PMCID: PMC6948855.
87. Paulk NK, Pekrun K, Zhu E, Nygaard S, Li B, Xu J, Chu K, Leborgne C, Dane AP, Haft A, Zhang Y, Zhang F, Morton C, Valentine MB, Davidoff AM, Nathwani AC, Mingozzi F, Grompe M, Alexander IE, Lisowski L, Kay MA. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol Ther. 2018;26(l):289-303. Epub 2017/10/23. doi: 10.1016/j.ymthe.2017.09.021. PubMed PMID: 29055620; PMCID: PMC5763027.
88. Ogden PJ, Kelsic ED, Sinai S, Church GM. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science.
2019;366(6469):l 139-43. doi: 10.1126/science.aaw2900. PubMed PMID: 31780559.
89. Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A, Rabinowitz J, Agbandje-McKenna M, Samulski RJ. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol. 2012;86(15):7752-9. Epub 2012/05/18. doi: JVT.00675-12 [pii] 10.1128/JVL00675-12. PubMed PMID: 22593151 ;
PMC ID: 3421647.
90. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H, Hallek M. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 2003;! 0(26):2139-47. doi:
IO.1038/sj .gt.3302123. PubMed PMID: 14625569.
91. Steines B, Dickey DD, Bergen J, Excoffon KJ, Weinstein JR, Li X, Yan Z, Abou Alaiwa MH, Shah VS, Bouzek DC, Powers LS, Gansemer ND, Ostedgaard LS, Engelhardt
JF, Stoltz DA, Welsh MJ, Sinn PL, Schaffer DV, Zabner J. CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes. JCI Insight. 2016;l(14):e88728. Epub 2016/10/05. doi: 10.1172/jci.insight.88728. PubMed PMID: 27699238; PMCID: PMC5033908.
92. Marsic D, Govindasamy L, Currlin S, Markusic DM, Tseng YS, Herzog RW, Agbandje-McKenna M, Zolotukhin S. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther.
2014;22(l 1): 1900-9. Epub 2014/07/23. doi: 10.1038/mt.2014.139 mt2014139 [pii], PubMed PMID: 25048217.
93. Bates E, Miller S, Alexander M, Mazur M, Fortenberry JA, Bebok Z, Sorscher EJ, Rowe SM. Bioelectric effects of quinine on polarized airway epithelial cells. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2007;6(5):351-9. Epub 2007/03/03. doi: 10.1016/j .jcf.2007.01.001. PubMed PMID: 17329172; PMCID: 2077327.
94. Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, Slaughter C, Ng CY, Zhou J, Lozier JN, Mandrell TD, Vanin EF, Nienhuis AW. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno- associated virus encoding the hFIX gene in rhesus macaques. Blood. 2002;100(5):1662-9. doi: 10.1182/blood-2002-02-0589. PubMed PMID: 12176886.
95. Duncan GA, Jung J, Joseph A, Thaxton AL, WestNE, Boyle MP, Hanes J, Suk JS. Microstructural alterations of sputum in cystic fibrosis lung disease. JCI Insight.
2016; 1 (18):e88198. doi: 10.1172/jci.insight.88198. PubMed PMID: 27812540; PMCID: PMC5085601 developed by Kala Pharmaceuticals. J. Hanes is a cofounder of Kala Pharmaceuticals. He owns company stock, which is subject to certain restrictions under Johns Hopkins University policy. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies.
96. Suk JS, Kim AJ, Trehan K, Schneider CS, Cebotaru L, Woodward OM, Boylan NJ, Boyle MP, Lai SK, Guggino WB, Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release. 2014;178C:8-17. Epub 2014/01/21. doi: 10.1016/j .jconrel.2014.01.007. PubMed PMID: 24440664.
97. Akil O, Dyka F, Calvet C, Emptoz A, Lahlou G, Nouaille S, Boutet de Monvel J, Hardelin JP, Hauswirth WW, Avan P, Petit C, Safieddine S, Lustig LR. Dual AAV-mediated
gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci U S A. 2019. Epub 2019/02/21. doi: 10.1073/pnas.l817537116. PubMed PMID: 30782832; PMCID: PMC6410774.
98. Al-Moyed H, Cepeda AP, Jung S, Moser T, Kugler S, Reisinger E. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019; 11(1). Epub 2018/12/05. doi:
10.15252/emmm.201809396. PubMed PMID: 30509897; PMCID: PMC6328916.
99. Carvalho LS, Turunen HT, Wassmer SJ, Luna-Velez MV, Xiao R, Bennett J, Vandenberghe LH. Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting. Front Neurosci. 2017; 11:503. Epub 2017/09/26. doi: 10.3389/fnins.2017.00503. PubMed PMID: 28943836; PMCID: PMC5596095.
100. Kim YC, Hsueh HT, Kim N, Rodriguez J, Leo KT, Rao D, West NE, Hanes J, Suk JS. Strategy to enhance dendritic cell-mediated DNA vaccination in the lung. Adv Ther (Weinh). 2021;4(2). Epub 2021/03/13. doi: 10.1002/adtp.202000228. PubMed PMID: 33709020; PMCID: PMC7941873.
101. Krotova K, Aslanidi G. Modifiers of Adeno- Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay. Hum Gene Ther. 2020;31(19-20): 1124-31. doi: 10.1089/hum.2020.074. PubMed PMID: 32495655, PMCID: PMC7588322.
102. Krotova K, Day A, Aslanidi G. An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. Mol Ther Oncolytics. 2019;15: 166-77. doi: 10.1016/j.omto.2019.10.001. PubMed PMID: 31720373; PMCID: PMC6838889.
[00145]
OTHER EMBODIMENTS
[00146] While the disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
[00147] The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
Claims
1. A method of delivery of nucleic acid, through a mucus gel layer comprising administering a composition comprising a virus vector associated with an extracellular vesicle, wherein the virus vector comprises the nucleic acid.
2. The method of claim 1, wherein the virus vector is associated externally with the extracellular vesicle and/or is contained within the extracellular vesicle.
3. The method of claim 1, wherein the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
4. The method of claim 3, wherein the virus vector comprises one or more mutations.
5. The method of claims 3 or 4, wherein the virus vector is an AAV vector.
6. The method of claim 5, wherein the AAV vector comprises one or more AAV capsid protein(s) comprising modified amino acid sequences.
7. The method of claim 6, wherein the modified amino acid capsid protein(s) comprise one or more insertions, deletions, or substitutions of one or more amino acids.
8. The method of claims 6 or 7, wherein the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
9. The method of claims 6 or 7, wherein the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
10. The method of any one of claims 5-9, wherein the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ, DJ/8, or mutants thereof.
1 1 . The method of claim 10, wherein the AAV is AAV serotype 6 (AAV6).
12. The method of claim 1, wherein the extracellular vesicle is derived from eukaryotic cells.
13. The method of any one of claims 1-12, wherein the composition is formulated for oral, intratracheal/oropharyngeal cervicovaginal, ocular, rectal or nasal delivery.
14. The method of claim 10, wherein the composition is aerosolized for delivery to the airways and/or alveolar sacs by inhalation or the oropharyngeal cavity.
15. The method of claim 10, wherein the composition is formulated as a liquid or gel for delivery to mucosal surfaces.
16. The method of claim 10, wherein the composition is formulated as a suppository.
17. A composition comprising a virus vector associated with an extracellular vesicle, wherein the virus vector comprises a transgene.
18. The composition of claim 17, wherein the virus vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
19. The composition of claim 17, wherein the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
20. The composition of claim 19, wherein the virus vector is an AAV vector.
21. The composition of claim 20, wherein the AAV vector comprises one or more AAV capsid protein(s) comprising modified amino acid sequences.
22. The composition of claim 21, wherein the modified amino acid capsid protein(s) comprise one or more insertions, deletions, or substitutions of one or more amino acids.
23. The composition of claims 21 or 22, wherein the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
24. The composition of claims 21 or 22, wherein the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
25. The composition of claims 21 or 22, wherein the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
26. The composition of claim 17, wherein the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8.
27. The composition of claim 26, wherein the AAV is AAV serotype 6 (AAV6).
28. The composition of claim 26, wherein the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
29. The composition of claim 17, wherein the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence.
30. The composition of claim 17, wherein the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids.
31. The composition of claim 17, wherein the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moieties.
32. The composition of claim 17, wherein the extracellular vesicle is derived from eukaryotic cells.
33. A device for delivery of the composition of any one of claims 17-32 to an oral cavity, nose, pharynx or to a subject in need thereof.
34. A method of treating a lung disease or disorder or an oropharyngeal disease comprising administering the composition of any one of claims 17-32 to a subject in need thereof.
35. The method of claim 33, wherein a lung disease or disorder comprises cystic fibrosis, chronic obstructive pulmonary disease (COPD), lung inflammation, asthma, lung cancer, bronchitis, infections, or allergies.
36. A method of modulating an immune response for treating an immune related disorder in a subject in need thereof, comprising administering a composition comprising an extracellular vesicle and an adeno-associated virus (AAV) vector, the AAV vector comprising a nucleic acid sequence encoding an immunomodulatory molecule.
37. The method of claim 36, wherein the AAV comprises one or more amino acid mutations in the AAV capsid proteins.
38. The method of claim 37, wherein, the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
39. The method of claim 37, wherein the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
40. The method of claim 37, wherein the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
41. The method of claim 40, wherein the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8.
42. The method of claim 41, wherein the AAV is AAV serotype 6 (AAV6).
43. The method of claim 36, wherein the AAV is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
44. The method of claim 36, wherein the immunomodulatory molecule comprises thymulin, interferons, chemokines, cytokines, tumor necrosis factor alpha, modulators of checkpoint inhibitors or ligands of checkpoint inhibitors or combinations thereof.
45. The method of claim 36, wherein an immune related disease or disorder is asthma or allergies.
46. The method of claim 36, wherein the composition is formulated for oral, intratracheal/oropharyngeal, cervicovaginal, ocular, rectal or nasal delivery.
47. The method of claim 36, wherein the composition is aerosolized for delivery to the airways by inhalation or the oropharyngeal cavity.
48. The method of claim 36, wherein the composition is formulated as a liquid or gel for delivery to mucosal surfaces.
49. The method of claim 36, wherein the composition is formulated as a suppository.
50. An adeno-associated virus (AAV) vector comprising one or more amino acid mutations in the AAV capsid proteins.
51. The AAV vector of claim 50, wherein the one or more mutations are located at one or more conserved phosphorylation sites.
52. The AAV vector of any one of claims 50-51, wherein the AAV vector is associated externally with the extracellular vesicle or is contained within the extracellular vesicle.
53. A composition comprising a modified extracellular vesicle and a virus vector comprising a transgene.
54. The composition of claim 53, wherein the extracellular vesicle is a modified extracellular vesicle derived from a cell transduced with an exogenous nucleic acid sequence.
55. The composition of claim 53, wherein the extracellular vesicle is a modified extracellular vesicle comprising one or more modified lipids.
56. The composition of claim 53, wherein the extracellular vesicle is a modified extracellular vesicle comprising one or more targeting moieties.
57. The composition of claim 53, wherein the extracellular vesicle is derived from eukaryotic cells.
58. The composition of claim 53, wherein the virus vector comprises: adenovirus vectors, adeno-associated virus (AAV) vectors, herpes simplex virus vectors, influenza virus vectors, lentivirus vector, retrovirus vectors, alphavirus vectors, flavivirus vectors, rhabdovirus vectors, measles virus vectors, Newcastle disease virus vectors, poxvirus vectors, vaccinia virus vectors, modified Ankara virus vectors, vesicular stomatitis virus vectors, picornavirus vectors, chimeric
virus vectors, synthetic virus vectors, respiratory syncytial virus vectors, parainfluenza virus vectors, foamy virus vectors, recombinant viral vectors, mosaic virus vectors, or pseudotyped virus vectors.
59. The composition of claim 58, wherein the virus vector is an AAV vector.
60. The composition of claim 59, wherein the AAV vector comprises one or more AAV capsid protein(s) comprising modified amino acid sequences.
61. The composition of claim 60, wherein the modified amino acid capsid protein(s) comprise one or more insertions, deletions, or substitutions of one or more amino acids.
62. The composition of claims 60 or 61, wherein the one or more capsid amino acid mutations enhance intracellular trafficking to a target cell nucleus as compared to an AAV lacking the capsid amino acid mutations.
63. The composition of claims 60 or 61, wherein the capsid amino acid mutations enhance the interactions with target cells and/or the penetration through the mucus gel layer as compared to an AAV lacking the capsid amino acid mutations.
64. The composition of claims 60 or 61, wherein the capsid amino acid mutations reduce immunogenicity as compared to an AAV lacking the capsid amino acid mutations.
65. The composition of claim 64, wherein the AAV comprises AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, DJ or DJ/8.
66. The composition of claim 65, wherein the AAV is AAV serotype 6 (AAV6).
67. A nucleic acid-based vaccine comprising an extracellular vesicle and a virus vector wherein the virus vector comprises at least one transgene.
68. The nucleic acid-based vaccine of claim 67, wherein the virus vector encodes an immunogenic/antigenic molecule.
69. The nucleic acid-based vaccine of claim 68, further comprising an adjuvant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263394498P | 2022-08-02 | 2022-08-02 | |
US63/394,498 | 2022-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024030514A1 true WO2024030514A1 (en) | 2024-02-08 |
Family
ID=89849717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/029349 WO2024030514A1 (en) | 2022-08-02 | 2023-08-02 | Extracellular vesicle-associated adeno-associated virus vectors for inhaled gene therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024030514A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017201121A1 (en) * | 2016-05-17 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Recombinant aav for gene therapy in lungs |
US20190153471A1 (en) * | 2016-04-29 | 2019-05-23 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2020215010A1 (en) * | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
-
2023
- 2023-08-02 WO PCT/US2023/029349 patent/WO2024030514A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190153471A1 (en) * | 2016-04-29 | 2019-05-23 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017201121A1 (en) * | 2016-05-17 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Recombinant aav for gene therapy in lungs |
WO2020215010A1 (en) * | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11905312B2 (en) | Methods and compositions for gene transfer across the vasculature | |
JP6873907B2 (en) | Methods and Compositions for Treating Hereditary Eye Diseases | |
TW201837170A (en) | Novel AAV mediated influenza vaccines | |
WO2015126972A1 (en) | Methods and compositions for gene delivery to on bipolar cells | |
AU2019202958B2 (en) | Aav-based gene therapy for multiple sclerosis | |
CA3137015A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
CN116121274A (en) | Acquisition and application of liver targeting novel adeno-associated virus | |
CN111936172A (en) | Compositions and methods for treating retinal disorders | |
CA3137078A1 (en) | Methods and compositions for transgene expression | |
Kochergin-Nikitsky et al. | Tissue and cell-type-specific transduction using rAAV vectors in lung diseases | |
US20210301305A1 (en) | Engineered untranslated regions (utr) for aav production | |
US20230242941A1 (en) | Methods and compositions for administering recombinant viral vectors | |
EP4159863A1 (en) | Codon-optimized nucleic acid encoding smn1 protein | |
CN112029773B (en) | Nucleic acids encoding BDNF and uses thereof | |
WO2024030514A1 (en) | Extracellular vesicle-associated adeno-associated virus vectors for inhaled gene therapy | |
WO2022121860A1 (en) | Methods and kits for inducing immunotolerance to gene delivering target vehicle | |
CN117177776A (en) | Reasonable polyploid AAV virions that cross the blood brain barrier and elicit a reduced humoral response | |
JP2023530277A (en) | Baculovirus expression system | |
EP4323011A1 (en) | Methods and compositions for treatment of cystic fibrosis | |
EP4314021A1 (en) | Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same | |
AU2020212026A1 (en) | Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design | |
CN115160410A (en) | Novel muscle high-efficiency affinity adeno-associated virus serotype and related application | |
OA21075A (en) | Codon-optimized nucleic acid that encodes SMN1 protein, and use thereof | |
NZ713958A (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23850726 Country of ref document: EP Kind code of ref document: A1 |